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Diagnosis of diseased state and regular monitoring during treatment is essential to effective 
management of diseases. Detection of biomarkers in body fluids such as blood, urine, saliva, 
and sweat is the basis for diagnosis. In addition to these body fluids, interstitial fluid (ISF) is 
a major body fluid that surrounds the cells and tissues in the body and connects blood vessels 
with cellular matter. ISF is currently used for a few diagnostic applications such as 
continuous glucose monitoring and to monitoring local drug concentrations in skin. 
However, even though ISF is a valuable source of biomarkers, its use in diagnostic research 
and clinical applications is limited because the current methods to sample ISF are 
cumbersome, time-consuming, invasive, and can cause discomfort to the patient.  
In this study, we have developed a simple, reliable method that can sample multiple 
microliters of ISF through skin using a microneedle (MN) based system. MNs are 
microscopic needles that can penetrate past the upper skin layers and reach the lower dermis 
and access the ISF in the lower skin layer. Since MNs are small and easy to handle, they are 
ideal as a minimally-invasive device to sample ISF.  
We designed four MN systems that utilize different mechanisms and driving forces to push 
the ISF from the dermis into the MNs and eventually towards the skin surface. Hydrogel 
MNs, porous MNs, and hollow MNs absorb surrounding ISF, creating a concentration 
gradient for ISF. An osmosis based MN system and a direct pressure based MN system 
created a pressure gradient in the dermis for ISF flow. Experimentally, it was observed that 
the highest ISF sampling rate was obtained with a pressure induced gradient. To evaluate the 
transport of ISF through skin, a theoretical model was developed exploring ISF flow with 
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various driving forces and the rate limiting steps. The major resistance to ISF flow is flow 
through dermis and hence a pressure gradient in the dermis greatly enhances flow rates 
compared to a concentration gradient. We translated these experimental and theoretical 
findings in human volunteers. MNs were used to create micropores in the skin surface with 
suction applied over these micropores to drive the ISF from the dermis towards the skin 
surface. This method sampled multiple microliters of ISF from human participants within 
minutes. 
To evaluate the composition of ISF, we investigated the metabolomic profile of suction 
blister ISF and compared it with plasma in 10 human participants. Common biomarkers such 
as glucose, creatinine, and urea were detected in both fluids, indicating the possible utility of 
ISF as a surrogate for blood. Several metabolites were also found uniquely in ISF or elevated 
in ISF indicating it may offer additional value compared to blood for detection of certain 
metabolites. Several amino acids, creatinine, cartinine and betaine metabolites correlated 
well between ISF and blood, indicating that ISF can reliably detect biomarkers with similar 
accuracy as in blood. 
To evaluate the performance of MNs in-vivo in human volunteers, we first optimized the 
MN system to reliably sample multiple microliters of clear ISF from the forearm. A 
metabolomics analysis of ISF vs. blood from 20 participants revealed that almost 2/3rd of the 
features found were common between all fluids. Similar to the previous study, several 
important clinical markers were detected in ISF and plasma, which indicated the possible 
utility of this method for detection of these markers in the clinic. Many clinically relevant 
metabolites were found uniquely in ISF compared to plasma. This indicated that MNs could 
be used to research metabolic processes and dermatological markers that are otherwise 
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difficult or impossible to find in blood. The concentration of biomarkers in ISF correlated 
well with the concentration in blood in dynamic situations suggesting that the MN system 
can capture variations in biomarker concentrations over time with similar accuracy as blood. 
The MN treatment was generally well tolerated, with the pain not significantly different from 
pain of venipuncture or fingerstick. Mild erythema was observed at the site of MN treatment 
that resolved within a few days.  
This MN-based technique is a significant improvement over other ISF sampling techniques 
because of its minimally-invasive nature and ease of use. We believe that this MN system 
can become a platform technology that can be used by researchers and clinicians to access 
ISF for diagnostic purposes in the future. Initially, this technique may be limited to research 
on ISF and the biomarkers or metabolic processes within ISF. Eventually, we hope that this 
technology gets translated into clinical use to sample ISF in a simple reliable manner and use 








1 CHAPTER 1. INTRODUCTION 
Detection of biomarkers in various body fluids is essential for effective diagnosis, 
monitoring, and treatment of diseases. Common body fluids used for detection are blood, 
urine, saliva, and sweat. However, another major body fluid and a source of valuable 
markers, the ISF, is largely unexplored in major part due to lack of simple, reliable 
techniques to sample this fluid. MNs are a promising device to sample this fluid as they 
can access the ISF through skin in a minimally-invasive and simple manner. Our goal is to 
develop a MN based system to sample clinically relevant volumes of ISF (1-10 µL) through 
skin within a practical time frame of 20 min. By showing clinical utility of this device and 
establishing the value of ISF as a source of valuable biomarkers, we hope to develop this 






2 CHAPTER 2. BACKGROUND 
 Diagnosis and monitoring of disease 
Detection and regular monitoring of disease states is essential to prevention, diagnosis, 
prognosis, and treatment of the disease. Detection of various physiological and molecular 
markers in the body, also called biomarkers, are key elements for diagnosis [1] [2]. WHO 
has stated that a true definition of biomarkers includes “almost any measurement reflecting 
an interaction between a biological system and a potential hazard, which may be chemical, 
physical, or biological. The measured response may be functional and physiological, 
biochemical at the cellular level, or a molecular interaction” [3].  
Several biomarkers are currently validated for monitoring the onset, progression and 
treatment of many diseases. The discovery of new biomarkers and methods to detect these 
has changed the landscape for how various conditions are diagnosed and monitored. Early 
disease diagnosis has great potential to reduce the rising healthcare costs [4-6]. Infectious 
diseases such as tuberculosis, malaria, dengue can be diagnosed easily with a blood test, 
ensuring timely treatment. Regular monitoring in chronic diseases is key to their effective 
management [7, 8].  
Diabetics test their blood sugar multiple times a day, patients with high cholesterol have 
their cholesterol and blood pressure tested regularly and those on blood thinning medicines 
have their clotting time routinely monitored. There is growing research interest in 
identifying novel biomarkers that help in diagnosing disease, predicting therapeutic 




has evolved over the years from simple physiological characteristics such as blood pressure 
or heart rate, laboratory blood tests such as blood glucose, complete blood count to now 
cutting-edge predictive DNA microarray [11, 12], personalized testing such as 
mammaPrint for predicting breast cancer recurrence [13, 14], and monitoring local drug 
concentrations to determine drug bioavailability and pharmacokinetics [15].  
2.1.1  Source of biochemical biomarkers 
Molecular biomarkers are detected most commonly in body fluids such as blood [16], urine 
[17, 18] sweat [19], or saliva [20, 21]. Blood is the gold standard for most diagnostic tests 
because it is systemic and has well established protocols for sampling in the clinic. The 
ability to draw blood by fingersticks has further enabled the acceptance of blood for 
diagnostics in the clinic and the emergence of new point-of-care diagnostics [22]. 
Fingersticks are routinely done by the patients themselves to collect capillary blood. 
Common fingerstick tests that can be done at home include glucose testing for diabetics, 
cholesterol testing for people with high cholesterol, prothrombin testing or patients on 
drug-thinning medicines. Although blood tests are commonplace, the inability to draw 
blood by the patients themselves, the clinical expertise required, and the pain and 
apprehension felt by patients, limits the use of blood tests. The blood volume with capillary 
fingersticks is small and variable and there is possibility of contamination with ISF and 





Urine, sweat, and saliva are more easily accessible for sampling and hence have generated 
more interest in diagnosis. Urine-based tests are routinely used for determination of 
ovulation, pregnancy, or menopause by measuring the concentrations of specific hormones 
present in the urine [25, 26]. However, circadian rhythm and water intake can have a 
significant effect on the concentration of biomarkers in urine, thus impacting the accuracy 
of the tests [27, 28].  
Saliva is a source of biochemical information available in a minimally-invasive manner. 
Monitoring saliva is useful for determination of drug concentrations and biomarkers of 
diseases of the oral cavity and GI tract [29]. Saliva-based HIV [30] tests are also now 
regularly used in the field. However, there are many elements that can interfere with the 
accuracy of saliva-based assays such as presence of different food substances in the mouth.  
There has been a significant increase in sweat analysis in recent years due to its potential 
for non-invasive monitoring of fluid, hydration, and electrolyte loss by elite athletes [31]. 
Diagnosis of cystic fibrosis is made by determination of chloride levels in sweat [32]. 
Current methods to sample sweat require techniques such as pilocarpine induced sweat 
collection and are not optimized for at-home detection. Also, since sweat, and saliva have 
limited fluid volumes, the biomarkers found in these body fluids is limited. 
2.1.2 Recent trends in diagnostics 
A recent trend dominating diagnostics is the emergence of point-of-care technologies.  
Decentralization of healthcare is an intrinsically powerful concept that can lay the 




Decentralization mainly involves movement of acute services from centralized institutes 
such as hospitals and clinics to home. Aging population, huge discrepancy between 
healthcare in the developing and the developed world and the increasing burden of 
healthcare costs on the economy make this shift welcome and essential.  
The emergence of point-of-care devices marks this quiet revolution happening in the 
healthcare industry. Point-of-care diagnostics enables rapid diagnosis, early detection and 
management of a variety of conditions and diseases under various settings, such as at home, 
in an ambulance, in a clinic or out on the field [33]. The glucose self-monitoring system 
and the home pregnancy test kits are textbook examples of high impact point-of-care 
diagnostic systems that have revolutionized management of diabetes and onset of 
pregnancy. The global point-of-care diagnostics market was valued at $13.8 billion in 2011 
[34] and is estimated to grow rapidly. It has huge implications in global health where such 
devices can play important role in detection of infectious diseases, STDs, malnutrition in 
low-resource settings, provide critical surveillance data and help manage long-term health 
strategies [35]. Portable blood chemistry analyzers, triage for cardiovascular markers, 
continuous glucose monitors have been commercialized and well accepted in developed 
countries [1, 2, 33, 36, 37]. 
A subset of point-of-care diagnostics marker is smart wearable devices. Smart wearable 
systems market shows big potential and profit [38-40].  There are countless variations of 
these systems in the form of sensors, smart fabrics, wireless communicators, cellphone 
apps, etc. This includes physical as well as chemical sensing. Monitoring physical 




established through devices such as wrist bands, chest electrodes, and cellphones [41]. 
However, for complete information about the overall health of a user, it is critical to 
monitor essential biomarkers along with physical parameters. These biomarkers include 
electrolytes, glucose, dissolved gases, heavy metals, environmental pollutants, etc. The 
most common currently used wearable chemical sensors include continuous glucose 
monitors. These sensors need to be inserted and removed from the body on a weekly basis.  
There are several limitations in monitoring chemicals within the body. Chemical sensors 
are usually bulky, making them unviable to be adapted towards wearable technology. 
Implantable chemical sensors require surgery to insert and remove. A majority of wearable 
chemical sensors like the continuous glucose monitors needs frequent calibration. Their 
response may not be stable over time requiring frequent sensor change. Current chemical 
sensor designs do not lend themselves well to multiple analytes being tracked 
simultaneously to get comprehensive data on the wearer and surroundings. Thus, there is a 
growing demand to develop multifunctional wearable devices that can monitor analytes 
continuously with a low turnaround time and communicate the data effectively to the 
user/healthcare practitioner [42]. Towards that end, devices under development like the 
Biostamp involve a thin skin-like sensor that has the capability to monitor multiple analytes 
and physiological parameters simultaneously [19]. There are numerous challenges towards 
development of fully-integrated chemical sensors such as sensor stability, portable power 
sources as well as data integration and privacy. Development of such devices will require 
collaborative efforts between researchers, engineers, and physicians and will enable users 




 Interstitial fluid  
ISF bathes and surrounds the cells and tissues of the body. It makes up a large fraction of 
the body – around 20-25% of body weight [43]. About 60-70% of body fluid content is 
constituted by ISF. ISF is formed as plasma traverses blood vessels and equilibrates with 
the cell and tissue environment. It provides a means of delivering materials to the cells, 
enables intercellular communication and removes metabolic waste. ISF transports nutrients 
from the blood vessels to the cells and waste products from the cells to the blood stream. 
The driving force for flow of fluid from plasma to ISF is generated by the pressure 
difference arising from hydrostatic pressure generated by blood vessels and osmotic 
pressure of ISF (Figure 2.1) [44, 45]. Water and dissolved solutes, other than large proteins, 
exit capillaries near the arteriolar end because the capillary pressure is much greater than 
that of the ISF. As the volume of the water in the capillary decreases, the pressure within 
the capillary also decreases but remains greater than ISF. 
Proteins remaining in the capillary contribute an osmotic force that tends to draw water 
back into the capillary. The combination of decreased pressure within the capillary and the 
osmotic force caused by proteins leads to the recapture of much of the water that left the 
capillary. Lymph vessels drain any excess fluid from the interstitial space. The schematic 







Figure 2.1: Schematic of flow of ISF from blood vessels to the interstitium under 
osmotic pressure and eventual uptake by the lymphatic system. 
The endothelium of capillaries separates plasma from ISF. Red blood cells, large plasma 
proteins and platelets cannot pass through this endothelium. However, most hydrophilic 
small molecules freely equilibrate between plasma and ISF, for example electrolytes such 
as sodium, chloride and small molecules such as glucose and uric acid. Thus, the 
composition of ISF is similar to plasma without the plasma proteins. In addition, the ISF 
contains metabolites generated from local cell processes and other cellular components 
such as nucleosides and lipids.  This constitutes mainly amino acids, sugars, salts, fatty 
acids, coenzymes, hormones, neurotransmitters, waste products from cells as well as cell 
debris resulting from cell necrosis [47-49].  
ISF is an attractive body fluid to screen for biomarkers. Previous studies have shown that 
it contains various biomarkers that are uniquely found in ISF and also many that are 
elevated in the ISF compared to plasma [50, 51]. These include systemic as well as local 
biomarkers. Unlike plasma that acts at a systemic level, ISF operates at a local level. Cell 
necrosis or cell apoptosis lead to formation of cell debris which releases unique biomarkers 




Biomarkers related to tumors are found in tumor ISF [52-54]. Similarly, bronchoalveolar 
lavage fluid [55, 56] and cerebrospinal fluid [57-59] contain important local biomarkers. 
Drug concentrations in the skin are monitored by measuring the concentrations of these 
drugs in the skin ISF [60, 61]. 
ISF does not clot and is hence useful for continuous monitoring of biomarkers unlike blood 
that requires discrete measurements [62, 63]. Continuous monitoring of glucose in ISF in 
the subcutaneous space is widespread with commercial devices by Dexcom, Abbott, and 
Medtronic [64-66]. There is growing interest in other non-invasive means to monitor 
glucose [67].  
Proteins in plasma are present in wide dynamic concentrations from very high levels for 
albumin to very low levels for regulatory proteins/hormones. Since disease-specific bio-
markers are typically present at low concentrations, they are consequently masked by the 
high abundant proteins and can remain undetected. Depletion of high-abundance proteins 
from the serum is challenging as it causes some of the low-abundance proteins to be lost 
due to non-specific binding. Even after depletion, low-abundance protein concentrations 
are about 2-3 orders of magnitude lower than high-abundance proteins. ISF has much lower 
concentrations (about an order of magnitude) of high-abundance proteins like albumin and 
globulin [68]. Thus, biomarkers which cannot be detected in plasma may be detected in 
ISF. 




The skin is the largest and most accessible organ of the body and that makes it attractive 
for minimally-invasive sampling techniques. It acts as a protective shield, regulates body 
temperature, functions as a sensory organ, and prevents loss of water from the body or 
entry of pathogens into the body and stores water and fat [69]  
2.3.1 Skin anatomy  
Although, skin characteristics vary throughout the body, skin is essentially constituted of 
three layers – the epidermis, the dermis and the subcutaneous fat layer.  
The stratum corneum is outermost layer of the epidermis. It ranges in thickness from 8-20 
um. It is made of 10-30 layers of flat dead corneocytes arranged in a brick and mortar type 
of model tightly joined by lipidic intercellular glue. Although it is a dead tissue, it plays an 
important role in skin physiology. It is responsible for the barrier properties of skin against 
loss of body fluids and penetration of chemicals into the body [70, 71].  
The viable epidermis lies below the stratum corneum. It consists of ten layers of randomly 
oriented living cells like keratinocytes and basal cells. It is devoid of blood vessels. The 
thickness of viable epidermis typically is 50-100 μm. The most important role of the viable 
epidermis is to renew the stratum corneum. It does this by continuous division and 
keratinization of keratinocytes in the upper layers of the viable epidermis. The deeper 
layers of epidermis provide cells that mature and form new stratum corneum. The total 
turnover time is about 15 days. Besides, the epidermis also provides an immune barrier, 




The epidermis is separated from the dermis by a basement membrane. The dermis is the 
thickest layer of skin with thickness ranging from 1-2 mm. The backbone of the dermis is 
an interconnected network of collagen and elastin fibers. This network is embedded in an 
interstitial ground substance made of nonfibrillar collagen, proteoglycans and 
glycoproteins. The hygroscopic nature of glycoproteins attracts water which makes up 
almost 70% of dermis volume. The dermis contains nerve endings, lymphatics, vasculature, 
hair follicles, sebaceous glands and sweat glands. The dermis can be separated into two 
layers – the papillary and adventitial dermis (20-100 um) and the reticular dermis (over 
500 um). The papillary dermis plays a role in immune response, provides nutrition to the 
epidermis and plays an important role in inflammatory response. The reticular dermis plays 
a mechanical role, holding the structure of the tissue in place protecting against mechanical 
aggressions [71].  
The subcutaneous tissue lies between the dermis and underlying muscle. It consists of 
interstitial tissue and adipose tissue. The thickness of the subcutis depends on body sites 
and varies between individuals. The interstitial tissue is similar to dermis with more fluid 
content. The adipose tissue constitutes a major component of body fat mass. The subcutis 
preserves body heat and prevents injury by acting as a shock absorber [71, 72].  
2.3.2 Current methods sampling interstitial fluid via skin 
The barriers of stratum corneum and viable epidermis prevent easy access to the underlying 




ISF through the skin. These include suction blisters, suction effusion, 
microdialysis/microperfusion, reverse iontophoresis and use of ultrasound.  
2.3.2.1 Suction Blister method:  
Suction blisters are a widely used technique to sample ISF from skin. Negative pressure is 
applied to the skin for up to 2 hours sometimes at elevated temperatures of up to 400C. This 
causes the dermis and epidermis to separate. Dermal ISF is drawn into this gap by suction, 
forming a blister. The ISF in the blister can be sampled with a conventional needle and 
syringe [73].  This technique has been used widely in literature to study wound healing 
properties of the epidermis [74, 75], to study diseased skin [76] and also for treatment of 
skin diseases such as psoriasis and vitiligo [77]. Major drawback of this method is the 
requirement for specialized equipment for generating vacuum over long periods of time, 
trained personnel to perform the procedure, and injury at the site of treatment that can take 
weeks to heal. There are various risks involved in the procedure such as increased chances 
of infection, bleeding. There is also the possibility of a discoloration left at the skin site 
where the suction blister was applied. All these factors make suction blisters unattractive 
as a clinical method to sample ISF. It however remains the only technique to sample a large 
volume of ISF (e.g., > 10 µL) from skin.   
Suction effusion: This method involves tape stripping a small part of the skin to remove 
the stratum corneum followed by application of negative pressure. The absence of stratum 
corneum allows ISF to come up to the surface [78]. However, similar to suction blister 




There is discomfort associated with tape stripping as well as application of suction for 
prolonged times that may lead to skin damage.  
2.3.2.2 Microdialysis and microperfusion 
Microdialysis is a sampling technique that is used for continuous measurement of free, 
unbound analyte concentrations in the extracellular fluid of virtually any tissue. For the 
skin, this involves implantation of a probe with a semipermeable hollow fiber into skin. A 
physiological solution also known as the perfusate, is flown through the probe at very low 
flow rates (0.5-5 µL/min). Because of the concentration gradient, solutes passively diffuse 
into the tube and equilibrate with the perfusate. The perfusate at the outlet contains 
components of ISF [79]. This is a useful technique to measure concentration of low 
molecular weight analytes without interference from proteins owing to the semi-permeable 
membrane. Microdialysis has been used for continuous monitoring of analytes like glucose, 
various metabolites in tissues such as the brain, skin and subcutaneous space [80-82]. 
Microdialysis is routinely used to gather information about local drug concentrations in 
skin. However, it is unsuitable for measurement of proteins because of MN cut off and low 
rates of diffusion. Frequent calibrations and fine-tuning is required to maintain sensitivity 
and the measured concentration is not the true concentration of the analyte in ISF.  
Open flow microperfusion requires implantation of a stainless-steel mesh instead of a 
semipermeable membrane into the skin. The direct liquid pathway between the probe’s 
perfusate and the surrounding ISF provides a diluted but otherwise unchanged ISF sample, 




on the molecular weight of analytes that can be sampled using this method. This results in 
a complete representation of the ISF for relative and absolute quantification in the target 
tissue [83]. This technique has been used to monitor drug concentrations in skin and 
evaluate its bioavailability as well as pharmacokinetics [84, 85].  
2.3.2.3 Reverse Iontophoresis 
A small electric current applied across the skin can be used to non-invasively extract small 
analytes such as glucose and electrolytes. The skin is negatively charged at physiological 
pH, and acts therefore as a permeselective membrane to cations. This preferential passage 
of counterions induces an electroosmotic solvent flow that carries neutral molecules in the 
anode-to-cathode direction. The flux of analytes across the skin depends on charge applied, 
permeability of the analyte and concentration of the analyte. The non-invasive nature of 
this technique makes it an attractive candidate for potential point-of-care applications[86, 
87]. Glucowatch is one such device that measures glucose concentration in ISF of the skin 
by electro-osmosis that results from reverse iontophoresis [88]. However, since this is an 
indirect measurement of concentration that is influenced by a variety of parameters, 
frequent calibration is required to maintain the accuracy of this device [89]. Continuous 
wear and application of current across the skin sometimes resulted in skin irritation. Hence, 
the device eventually turned commercially unviable. 
2.3.2.4 Low frequency ultrasound 
Low frequency ultrasound (frequency in the range 1–3 MHz, and intensity <0–2 W/cm2) 




of stratum corneum. This can thus be exploited to sample dermal analytes in a non-invasive 
manner [90].  
Use of implantable sensor: Implantation of a small, wearable sensor inside the body is 
commonly used for detection of analyte concentrations in the subcutaneous space. Such 
sensors are commonly used to monitor the glucose levels in the body continuously. The 
sensor inserted into the subcutaneous space detects the concentration of glucose in the 
subcutaneous space [91].  
The techniques mentioned above have limitations and so far, have been unsuccessful in 
being widely adopted for minimally-invasive, cost-effective diagnostic technologies. Thus, 
there is a need to develop a simple, reliable and low-cost method to sample ISF through 
skin. 
2.3.3 Metabolomics of interstitial fluid 
The field of metabolomics is a key discipline in the study of the metabolism of living 
organisms in a wide range of conditions, including health and disease. Metabolites are the 
downstream products of cellular function and represent a sensitive measure of the actions 
of upstream molecular species such as genes, transcripts, and enzymes, including the 
effects of disease, drugs, toxicity, and the environment. Hence, identification and 
quantitative analysis of metabolites in humans and animal and cell models of numerous 
human diseases offer avenues for understanding, diagnosing, and managing human 
diseases; assessing disease risk factors associated with drugs, toxins, and the environment; 




Metabolomic analysis of body fluids has seen considerable research interest due to the 
development of highly sensitive, high throughput techniques such as mass spectrometry 
[93]. Mass spectrometry is a powerful analytical technique that can detect analytes in the 
picomolar to attomolar range. This can be used to identify and analyze hundreds of 
compounds in a single sample. Mass spectrometry measures the mass-to-charge ratio (m/z) 
of ions to identify and quantify molecules in simple and complex mixtures. Mass 
spectrometry is widely used tool in research to identify biomarkers, study drug mechanisms 
[94].  
Since ISF contacts tissue, it transports analytes of various metabolic processes between 
cells and blood vessels. Thus, metabolomics of ISF presents a useful tool to study different 
metabolic processes and identify new biomarkers that are not otherwise found in blood, 
urine or saliva [50, 51, 54, 95, 96] 
 Microneedles for biosensing 
2.4.1 Introduction to microneedles 
MNs are microscopic needles with length varying from 100-1500 µm. Several MNs are 
typically incorporated onto a single backing layer to form a MN patch [97]. They are 
around 50-500 µm at base and taper to a sharp tip with tip radius of less than 1 µm up to 
about 20 µm. They are sharp enough to penetrate through the stratum corneum, creating 
micropores into the underlying epidermis and dermis. These micropores can be used to 
either deliver therapeutics into the skin or to sample fluid/tissue from skin. MN patches 




inexpensive, pain-free and absent of sharps waste make MNs an attractive option in a point 
of care setting.  
There are three basic types of MNs: solid MNs, hollow MNs and dissolving MNs. A 
schematic of the different types of MNs and the different approaches for drug delivery are 
shown below in Figure 2.2. Solid MNs are made from materials such as stainless steel, 
glass, various polymers. They penetrate skin and leave micron sized holes on the skin. This 
increases permeability of skin to a drug. The drug can then be delivered using a transdermal 
patch [98]. Alternately the drug is coated on to the surface of the MNs and the drug load 
can be delivered as the MNs are inserted and the coating dissolves off [99]. Hollow MNs 
are usually made from metal and have a hollow bore in the center similar to a conventional 
hypodermic needle. This allows infusion of a larger quantity of drug into the skin [100, 
101]. Dissolving MNs are made from water-soluble polymers. The drug of interest is 
incorporated into the MNs. The needles dissolve upon contact with ISF in the skin and 
incorporated drug is released [102] 
MN insertion into skin is considered generally painless. It causes minimal trauma to the 
patient. Also, use of MNs minimizes chances of any adverse skin effects such as erythema. 






Figure 2.2: Four different types of MN patches. (A) MN patches upon initial insertion 
into skin. (B) Drug being delivered across the stratum corneum into the dermis and 
epidermis. Reproduced from [97] 
2.4.2  Microneedles for sampling interstitial fluid 
Research in MN array devices has progressed rapidly after microfabrication techniques 
made fabrication of MNs feasible in the 1990s. Although most research has focused on 
drug delivery applications, use of MN technology as a diagnostic tool via extraction of 
bodily fluids such as ISF and blood has received significant interest in recent years [105-
107]. Since MNs can reach beyond the barriers of stratum corneum and viable epidermis, 
they can access the dermal ISF. This can enable minimally-invasive sampling of dermal 
ISF. MNs can be easily adapted to point-of-care devices and especially to wearable 
systems. MN patches can be worn as a patch/band aid and they conform well to the skin. 
They are lightweight making them portable and making them ideal for wear long term.  
Use of MNs for diagnostics offers significant advantages over conventional techniques. 




can obtain continuous or time-averaged measurements of biomarkers. Unlike traditional 
transdermal patches, MNs have access to a deeper body fluid source that reduces the 
chances of contamination occurring from environmental agents. Thus, the system can be 
more robust and accurate. Measurement of biomarkers in ISF is expected to be more 
accurate than using body fluids such as saliva, sweat or urine where concentration of 
biomarkers is dependent on degree of hydration, time of day, etc. Since ISF flows from the 
dermis into the MNs, contaminants on the skin surface may not interfere with ISF 
composition giving improved sensitivity and accuracy.  
There are two main approaches to using MNs for diagnostics. The first approach is to have 
MNs/micropores as conduits to take a sample of ISF out of the body. The fluid is then 
analyzed for biomarkers. Sampling ISF typically yields larger volumes of ISF. This can be 
used for higher-order analysis of ISF like advanced testing on equipment that cannot be 
miniaturized. The other approach is to integrate a biosensor on the MN. This facilitates in-
situ detection of biomarkers making it more suited for point-of-care. But the approach can 
only be used to detect a few specific biomarkers at a time using custom-designed assays.  
2.4.3 Review of previous research-Microneedles for biosensing 
MNs give access to ISF as they reach beyond the stratum corneum and the viable epidermis 
into the dermis. MNs themselves can only create pathways into the skin and other 
mechanisms need to be employed to extract ISF. This can be done in a variety of ways by 
using diffusion, hollow MNs that utilize capillary action, hydrogel MNs that swell and 




sample ISF started with a hollow MN to draw ISF through the bore utilizing capillary action 
or suction. Recently other approaches such as solid MNs with application of suction and 
hydrogel needles that swell up on contact with ISF are being explored for sampling ISF. 
The various approaches used to adapt MNs for biosensing applications are described 
below. 
2.4.3.1 Approaches based on hollow microneedle designs 
One of the approaches has been to design MNs to mimic blood-extraction action of a 
mosquito. Kobayashi [108] and Suzuki [109] described hollow MNs with a phase transition 
gel as an actuator. This setup was later adapted for continuous monitoring for an extended 
time period (10 h) by changing the gel characteristics [110]. They demonstrated proof-of-
principle that glucose concentrations in a buffer solution could be measured continuously 
over time. Gattiker et al. described a similar system to extract ISF with microelectronics to 
allow in-situ detection of glucose [111]. Tsuchiya et al. also developed a MN device 
mimicking a mosquito with a piezoelectric actuator to extract blood via skin [112]. They 
showed extensive modelling to validate the feasibility of this approach [113, 114]. 
However, challenges in system integration, miniaturization and batch manufacturing 
render practical implementation of this design difficult.  
Hollow MNs with capillary action: Mukhererjee et al. described a hollow MN patch with 
a 20x20 array of 250-350 µm long MNs. Deep Reactive Ion Etching was used to etch 
needles in a silicon substrate. ISF entered these needles via capillary forces and was 
subsequently drained into a reservoir which was connected to the needles via micro-




ISF and blood. The design was also tested on one human earlobe. Glucose was detected on 
a colorimetric test paper after 15-20 min of extraction. However, no quantitative results 
were shown [115, 116]. Ebah et al. [117] extracted ISF from edematous patients. They 
observed that extraction of ISF was successful in subjects with increased ISF.  
MNs with electrochemistry: Miller et al. [118] developed MNs that integrated carbon fibers 
within the MN bore for detection of hydrogen peroxide and ascorbic acid. They later 
modified the design to fill the MN bore space with an enzyme functionalized carbon paste. 
This makes the design of MNs more robust. Also, easy regeneration capacity of carbon 
paste electrodes facilitates re-use of the MN array. The device successfully detected 
hydrogen peroxide and lactate concentrations in vitro [119]. Miller et al. [120] also 
developed a multiplexed MN sensor that could simultaneously detect pH, lactate and 
glucose in one device framework. The device showed suitable performance in vitro for 
physiologically relevant concentration ranges. A hollow MN device with solid state ion 
sensitive electrodes was also developed to detect concentration of K+ ions. The on-chip 
response of the electrodes to physiological concentrations of K+ was determined [121]. 
Keum et al. [122] attached a MN sensor onto an endomicroscope for detection of nitric 
oxide during endomicroscopy. The polymer MNs were coated with PEDOT and 
functionalized with hemin that has high binding capacity towards nitric oxide. The MN 
system showed excellent sensitivity towards nitric oxide. The nitric oxide levels detected 
were twice as high in melanoma tissues compared to control. The sensor was also tested in 
vivo for mice with melanoma. The device could detect micromolar concentrations of nitric 




of simultaneously detecting multiple analytes in physiologically relevant tissue 
environments was developed [120].  
2.4.3.2 Use of suction 
Wang et al. [123] used glass MNs that were used to make micropores into skin. Suction 
(200-500 mmHg) was applied for 2-10 min. Droplets of ISF, typically 1-10 µL, were drawn 
to the skin surface of skin in sedated rats and awake humans. Glucose concentration in the 
extracted ISF and plasma were shown to correlate well. The lag time between change in 
glucose concentration in plasma and ISF was observed to be around 10 min. Li et al. [124] 
described a single 1800 um long hollow MN system connected to a syringe that applies 
negative pressure on the system. The device could extract blood from the tail of a mouse 
at the rate of 0.8 uL/s on application of 100 mmHg negative pressure. However, repeated 
MN deformation was observed due to the high aspect ratio of the system. Recently Seventh 
Sense Biosystems, Inc. has developed a MN-based blood-sampling device that enables 
blood to be drawn through a virtually painless, one step process [125, 126]. 
2.4.3.3 Microneedles with in-built sensing 
MNs with in-built glucose sensors: Zimmerman et al. [127, 128] first developed a MN 
patch with a glucose sensor built into the device. The MNs were 250 um long. ISF is 
extracted through the MN bore by capillary action and is pumped towards a miniature 
glucose sensor. The device showed a linear response to glucose concentration in the 
working range. However, the device response was seen to vary with flow rate which was 
not constant in vivo by capillary action alone. Chua et al. [129] and Jina et al. [130] describe 




continuous glucose monitoring. Glucose transport happened by passive diffusion through 
the MN bore which opens up into a central sensing chamber which is located outside the 
body. It was tested on 10 human subjects. Of a total 1396 paired points obtained, 75% were 
in region A of the Clarke Error Grid. The device was being commercialized as part of 
system under development by ArKal Medical, Inc. However low accuracy of the device 
over time rendered the venture commercially unviable. Invernale et al. [131] described a 
solid MN array coated with a conducting polymer PEDOT on which glucose oxidase was 
immobilized. This enabled faster response to changes in glucose concentration and the 
sensors showed a linear response over physiological glucose range. Various innovations 
are coming forward in this research area - such as a self-powered biofuel cell-based glucose 
sensor[132] and glucose responsive insulin delivery where the detection and delivery 
mechanisms are both integrated into a single patch system[133]. 
Corrie et al. [134] developed a MN array where the MNs were coated with a layer of 
capture protein. When inserted into the ear of a mouse immunized with flu vaccine, the 
capture protein on the MNs bound to the antibodies in the mouse plasma and ISF. This 
binding was quantified and found to be significantly different from control. Similar 
experiments were done by Muller et al. [135] by coating the MNs with NS1 and IgG 
specific capture proteins. The levels of NS1 in skin were measured by using the MNs and 
compared against blood and they appear to correlate well. This demonstrates the feasibility 
of this approach. However, there are limitations on the number of analytes that can be 
measured at a time and also the variety of analytes for which this technique can be 




array by measuring concentrations of pfHRP2 protein from the skin of live mice along with 
NS1 as a negative control and IgG as a positive control, making the device more robust. 
2.4.3.4 Hydrogel based microneedle systems 
MNs with external glucose detection: Sato et al. [137]developed a MN treatment system 
to measure interstitial glucose AUC. A study was carried out on 30 healthy human 
volunteers. The skin site was pre-treated with solid MNs to make micropores and a 
hydrogel patch with an osmolyte was placed on the pretreated site for ISF extraction. Blood 
glucose and interstitial glucose curves over 3h were well correlated. Further studies were 
done to compare glucose response in patients with and without diabetes[138]. The AUC in 
subjects with and without diabetes also correlated well with a lag time of ~10 min. This 
study demonstrated the feasibility of using MN patches for continuous glucose monitoring. 
Hydrogel MNs: Donnelly et al. [139-141] developed hydrogel MNs that penetrate through 
skin in dry state. Upon insertion, they swell on interacting with ISF of the skin. Caffarel-
Salvador et al. [142] inserted MN patches in human subjects and correlated caffeine and 
glucose intake by the subjects over time to caffeine and glucose levels in the patch. 
However, the lag times in glucose detection in blood and in skin via MNs was as high as 3 
hours. Also, the amount of caffeine and glucose detected in the patch over 1h was 2-3 
orders of magnitude lower than the amount detected in 15 uL of blood which demonstrates 
the extremely low flow rates of ISF extraction into hydrogels. The low volumes of ISF 
absorbed create challenges in effectively analyzing fluid for a range of biomarkers. 
Romanyuk et al. [143] developed a method to effectively collect the ISF absorbed by 




cellulose (CMC) were shown to swell up on contact with hydrated rat skin in a Franz cell 
setup. The swelling up of CMC is presumably due to osmotic forces [144]. Chang et al. 
[145] showed that a MN patch made from a highly swellable hydrogel material was able 
to sample up to 3 µL from rats in 30 min. They showed that they could capture variations 
in glucose concentration and monitor glucose levels in the ISF and in the blood post-meal 
and post-insulin. Similarly, they were also able to show a strong correlation between 
cholesterol levels in blood and in ISF.  
2.4.3.5 Microneedles with microdialysis functionality 
Microdialysis MNs: Zahn et al. [146-148] developed a microdialysis MN that was 
selectively permeable to small molecular weight analytes such as glucose while excluding 
large molecular weight proteins. This increased the sensitivity and accuracy of detection. 
The MN was a hollow MN covered by a microdialysis membrane. The dialysis perfusate 
was flown within the MN bore which enabled diffusion of glucose into the bore due to 
concentration gradient.  
2.4.4 Impact and possible applications 
The goal of this study is to design a MN-based system that can sample ISF through skin in 
a minimally-invasive, reliable, and reproducible manner. Although ISF is a major body 
fluid, its use in research and clinic is limited because of a general lack of simple methods 
to sample this fluid. The development of a reliable and simple MN-based method could 
enable exploratory research on novel biomarkers within ISF. This could include exploring 




fluids. This could lead to discovery of unique metabolites, metabolite pathways in ISF and 
in the skin. Eventually this could lead to clinical utilization of ISF for diagnostics as certain 
analytes that are unique to or elevated in ISF are preferentially sampled in the ISF instead 
of blood. 
Development of such a method has potential for a large impact on clinical medical 
diagnostics. This includes continuous monitoring of analytes in the body. MNs can be worn 
on the body for longer periods of time. They are also easily portable, making them ideal to 
be worn on the skin surface. Another critical application for such MN-based devices is 
lifestyle monitoring. Such devices can monitor biomarkers for everyday fitness, stress, 
physical activity or exercise/ overtraining. Cortisol and testosterone are markers for stress 
[149]. Lactate, creatine phosphor kinase, creatinine, ammonia, urea, uric acid give valuable 
information about quality of exercise or any overtraining/muscle fatigue that can occur 
during exercise [62, 150]. Such devices can be valuable for elite athletes, mountaineers and 
people with high stress jobs such as surgeons and military. 
Chronic conditions such as diabetes, cardiovascular diseases, chronic conditions, obesity 
have introduced a large healthcare burden on economy especially in the developed 
world[151]. Continuous glucose monitoring for patients with type I/II diabetes has been 
receiving widespread attention. Various biomarkers are under review for understanding of 
Chronic kidney disease[152],  monitoring of cardiovascular diseases[153], cardiometabolic 
diseases [154]. Having a portable MN patch that can be used for monitoring the progression 
of these diseases by patients at home can be hugely beneficial for effective management 




especially useful to monitor levels of biomarkers that vary daily e.g. monitoring ovulation 
patterns in women, daily cortisol levels for stress management, monitoring drug levels in 
a patient undergoing treatment. Taking frequent blood draws from infants or children can 
be difficult. MN-based devices could be a suitable substitute especially for newborns where 
continuous monitoring of critical analytes is needed. 
It is also possible to get time-averaged readings of biomarkers by keeping the patch on for 
a longer period. In addition to regular health monitoring for known conditions and their 
treatment progression, such patches can also be used for preventive care. People with high 
cholesterol or blood pressure who are at risk for cardiac arrest can have their troponin levels 
monitored. A sudden increase in troponin levels can indicate heart failure. Similarly, such 
devices can be used for detecting and preventing stroke for people at high risk or fits in 
patients with multiple sclerosis. 
MN patches can lend themselves well to over-the-counter patches to screen for various 
conditions/diseases. These tests can vary widely from screening for HIV/AIDS, STDs to 
looking at individual nutritional status or any nutritional deficiencies such as 
vitamin/micronutrient deficiency [155, 156]. They can also extend to looking at exposure 
to environmental pollutants [157] by measuring concentrations of these agents that may 
have accumulated in ISF over time. These devices can be used by people at home and can 
enable them to get better control over their health and health choices.  
The cost and convenience of MN patches lends themselves well to their use in the field in 




workers to monitor for infectious diseases like malaria, HIV, tuberculosis. They can also 
be used for screening large populations for various conditions such as nutritional 
deficiencies.  
There is an unmet need for development of a simple, reliable, low-cost device and method 
to sample useful volumes of ISF. This technology can have tremendous impact on research 
within drug development, diagnostics, as well as understanding cellular processes. This 
device can be used in the clinic to routinely monitor biomarker levels and can serve as an 






3 CHAPTER 3. SPECIFIC AIMS 
Specific Aim 1: Evaluate mechanisms of sampling ISF by MNs through experimental 
studies and theoretical modeling of transport of ISF transport in skin. 
Specific aim 2: Determine the composition of human suction blister ISF using high-
resolution mass spectrometry. 
Specific aim 3: Develop a MN system to sample ISF in human participants and identify 





4 CHAPTER 4. EVALUATE MECHANISMS OF SAMPLING INTERSTITIAL 
FLUID BY MICRONEEDLES THROUGH EXPERIMENTAL STUDIES AND 
THEORETICAL MODELING OF TRANSPORT OF INTERSTITIAL FLUID 
TRANSPORT IN SKIN. 
 Introduction 
Diagnosis and management of disease is increasingly facilitated by measurements of 
biomarkers from blood, urine, saliva and other bodily fluids. Continuing progress in 
biomarker discovery has enabled early diagnosis, real-time monitoring and improved 
disease management [158]. Blood is the most common source of biomarkers, but is limited 
by inability of patients to draw venous blood themselves and apprehension and sample 
quality of fingerstick capillary blood [159]. Urine and saliva are constrained by their 
limited number and variable concentration of biomarkers [21, 160]. Interstitial fluid (ISF) 
is another source of valuable and unique biomarkers, but is difficult to sample from the 
body [48]. This fluid surrounds cells and tissues throughout the body and is formed by 
extravasation of plasma from capillaries and modified by metabolic and other processes in 
the tissue [46]. ISF shuttles nutrients and waste products between blood vessels and cells 
and is roughly a combination of serum and cellular materials.  
Previous studies showed that 83% of proteins found in serum are also in ISF, but 50% of 
proteins in ISF are not in serum, suggesting that ISF may be a source of unique biomarkers 
as well as biomarkers found in blood [50, 51]. Moreover, ISF may be suitable for 




indwelling sensors for glucose that access ISF in the subcutaneous space [91]. ISF is a 
better indicator of local tissue events as shown in tumor ISF collected from tissue biopsies 
[161].  
Skin is the most accessible organ and therefore an attractive source of ISF containing 
systemic and dermatological biomarkers. ISF can currently be collected from skin using 
suction blisters by applying suction to skin at elevated temperature for up to 1 h to create 
blisters filled with ISF [73]. Dermal ISF can also be sampled by implantation of tubing in 
skin to collect ISF biomarkers by microdialysis or open flow microperfusion, which require 
local anesthesia and expert training [82, 85]. The time-consuming nature of these 
procedures, risks to patients, need for medical expertise and specialized equipment limit 
their use to basic research. Collection of ISF for more widespread research and possible 
future medical applications will benefit from a simpler, minimally invasive sampling 
method. This could enable further research into the nature and composition of ISF and the 
clinical utility of ISF as a body fluid for diagnostic applications. 
We propose that microneedles (MNs) can be used to create micron-scale pathways for ISF 
transport out of skin across skin’s outer barrier layer of stratum corneum. When coupled 
with a suitable driving force, a MN patch could be used to sample ISF from skin in a simple, 
minimally invasive manner. MNs are needle-like projections typically made from metal or 
polymer that measure hundreds of microns in length and thereby penetrate upper layers of 
skin and access skin’s ISF [140, 162]. MN patches have been studied extensively for drug 




clinical trials and other studies. However, relatively little work has been done to develop 
MN patches for removal of ISF from skin.  
Most of skin’s ISF is in dermis [72], which comprises a network of collagen and elastin 
fibers surrounded by extracellular matrix that limit ISF flow due to binding and tortuosity. 
Hence, sampling ISF using MNs is a complex process involving three steps: (i) flow of ISF 
through dermis towards MNs, (ii) partition of ISF from dermis into MNs and (iii) flow of 
ISF through MNs to the skin surface. 
Most prior efforts to collect ISF using MNs have been limited by collection of small 
volumes of fluid and have emphasized demonstrations of device performance rather than 
systematic device analysis and design [106]. Generally, diagnostic tests require at least 
multiple microliters of fluid for accurate measurement of analytes [163-165]. Here, we 
used experimental and theoretical analysis to systematically evaluate ISF collection from 
skin by MN patches using transport mechanisms mediated by diffusion, capillary action, 
osmosis, and pressure-driven convection with the goal of collecting 1-10 µL of ISF within 
20 min, and then used the optimal design to sample ISF from human volunteers.  
 Results  
4.2.1  ISF content in skin 
To estimate the maximum amount of ISF that could be sampled from skin, we first 
determined that pig cadaver skin used in our studies contained 61±9 wt% fluid by fully 




only ~10% of skin volume and there are very few cells in the dermis, this figure is 
representative of the amount of fluid present in the interstitium, i.e., ISF. This value is 
similar to reported values of ~70 wt% of human dermis comprising ISF [166]. Because pig 
cadaver skin mass was 0.25±0.04 g/cm2, this corresponds to ISF content ~150 µL/cm2 of 
skin. When pig skin was subjected to a large pressure (890 kPa), ISF was lost from skin 
through dermis at ~1 wt% per minute, such that 24±6 wt% was lost after 20 min, 
corresponding to ISF loss of ~60 µL/cm2 after 20 min (Figure A. 1 in Appendix A). This 
value represents the volume of mobile ISF, i.e. fluid that is not otherwise bound and may 
provide an upper bound to the amount of ISF that could be withdrawn from skin within 20 
min ex vivo, although the situation might be different in vivo due to blood flow and other 
effects.  
4.2.2 ISF collection by diffusion into hydrogel microneedles and micropores 
One mechanism of ISF collection involves diffusion of ISF into MNs, which can be 
accomplished by inserting dry hydrogel MNs into skin. To study this mechanism of ISF 
collection, we prepared patches each containing 100 pyramidal MNs composed of cross-
linked polyvinyl alcohol (PVA) (Error! Reference source not found.). Upon insertion 
into skin, the MNs became swollen with ISF (Error! Reference source not found.b-c). 
After 12 h in skin, 0.0030 µL of ISF was absorbed per MN (0.30 µL/patch).  
We also studied diffusion through micropores (µpores) created by puncturing and then 
removing metal MNs in skin (Error! Reference source not found.). The volume of ISF 




faster ISF collection through µpores may be due to lack of transport barriers found in 
µpores.  
 
Figure 4.1: ISF collection by diffusion into hydrogel MNs and skin µpores. (a) 
Representative patch containing 10x10 array of dried hydrogel MNs made of 
polyvinyl alcohol (PVA). Magnified views of representative (b) dried hydrogel MN 
(520 µm tall) before insertion into skin, (c) hydrated hydrogel MN after swelling in 
pig skin for 12 h ex vivo and (d) two stainless steel MNs (750 µm tall) 
 
4.2.3 Collection by capillary flow through porous and hollow microneedles  
The second mechanism of ISF collection we considered involves capillaries to draw ISF 
from skin. This can be accomplished by flow through either a network of microcapillaries 
in a porous MN or a single capillary in a hollow MN.  
To study porous MNs, we prepared patches each containing five MNs made from paper, 
which were sandwiched between two stainless steel MNs of similar dimensions for 
mechanical support (Figure 4.2a). Similar paper has been characterized to have porosity of 
68% [167] and pore size of 2-10 µm [168]. Upon insertion into skin, microcapillaries in 
the porous paper matrix absorbed 0.0033 µL/MN of ISF after 20 min (Figure 4.2b,d). To 




diameter (Figure 4.2c), which collected ~0.01-0.03 µL ISF after 20 min (Figure 4.2d). The 
greater ISF collection by hollow MNs may be explained in part because the MN orifice 
surface area was greater than the exposed surface area of porous MNs sandwiched between 
metal MNs. 
 
Figure 4.2: ISF collection by capillary action through porous and single-capillary 
MNs. (a) Representative porous paper MN sandwiched between two stainless steel 
MNs for mechanical support (750 µm tall). (b) Representative porous paper MN that 
has absorbed ISF from pig skin soaked in fluorescein to facilitate ISF imaging. (c) 
Representative hollow stainless steel MN (750 µm tall) with a single hollow capillary 
to draw fluid out of skin. (d) ISF volume sampled from pig skin after 20 min: porous 
paper backing with no MNs (negative control); porous paper MNs; and hollow, 
single-capillary MNs of 33G (108 µm inner diameter (ID)), 30G (159 µm ID) and 25G 
(260 µm ID). Data show mean ± SD (n = 4) *p<0.05 
 
4.2.4 ISF collection by osmotically driven flow via micropores  
The third mechanism to sample ISF from skin uses an osmotic driving force to flow ISF 
from skin into µpores created by MNs. To generate an osmotic pressure gradient, we filled 




Lacking a permselective membrane between µpores and dermis, solutes in µpores could 
diffuse into dermis, which accelerated the decrease of osmotic pressure gradient over time.  
A 10-MN patch coated with ~20 µg of maltose per MN (Figure 4.3a) was inserted into skin 
for 2 min to allow maltose to dissolve, and were then removed. The maltose created an 
initial ionic strength of ~1.17 M in the µpore, which is much higher than surrounding ISF 
(0.29 M [71]) and corresponds to an osmotic pressure difference of 2.2 kPa. After 20 min, 
0.0056 µL of ISF was collected at the skin surface per µpore (Figure 4.3b). In contrast, 
leaving MNs in skin during the 20 min ISF collection time yielded significantly less ISF 
(0.0006 µL/µpore), probably because MNs blocked ISF transport pathways out of skin 
(Figure 4.3b).  
To better maintain an osmotic driving force over time, we punctured skin for 2 min with a 
patch containing 10 uncoated or maltose-coated MNs, and then, after removing MNs from 
skin, applied a 1.17 M solution of maltose to the skin surface, thereby initially filling 
µpores with ~1.17 M. After 20 min, treatment using uncoated or coated MNs collected 
0.024 or 0.021 µL/µpore, respectively (Figure 4.3b), which were not significantly different 
from each other, but were greater than treatment with coated MNs without adding maltose 
solution. ISF collection rate during osmotically driven transport increased steadily over the 
course of 60 min to a total volume of 0.070 µL/µpore (Figure A. 2 in Appendix A). Varying 
the number of MNs from 10 to 50 increased ISF collected in rough proportion to number 




As a control, we punctured skin with 10 uncoated MNs and then applied water to the skin 
surface, which provided no osmotic driving force. This collected 0.0039 µL ISF/µpore after 
20 min (Figure 4.3b), which was significantly less than collected with an osmotic driving 
force and similar to ISF collection during diffusion through µpores (Figure 4.2).  
To achieve still higher osmotic strength, we applied a solution of MgCl2 with 12 M osmotic 
strength to skin punctured with a 10-MN patch. This collected 0.03 µL/µpore after 20 min 
(Figure 4.3b). This order-of-magnitude increase in osmotic strength increased ISF 
collection ~2-fold. This may be explained by a faster dissipation of osmotic driving force 
due to faster diffusion of MgCl2 away from µpores compared to maltose.  
 
Figure 4.3: ISF collection by osmosis through µpores. (a) Representative MN coated 
with maltose (bar shows coated region). (b) ISF volume collected from pig skin ex vivo 
punctured with coated and uncoated MNs followed by application of aqueous 
solutions of different osmotic strength for 20 min. Data show mean ± SD (n≥4) 
*p<0.05 **p<0.01 
 




A pressure difference between the dermis and skin surface can drive ISF from dermis into 
and through µpores. This can be accomplished by suction to create negative pressure on 
the skin surface at the site of µpores or by positive pressure on the skin surface at sites 
distant from µpores (e.g., pinch the skin), thereby creating a positive pressure in skin near 
µpores (Figure A. 8 in Appendix A).  
To study effects of suction on ISF collection, we punctured skin with 10-MN patches and 
then applied -85 kPa suction for 20 min. This produced just 0.0064 µL ISF/µpore (Figure 
4.4a). We hypothesized that suction might be collapsing µpores, so we placed skin on 
curved surfaces (with ~5 mm or ~8 mm radius of curvature) to help spread µpores open. 
This increased ISF collection by two orders of magnitude to 0.30 or 0.47 µL/µpore, 
respectively (Figure 4.4a). Stretching skin with a strain of ~100% on a flat surface or a 
curved surface produced 0.84 or 0.60 µL/µpore, respectively Figure 4.4a). Altogether, 
these data show that suction withdrew by far the most ISF from skin, but the skin surface 
needed to be curved and/or stretched, apparently in order to keep µpores open.  
We next placed different kinds of absorbent paper on the skin above µpores to capture ISF 
collected during -85 kPa suction for 20 min. Compared to ISF collected without paper (0.71 
µL/µpore), placement of thin tissue paper (Kimwipe) on skin had no significant effect (0.29 
µL/µpore) (Figure 4.4b). However, placement of gauze (~680 µm thick) on skin, reduced 
ISF collected by two orders of magnitude to 0.0035 µL/µpore. We hypothesized that gauze 
inhibited ISF collection because of its thickness and poor aqueous wettability. Plasma 
treating (to increase hydrophilicity) or pre-wetting gauze significantly increased ISF 




tension played a role in ISF flow from skin to gauze. Using thinner gauze (~150 µm thick) 
collected 0.17 µL/µpore, which was significantly greater than when using thick gauze 
(Figure 4.4b). This suggests that gauze may have reduced the pressure drop within the skin 
and µpore, and that thinner gauze reduced it to a lesser extent.  
We also studied effects of other MN parameters on ISF collection during suction. Varying 
number of MNs from 5 to 10 to 50 increased ISF collected in rough proportion to number 
of MNs (Figure A. 4 in Appendix A). Increasing MN length between 250–750 µm on 10-
MN patches showed a trend of less ISF collected as MN length increased, but this was not 
statistically significant (Figure A. 5 in Appendix A). Use of patches with polymer MNs 
that tapered from a wide base (which was needed for mechanical strength of polymer MNs) 
was less effective compared to thin metal MNs used in the rest of this study (Figure A. 6 
in Appendix A), probably because polymer MNs did not insert as deep into skin [162]. 
Finally, using three different MN designs, we compared curved skin to stretched skin, and 
found they each provided similar ISF collection under the conditions used (Figure A. 7 in 
Appendix A).  
Finally, we generated positive pressure in skin by pinching to drive ISF out of the skin 
(section A1.8 in Appendix A). After applying a 10-MN patch and then administering a 
positive pressure (estimated to be 25 kPa inside skin below µpores) for 20 min, 0.16 µL 
ISF/µpore was collected (Figure 4.4c). We also found that amount of ISF collected 






Figure 4.4: ISF collection by pressure-driven convective flow through µpores. ISF 
collected from MN-punctured pig skin ex vivo after 20 min of suction (-85 kPa) (a) 
for skin under different degrees of tension and (b) for skin covered by different 
absorbent papers. (c) ISF collected from pig skin ex vivo after different durations and 
levels of suction and positive pressure applied to skin. Data show mean±SD (n≥3) * 
p<0.05 ** p<0.01 *** p<0.001 
 
4.2.6 ISF collection from the skin of human volunteers 
Guided by the above findings, we used 50-MN stainless steel patches to create µpores 
followed by suction for 20 min (Figure A. 9). This collected 2.3±2.1 µL ISF per person 
based on 17 separate ISF collections from 6 different volunteers. Determination of ISF 
volume assumed that sodium concentration in human ISF is constant at 135 mmol/L, 
although this value may vary by ~10% in healthy individuals [89]. The collected fluid was 
clear, with little or no evidence of blood. Since ISF transport occurred through µpores and 
not the entire stratum corneum, ISF appeared as droplets on the skin surface (Fig. 5c). ISF 
flow rate was not quantified as a function of time, but our observation was that ISF first 




There was spatial heterogeneity of ISF collection within each array of 50 µpores, where 
some µpores produced visible amounts of ISF and others did not. Mild erythema was 
observed at the skin site, which resolved completely within 24 h (Figure 4.5). In a few 
cases, 15-20 faint, pink, sub-millimeter spots were visible at sites where individual MNs 
had penetrated skin, and disappeared within 24 h. The erythema was of possible cosmetic 
significance, but not clinically meaningful. Volunteers generally reported little or no pain 
associated with the procedure. No adverse events were recorded, and overall the procedure 
was well tolerated.  
Collected ISF from 11 subjects was analyzed for glucose and total protein content as 
representative biomarkers. The concentration of glucose in ISF was 91±11 mg/dL and total 
protein concentration was 90±21 mg/mL (Figure A. 10a). We also collected companion 
plasma samples from the subjects from fingerstick capillary blood. The concentration of 
glucose in plasma was 100±25 mg/dL and total protein concentration was 105±26 mg/mL 
(Figure A. 10b) which is comparable to the concentrations in ISF (Student’s t-test, p>0.05). 
 
Figure 4.5: ISF collection from human volunteers by suction through µpores. 
Representative images of skin (a) immediately after suction show faint erythema and 




through 50 µpores) and (b) 24 h after ISF collection show resolution of erythema. (c) 
Representative image showing ISF droplets on skin surface after collection by suction 
through µpores.  
 
4.2.7 Theoretical model to predict ISF collection rates  
To better understand underlying mechanisms governing ISF transport through skin, MNs 
and µpores, we modeled ISF transport in the scenarios explored in this study. Our goal was 
to predict ISF collection rates in each scenario and identify rate-limiting steps to enable 
improved ISF collection. The theoretical modeling considered three steps in the transport 
process: transport through skin to the MN (or µpore) interface, transport/partitioning across 
the skin-MN interface and transport through or within MN. To provide independent 
predictions of ISF behavior in skin, theoretical predictions were based on first-principle 
models using parameter values that were measured, independently calculated or adapted 
from literature; there were no fitted parameters. Predicted values match experimentally 
observed values reasonably well, especially given the simplified theoretical analysis with 
no fitted parameters, and are often within the error bars of the data (see Section S2.6 in 
Appendix A).                                                                                                                                                                                                                                                                                                        
ISF collection by hydrogel MNs was modeled as ISF diffusion through dermis and then, 
upon partitioning into the hydrogel, diffusion through the hydrogel matrix (Section S2.1 in 
Appendix A). As ISF diffusivity in dermis is greater than in PVA hydrogel used in this 
study, diffusion of ISF through hydrogel was rate-limiting and significantly constrained 




e.g., as described by Chang et. al. [169], can increase rates of ISF uptake. However, once 
ISF diffusivity in hydrogel approaches and exceeds that in dermis, dermis becomes a rate-
limiting step and further improvements to hydrogel permeability have diminishing impact. 
Similarly, ISF collection through µpores is limited by low ISF diffusivity in dermis, so 
dermis is a rate-limiting step (Section S2.2 in Appendix A).  
ISF collection by capillary flow into porous and hollow MNs involves rapid convective 
flow within MNs, effectively making MNs a sink, which maximizes the concentration 
gradient in nearby dermis (Section S2.3 in Appendix A). The rate-limiting step is 
exclusively in dermis, which makes ISF collection faster than in the case of hydrogel MNs 
or µpores where ISF diffusivity in the MN/µpore can be fast, but is still a barrier (Figure 
A. 13). Although changes in MN design to increase capillary forces may not increase ISF 
uptake further, ISF uptake scales directly with area of MN-dermis contact. This explains 
why ISF collected by hollow MNs was greater than porous MNs, because surface area of 
the hollow MN orifice was larger than of porous MNs.  
ISF collection by osmotically driven flow through µpores provides a transient convective 
driving force in the µpore and dermis (Section S2.4 in Appendix A). As osmolyte (e.g., 
maltose) diffuses from the µpore, a gradient of osmolyte is formed in surrounding dermis 
(Figure A. 14). The resulting osmotic pressure gradient within dermis drives ISF 
convectively to the µpore. This driving force for ISF convection in dermis differs from ISF 




However, osmotically driven convection was transient because over time osmolyte diffuses 
away from the µpore, such that the osmotic pressure gradient decays to zero. To increase 
ISF collection, osmotic driving force could be increased by increasing osmolyte 
concentration and could be sustained longer by decreasing diffusivity of osmolyte in 
dermis. Thus, high molar water solubility and high molecular weight are good, and perhaps 
competing, properties of optimal osmolyte.  
ISF collection by pressure-driven convection through µpores creates the largest pressure 
drop across the rate-limiting barrier of dermis to drive ISF into µpores (Section S2.5 in 
Appendix A). Whether by vacuum on the skin surface or positive pressure applied by 
“pinching,” pressure drop is inherently focused on regions with greatest flow resistance in 
dermis. While the initial osmotic pressure gradient was 49 kPa/mm, it dropped almost to 
zero after 20 min. Direct application of vacuum or pressure achieved larger pressure 
gradients (131 kPa/mm or 77 kPa/mm, respectively) that remained constant. ISF collection 
could be further increased by increasing vacuum or applied pressure, but would be limited 
by pain and skin damage [170].  
 Discussion 
 To improve on invasive and time-consuming methods to sample dermal ISF currently 
available [73, 82], prior studies developed hollow MNs to withdraw ISF by capillary action 
[116, 171], solid hydrogel MNs that swell with ISF [140, 143, 169, 172], and solid MNs to 
puncture µpores in skin for ISF collection under suction [123]. These prior approaches 




designs have selectively bound targeted biomarkers to MNs in skin [134, 135], which 
requires customized MNs and procedures to elute biomarkers off MNs for analysis. 
Here, we systematically evaluated mechanisms of ISF collection from skin with the goal 
of a minimally invasive, simple-to-administer MN-based system to sample >1 µL ISF from 
skin within 20 min. This volume suffices for many assays of clinical interest like sodium, 
glucose, troponin and cholesterol [163-165]. A 20 min sampling-time is compatible with a 
typical doctor’s visit and patient-administered testing at home. Theoretical modelling 
identified rate limiting steps to ISF flow. 
4.3.1 Analysis of ISF sampling methods 
Hydrogel MNs sampled the smallest ISF volume, which was limited by diffusion in dermis 
and MNs. As ISF diffusivity in hydrogel increases, the rate-limiting step shifts from MN 
to dermis. However, even when ISF diffusivity in MNs (or µpores) approaches that of free 
self-diffusion of water, diffusion through dermis remains rate-limiting. ISF sampling rates 
are constrained because of diffusion without convective forces. 
Capillary action increased ISF flow rate. Due to convective transport, flow through 
capillaries of porous or hollow MNs was not rate-limiting, leaving diffusion through dermis 
as the limiting barrier. Further optimization of MN design should increase MN-dermis 
interfacial area, which scales directly with ISF collection rate.  
ISF collection rate using osmosis increased by an order of magnitude. Diffusion of 




convective flow in the rate-limiting barrier of dermis. MNs coated with osmolyte were less 
effective to collect ISF probably because the small amount of osmolyte delivered into skin 
diffused away quickly. A reservoir of osmolyte on skin surface helped maintain high 
osmotic strength in µpores  and dermis, even as osmolyte diffused away, thereby increasing 
ISF collection. Flow of ISF into µpores was governed by two transient, competing 
parameters: osmotic pressure generated by osmolyte diffusion into dermis near µpores 
(increasing osmotic pressure) and osmolyte diffusion away from µpores in dermis 
(decreasing osmotic pressure). ISF collection could be increased by increasing number of 
µpores, increasing osmotic pressure by increasing osmolyte concentration or decreasing 
speed of osmotic pressure gradient decay by slowing osmolyte diffusion into dermis. 
While transient convection in dermis due to osmotic pressure gradients improved ISF 
collection, continuous application of pressure gradient across dermis via pressure or 
suction maximized ISF sampling. Effective ISF collection using suction required 
stretched/curved skin, which probably forced µpores open during vacuum application. ISF 
collection on the skin surface also depended on material covering the µpores to collect ISF. 
A thin hydrophilic cover did not interfere with pressure drop in skin and allowed ISF to 
readily flow out of the µpore. ISF flow varied linearly with time and pressure, and was 
limited by flow conductivity of dermis and applied pressure gradient. During suction, 
maximum possible pressure drop is 101 kPa (i.e., 1 atm), and both positive and negative 
pressure are further limited by sensitivity of skin tissue to pressure. Even with these 
constraints, ISF collection achieved the target of >1 µL within 20 min in pig skin ex vivo 




Future research should address limitations of the study, such as increasing ISF collection 
rate to produce more ISF in less time; reducing variability in amount of ISF collected 
probably due to interpersonal and time-dependent differences is tissue hydration and other 
properties; and enabling ISF collection using a smaller and simpler device compared the 
bulky pump used here.  
4.3.2 MN treatment acceptability, safety and impact 
ISF is a rich source of biomarkers that has received limited attention for lack of good 
collection methods. ISF can be an alternative to blood sampling; many proteins of medical 
interest found in blood were also in ISF from suction blisters [50, 51]. Skin proteins, like 
dermicidin and dermokine [173, 174], were preferentially found in ISF, suggesting that it 
could provide biomarkers not readily found in blood [51]. ISF is also valuable to 
dermatological pharmacokinetics in skin [82]. 
ISF sampling is currently done using suction blisters, microdialysis and microperfusion, 
which require expert technique, cause tissue trauma and are costly and time-consuming 
[73, 82, 85]. ISF collection using methods described here is minimally invasive, causes 
little or no pain, is simple to administer, is well tolerated by skin, and can collect useful 
amounts of ISF relatively quickly. Previous studies in human volunteers have shown that 
MNs like those used here (but without collecting ISF) create µpores that close and cause 
mild erythema that resolves within hours [104, 175].  
Here, MNs were combined with suction to withdraw ISF from human volunteers. This 




resolved within 24 h. Suction is well accepted and safely applied to skin in existing 
procedures such as negative-pressure wound therapy, suction electrodes for ECG 
recording, cupping in traditional Chinese medicine and vacuum pore suctioning for 
cosmetics [176-178]. Suction, although mild, may be contraindicated in certain people, 
such as infants or elderly who may have sensitive skin. We expect that mild, transient 
erythema, will be acceptable for clinical applications of MNs. Although skin infections 
have not been reported due to MNs in other contexts [179], formation of µpores may not 
be appropriate in certain populations, such as those with weak immune systems or certain 
skin diseases [180]. Safety of ISF collection using MNs needs additional study. 
This study should motivate further investigation of ISF composition compared to other 
body fluids such as plasma and in different populations, and identification of clinically 
valuable biomarkers in ISF. We believe that MN-based ISF collection can facilitate such 
studies and, in the future, make ISF routinely accessible for medical research, diagnosis 
and monitoring. Applications could include continuous analyte measurement for 
monitoring concentration of glucose or drugs with narrow therapeutic index, detection and 
typing of local skin diseases such as skin cancer, or monitoring stress levels in susceptible 
populations like military. Because ISF does not clot, it might be sampled continuously by 
a wearable system, possibly operated by patients themsevles. A versatile method of ISF 






ISF is a unique bodily fluid of great potential interest as a source of biomarkers, but has 
received little prior attention due largely to lack of straightforward methods to collect ISF 
from skin. This study found that ISF can be collected from skin using mechanisms that 
provide diffusive and/or convective driving forces with effectiveness in the following rank 
order: diffusion < capillary action < osmosis < applied pressure/suction. As determined by 
theoretical modeling (with no fitted parameters), ISF transport in skin was rate-limiting, 
such that methods providing convective forces in dermis (i.e., osmosis and applied 
pressure/suction) collected the most ISF. ISF collection by MNs combined with suction 
was well tolerated in human volunteers and produced ISF in sufficient quantity to identify 
biomarkers. Mechanistic understanding, MN device prototype development and successful 
demonstration in human volunteers shown here may enable ISF collection by MN patch to 
become a platform technology for diverse applications in medical research, diagnostics and 
monitoring. 
 Materials and methods 
4.5.1 Microneedle fabrication 
Hydrogel MNs were prepared by casting aqueous solution of PVA onto silicone molds in 
the inverse shape of MN arrays, followed by PVA crosslinking at elevated temperature and 
drying overnight (Fig 1a,b). Metal MNs were fabricated by chemical etching stainless steel 
sheets. 10-MN arrays were made by adhering two planar arrays of solid metal MNs with a 




metal MNs as a protective mask. This yielded paper MNs which were sandwiched between 
two metal MN arrays for mechanical strength (Fig 2a). Hollow MNs were made by 
shortening and rebeveling hypodermic needles using a rotary tool (Fig 2c). Coated MNs 
were made by dipping solid metal MNs into aqueous solution of maltose (Fig 3a). See 
Appendix A for details.  
4.5.2 Measurement of ISF content in skin 
ISF content in skin was measured by weight loss of pig ear skin after lyophilization. ISF 
that could be removed from skin was measured by weight loss after applying pressure to 
pig skin over time. See Appendix A for details.  
4.5.3  Measurement of ISF collected from skin during MN-based protocols 
Pig ear skin was equilibrated overnight with fluorescein solution. Hydrogel MN arrays 
were inserted into skin for 12 h to allow MNs to extract ISF. µpores were created with a 
10-MN patch inserted and removed immediately from pig skin. Fluid on skin surface was 
wiped off after 20 min for analysis. Porous MN arrays were inserted and left in skin for 20 
min to collect ISF. Hollow MNs attached to a syringe were inserted and left in pig skin for 
20 min to collect ISF. For osmosis, maltose from coated MN patch was allowed to dissolve 
to create µpores filled with maltose solution. To fill µpores with osmolyte solution, maltose 
solution was pipetted onto µpores created with plain/coated 10-MN arrays. The system was 
left for 20 min to allow micropores to take up ISF. Fluid on the skin surface was collected 
after 20 min with tissue paper. To evaluate ISF collected by pressure-driven convection, 




over µpores. To make a curvature on the skin surface, a disk was placed under the skin 
surface. To stretch out skin, the ends of the skin piece were stretched by hand and secured 
to a wooden board.  Suction was applied over the micropores for designated amount of 
time and ISF on the surface was collected by tissue paper. For MNs utilizing pressure, 
µpores were created in skin. The skin piece was folded in half with the pores at the apex, 
and placed horizontally on the benchtop. Pressure was applied over the skin surface using 
iron weights for a designated amount of time. To elute all ISF solutes absorbed using MN 
patches, the MNs or the tissue paper or gauze used to collect ISF was soaked in DI water 
for 24 h. ISF collected was measured by measuring amount of fluorescein in the sample 
and normalizing against fluorescein concentration in skin (i.e., 1 mg/mL). All reported 
fluxes and flow rates were averaged over the period of ISF collection (usually 20 min). 
ISF was collected from human volunteers over 20 min by applying 34-68 kPa suction over 
µpores created by a sterile 10-MN patch. ISF on skin surface was collected using sterile 
gauze pads, subsequently soaked in DI water to recover ISF. All volunteers provided 
informed consent. This study was approved by Georgia Tech Institutional Review Board. 
ISF volume was determined by sodium ion concentration normalized to its concentration 
in standard ISF. Glucose and protein were measured using glucose and micro-BCA assays, 
respectively. See Appendix A for details. 
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5 CHAPTER 5: DETERMINE THE COMPOSITION OF HUMAN SUCTION 
BLISTER INTERSTITIAL FLUID USING HIGH-RESOLUTION MASS 
SPECTROMETRY. 
 Introduction 
Biomarkers are a powerful tool to study the entire spectrum of disease, from the 
ascertainment of diagnosis, examination of disease progression, and assessment of 
therapeutic benefits[181]. Most commonly, biomarkers are measured in easily-accessible 
body fluids, such as blood, saliva, and urine. However, there are challenges associated with 
these fluids. Blood sampling by venipuncture is invasive, potentially painful, and requires 
trained personnel. Biomarker concentrations in blood samples obtained via finger pricks 
may be variable if not collected under properly-controlled conditions [159]. Many saliva 
biomarkers are detected at low concentrations, and there is potential for interference by 
food or drugs [21]. While urine samples are easier to obtain than blood, urinary biomarker 
concentrations can be highly variable due to differences in urine dilution [27]. 
Although ISF constitutes 60% of total body fluids in humans [45], it is greatly unexplored 
as a matrix for biomarker detection. ISF, which bathes and surrounds cells and tissues of 
the body, is formed as plasma traverses blood vessels and equilibrates with the cell and 
tissue environment (reviewed in [182]). ISF provides a means of delivering nutrients to 
cells, enables intercellular communication, and removes metabolic waste. 
The detection of biomarkers in ISF has several advantages to blood, urine, and saliva. Since 




detected in plasma may be detected in ISF. Unlike blood, ISF can be used for continuous 
biomarker monitoring, in part because it does not clot [62, 63]. For example, continuous 
glucose monitors sample ISF to measure glucose concentrations [65]. Unlike plasma, 
which provides an integrated measurement of biomarkers from multiple organ and 
metabolic systems, ISF can capture changes in the local environment [50]. For instance, 
ISF sampled from tumors has been studied as a source of cancer biomarkers [161, 183]. In 
addition, ISF has lower concentrations of high-abundance proteins like albumin and 
globulin compared to plasma [68], which makes it easier to screen ISF for low-abundance 
compounds without extensive protein depletion and sample cleanup strategies. 
There are limited techniques for ISF sampling, including suction blisters [73], 
microdialysis [82], open flow microperfusion [85], reverse iontophoresis [87], and MN 
patches [106, 143]. Suction blisters are a common method to sample large volumes of ISF, 
which are generated by applying vacuum to a skin area. A suction application separates the 
dermis and epidermis, and fluid from the surrounding tissues fills the gap, creating a blister. 
The blister fluid is withdrawn by a conventional needle and syringe. This fluid, referred to 
as suction blister ISF, is largely derived from ISF, but may also contain some intracellular 
components and inflammatory markers that are a consequence of the collection method 
[78]. Compared to other ISF sampling methods—including reverse iontophoresis, wherein 
an electric current is applied to skin, or microdialysis, wherein a small membrane is 
inserted into skin—suction blister sampling is a relatively non-invasive method for ISF 




The protein composition of suction blister ISF sampled from suction blisters has been 
studied using mass spectrometry. From suction blisters obtained from 8 healthy 
individuals, Muller et. al. [51] found that the proteome of ISF from suction blisters was 
heterogeneous, consisting of systemic plasma components, proteins originated from cell 
leakage, and proteins associated with skin tissue. Comparing proteins measured in suction 
blister ISF and plasma from 6 individuals, Kool et. al. [50] found that 83% of proteins 
found in plasma were also found in suction blister ISF, whereas only half of suction blister 
ISF proteins were common to plasma. The authors constructed a list of 34 clinically-
relevant protein biomarkers that were abundant in ISF: while 9 out of the 34 were 
epidermal-derived, the rest were known systemic biomarkers, suggesting the utility of ISF 
as a surrogate for blood-based biomarker detection, as well as a source of tissue-specific 
biomarkers. 
While previous research has explored the protein composition of suction blister ISF, to 
date, no study has characterized the small-molecule composition of ISF. Metabolites 
provide critical information on metabolic pathway intermediates, disease states, and 
exposure to environmental agents. Metabolite profiling is also a key tool to study the 
exposome, an emerging research paradigm involving the investigation of complex 
environmental exposures, biological responses to these exposures, and their impacts on 
human health and disease [184].  
Here, we profiled small-molecule metabolites in dermal ISF obtained from suction blisters 
to better understand the composition of the ISF metabolome. First, metabolites in plasma 




untargeted high-resolution metabolomics (HRM) [185]. which was used to characterize 
metabolites present in ISF. Second, we performed an untargeted screen for suction blister 
ISF metabolites that may be useful as biomarkers by identifying metabolite features that 
were elevated in suction blister ISF and/or strongly correlated between suction blister ISF 
and plasma. Collectively, the work characterizes the differences between the suction blister 
ISF and plasma metabolomes, as well as the potential utility of ISF for biomarker detection 
in clinical and exposome research. 
 Results 
5.2.1 Metabolomic profiles of suction blister interstitial fluid and plasma 
To examine the suction blister ISF and plasma metabolomes in volumes that can be feasibly 
sampled in clinical settings, we compared metabolite features detected in the volume of 
ISF collected via suction blister sampling (15 μl suction blister ISF diluted to final volume 
of 50 μl with LC-MS grade H2O) against 50 μl plasma collected via venipuncture, which 
is the standard sample volume used for this metabolomics assay [186]. HRM detected 
7,044 m/z features that were present in suction blister ISF and/or plasma (Figure 5.1). Note 
that m/z features do not necessarily correspond one-to-one with chemical compounds and 
may represent multiple adducts, isotopes, or fragments from the same parent ions. 
Comparison of suction blister ISF to plasma showed that the large majority of features 
were detected in both biofluids, even though suction blister ISF had been diluted to provide 
the minimum volume required for HRM analysis. There were 1,032 and 429 features 




of the feature in at least one of the 10 samples in one fluid, but not in any of the 10 samples 
of the other biofluid.  
We identified 105 metabolites (i.e., groups of adducts/isotopes derived from the same 
parent ions) with high confidence in the suction blister ISF samples that were matched to 
compounds in the Kyoto Encyclopedia of Genes and Genomes (KEGG) database [187] 
by accurate mass (see Appendix B). We also identified metabolites by comparing 
features to a library of metabolite biomarkers relevant to clinical and exposome research; 
compound identities were obtained by matching the accurate mass m/z values and 
retention times of the features to analytical standards in the library. The final curated list 




Table B. 1 
 
Figure 5.1: High-resolution untargeted metabolomic profiles of ISF and plasma. Venn 
diagram displaying the numbers of m/z features common and unique to ISF and 
plasma.  
We detected a wide range of metabolites in suction blister ISF involved in amino acid 
metabolism, lipid metabolism, and nucleotide metabolism, as well as clinical biomarkers 




Table B. 1 in Appendix B). Most endogenous metabolites were detected in the majority of 
suction blister ISF samples and were present in both ISF and plasma. We found matches 
for environmental toxicants, including several pesticides. Environmental compounds were 
generally detected in a greater number of plasma samples compared to ISF. 
 
Figure 5.2: Types of metabolites detected in ISF. Figure displays the classes of 
metabolites identified in ISF. Bars reflect the number of metabolites detected for each 
class, with endogenous and environmental compounds denoted by green and purple 
bars, respectively. The full list of individual metabolites can be found in  
. 
A limited number of metabolites were unique to plasma (Table B. 2 in Appendix B). 
Several were environmental chemicals, including the pesticides malathion, nabam, and 




mycotoxin aflatrem. Two metabolites were artifacts of the venipuncture sampling: skin 
disinfection was carried out with an iodine-containing compound, and 
ethylenediaminetetraacetic acid (EDTA) tubes were used for blood collection. 
5.2.2 Metabolites markedly elevated in interstitial fluid 
To identify unique characteristics of the suction blister ISF metabolome, we identified 
features that were elevated in ISF using a paired fold-change analysis. Since the suction 
blister ISF samples were diluted, these metabolites should reflect compounds that are 
greatly elevated in suction blister ISF relative to plasma. A curated list of all unique and 
elevated features with putative compound matches in the Human Metabolomics Database 
(HMDB) [189] is presented in Table 1.  
While 316 features were unique to and elevated in suction blister ISF based on our 
criteria, only 23 compounds were identified by accurate mass m/z matching (Table 1). 
This may be because some of the molecules present in suction blister ISF have not yet 
been identified or are not included in the HMDB database. We manually classified these 
metabolites into several groups, including five phospholipids, three purines, two 
spermidines, two methionine-related compounds, six other endogenous compounds, and 
five dietary-derived compounds. Several of these metabolites are promising biomarkers 
for human health outcomes (see Discussion). Of special note was urocanic acid, a 




Table B. 1 in Appendix B). Urocanic acid is produced in the stratum corneum and 
accumulates in the epidermis [190]. This finding is consistent with previous proteomic 
studies reporting an enrichment of skin-derived biomarkers in suction blister ISF [50]. 
Triethanolamine, another compound unique to suction blister ISF, is present in skin 
disinfectants used during the suction blister fluid sampling. The identification of this 
metabolite serves as a type of positive control, which increases the confidence in our 
metabolite identities.  
Table 1 Metabolites markedly elevated in interstitial fluid. 





Phospholipids Glycerophosphocholine 4 2.2 





 O-Phosphoethanolamine 3 3.1 
 Multiple phosphatidylinositols 1 1.8 
                                                 
1 Compound identification confidence score: 4, feature was successfully grouped into a 
parent metabolite cluster with a unique database match; 3, feature was successfully 
grouped, but compound was selected from multiple database matches; 2, feature was not 
successfully grouped, but had a unique database match for [M+H]+, [M+Na]+, or [M+K]+; 
1, feature was not successfully grouped and compound was selected from multiple database 





Purines 2-Deoxyinosine triphosphate 2 3.0 
 Hypoxanthine 3 4.2 
 Inosine 1 Unique 
Table 1 continued   
Spermidine N-Acetylspermidine 1 1.7 
 Spermidine 2 Unique 
Methionine N-Formyl-L-methionine 2 2.5 
 N-Acetyl-L-methionine 2 1.8 
Epidermal-
derived 
Urocanic acid 3 Unique 
Other 
enodgenous 
Creatine 3 3.8 
 4-Pyridoxic acid 2 1.8 
 Glutamyl-Valine 1 2.0 
 Glycylproline 1 Unique 
 Phosphocreatinine 4 1.5 
 Taurine 4 4.9 








 2,3,4-Trimethyltriacontane 4 Unique 
    





 Dibutyl disulfide 1 1.2 
 
5.2.3 Metabolites strongly correlated between interstitial fluid and plasma 
The identification of metabolites that are strongly correlated between plasma and suction 
blister ISF may provide insight into blood-based biomarkers that could be reliably 
monitored via suction blister ISF sampling. Thus, we examined the correlations between 
plasma and suction blister ISF intensities for 3,141 m/z features that were present in  4 
sample pairs, of which 223 were significantly correlated (p < 0.05; 182 positive 
correlations, 41 negative correlations).  
To explore the biological significance of the positively-correlated metabolites, we input 
the results into Mummichog [191] for pathway and module analysis (Figure 5.3). 
Metabolites correlated between plasma and suction blister ISF were commonly found in 




alanine, and threonine metabolism; aspartate and asparagine metabolism; Figure 5.3A). To 
explore the biological functions of the metabolites identified in the module analysis, KEGG 
IDs from the significant modules were input into KEGG BRITE [187], which found 
numerous peptides, lipids, and hormones/neurotransmitters among the correlated features 
(Figure 5.3B). The activity network, which contains metabolites whose identities could be 
predicted with high confidence, contained several amino acids (e.g., proline, glycine, 
homocysteine, betaine, methionine, tyrosine), nucleic acids (e.g., guanosine, guanine, 
uracil), and neurotransmitter-related metabolites (e.g., dopamine, methylhistamine; Figure 
B. 1 in Appendix B). 
We compared these results against metabolites identified in a manual annotation of highly-
correlated features. Here, we manually annotated 99 features with strong correlations 
between suction blister ISF and plasma (Spearman rho > 0.7) using HMDB (Table 2). 
Many metabolites were identified both in the activity network and Table 2, including 
homocysteine, betaine, methionine, proline, tyrosine, acetylcarnitine, and 
octenoylcarnitine, strengthening the evidence for these compound identifications. Results 
from pathway-associated metabolite set enrichment analysis (MSEA) [192] for metabolites 
in Table 2 found overrepresentation of metabolites in protein biosynthesis, betaine 
metabolism, methionine metabolism, and glycine, serine, and threonine metabolism (p < 
0.05), consistent with Mummichog pathway results. Metabolites annotated manually that 
were not identified by Mummichog were trimethylamine N-oxide (TMAO), a microbiota-




identified as a promising biomarker of cardiovascular disease [194], and caffeine and 






Table 2 Metabolites strongly correlated between interstitial fluid and plasma. 




Betaine/methionine Homocysteine 3 0.98 
 Betaine 3 0.96 
 Dimethylglycine 1 0.90 
 Methionine 3 0.78 
 Trimethylamine N-oxide 3 0.77 
                                                 
2 Compound identification confidence score: 4, feature was successfully grouped into a parent ion cluster 
with a unique database match; 3, feature was successfully grouped, but compound was selected from multiple 
database matches; 2, feature was not successfully grouped, but had a unique database match for [M+H]+, 
[M+Na]+, or [M+K]+; 1, feature was not successfully grouped and compound was selected from multiple 
database matches for [M+H]+, [M+Na]+, or [M+K]+ 





Amino acids Glutamine 4 0.92 
 Tyrosine 3 0.88 
 Proline 3 0.85 
 Proline betaine 3 0.83 
 Threonine 1 0.81 
Table 2 continued   
 Valine 3 0.76 
ATP-associated Creatinine 4 0.77 
 Phosphocreatine 2 0.75 
Carnitines Acetylcarnitine 4 0.84 
 trans-2-Dodecenoylcarnitine 4 0.83 
 Decanoylcarnitine 4 0.81 
 3,5-Tetradecadiencarnitine 4 0.80 
 2-Octenoylcarnitine 4 0.71 
Phospholipids LysoPE(20:5) 4 0.89 
 LysoPE(18:2) 4 0.88 




 Trigonelline 3 0.87 
Other endogenous N-Butyrylglycine 1 0.81 
Food-derived Lenticin 4 0.94 
 Polypropylene glycol 4 0.85 
 2-(1-Propenyl)-delta 1-piperideine 2 0.80 
Table 2 continued   






Figure 5.3 Biological roles of metabolites correlated between ISF and plasma. Results 
from Spearman correlations between ISF and plasma (for metabolite features present 
in  4 matched sample pairs) were input into Mummichog,[191] a Python program 
for network analysis and metabolite prediction in untargeted metabolomics datasets. 
Significant features (p < 0.05) were matched to compounds based on common adducts 
and isotopes, network modules (i.e., sub-communities of biologically-interconnected 
metabolites) were identified based on their “activity scores” (calculated from the 
number of significant features in the module, as well as the Newman-Girvan 
modularity Q), and pathway enrichment was estimated using a permutation 
procedure. (A) Metabolic pathways overrepresented among metabolites correlated 
between ISF and plasma (p < 0.01). (B) Radial plot of biological roles of metabolites 
identified in network modules, assessed using KEGG BRITE. The inner and outer 
rings display BRITE functional hierarchies, with the area proportionate to the 
number of metabolites that fall under each category. Gray boxes outlined in the outer 






This study describes the first detailed analysis of the metabolite composition of human 
suction blister ISF using untargeted HRM analysis. Matched suction blister ISF and plasma 
samples were collected from ten human volunteers, and clinically-relevant sample volumes 
were analyzed by liquid chromatography with high-resolution mass spectrometry to find 
similarities and differences between the chemical compositions of the two biofluids. 
Although the majority of metabolite features were detected in both suction blister ISF and 
plasma, the biofluids had distinct characteristics. A diverse range of metabolites of 
endogenous and environmental origin were detected in suction blister ISF. Several 
glycerophospholipid-, purine-, and spermidine-associated metabolites were elevated in 
suction blister ISF, and many amino acids, nucleic acids, hormones, and exogenous 
compounds were well correlated between suction blister ISF and plasma. Altogether, our 
results suggest that metabolomic profiling of suction blister ISF has the potential to provide 
information about local and systemic biological activities and may be useful for monitoring 
established and novel biomarkers. In some cases, metabolite detection in suction blister 
ISF is an alternative to blood, and in other cases, suction blister ISF contains metabolites 
that are absent from or found in lower abundance in blood. 




Table B. 1 were detected in both suction blister ISF and plasma, confirming that common 
endogenous compounds can reliably be detected in suction blister ISF. Amino acid, lipid, 
and nucleotide metabolites, along with the clinical biomarkers cholesterol, glucose, 
creatinine, and urea, were detected in almost all of the suction blister ISF samples. Among 
the few metabolites that were not detected in suction blister ISF, many were environmental 
in origin, including several toxicants of potential relevance to environmental health. 
Considering the small sample volume of suction blister ISF used in the current study, it is 
possible that these metabolites were present in suction blister ISF but too low for reliable 
detection using this assay.  
A primary goal of our study was to examine the usefulness of ISF sampling for metabolite 
biomarker detection as a substitute or companion to blood sampling via venipuncture. We 
identified several metabolites that were elevated in suction blister ISF compared to plasma, 
which reflect metabolites that may be uniquely and/or more easily assessed in ISF. 
Urocanic acid, an epidermal metabolite that accumulates in the stratum corneum, was 
unique to suction blister ISF. While it is a chromophore for ultraviolet radiation acting as 
a ‘natural sunscreen’, it has also been reported to have immunosuppressive effects and may 
play a detrimental role in photocarcinogenesis [196]. Spermidine, which has also been 
reported to be elevated in the epidermis [197], is a polyamine compound associated with 
anti-aging mechanisms [198]. Spermidine has promise as a biomarker for cancer 
aggressiveness [199], suicidal behavior in mood disorders [200], and response to breast 
cancer therapies [201]. Phosphocreatinine and creatine are important components of energy 




mitochondrial diseases [203, 204]. Hypoxanthine and inosine, nucleotide bases formed 
during purine metabolism, are increased in response to injury [205] and are biomarkers for 
cardiac ischemia [206]; however, future work should examine the impact of the suction 
blister sampling protocol on the levels of these metabolites.  
Several phospholipid-related compounds were elevated in suction blister ISF. 
Glycerophosphocholine, a building block for phospholipids in cell membranes, is a 
biomarker for breast cancer and myeloma, as well as Alzeimer’s disease [207, 208]. 
Glycerophosphocholine and glycerylphosphorylethanolamine in semen have been 
implicated as biomarkers for infertility problems [209]. O-Phosphoethanolamine has 
promise as a biomarker for major depressive disorder [210] and Amyotrophic Lateral 
Sclerosis [211]. 
Exogenous food-based compounds were also elevated in suction blister ISF. One 
compound unique to suction blister ISF, 3-methylsulfinylpropyl isothiocyanate, is obtained 
through the consumption of cruciferous vegetables [212]. Isothiocyanates, which are 
phytochemicals with chemoprotective activities, are believed to contribute to the health 
benefits of vegetable-rich diets [213]. Recently, a screen for toll-like receptor (TLR) 
inhibitors in vegetable extracts identified 3-methylsulfinylpropyl isothiocyanate as a 
compound with potent anti-inflammatory effects [214]. Another food-derived compound 
unique to suction blister ISF, 2,3,4-trimethyltriacontane, is found in fruits [215]. While 





We also identified metabolites that were positively correlated between suction blister ISF 
and plasma, which reflect metabolites whose ISF levels are informative of their blood 
levels. Many amino acids, neurotransmitters, and nucleic acids were strongly correlated 
between the fluids. Several clinically-relevant metabolites were also strongly correlated 
between ISF and plasma. Elevated homocysteine, a sensitive indictor of B-vitamin 
deficiency [216], is a biomarker for cardiovascular [217], and neurodegenerative [218] 
conditions. Creatinine is an important biomarker for kidney function [202]. Betaine is a 
metabolite that plays a role in osmoregulation [219], and TMAO is an osmolite generated 
by gut microbiota from betaine, choline, and carnitine [220]. Betaine and TMAO are 
biomarkers of cardiovascular outcomes [221, 222]. Two dietary-related compounds, 
caffeine and trigonelline, are found in coffee beans and are biomarkers of coffee 
consumption [223]. 
We acknowledge that our study has several limitations. The limited sample volume 
precluded the in-depth structural characterization of detected m/z features without database 
or library matches. The structural elucidation of these features is challenging due to the 
lack of reference standards, limited ISF sample volume, and low feature abundances. In 
addition, a limited number of the annotated metabolites were identified by comparison to 
authentic reference standards. The remaining metabolites were characterized using an 
annotation scheme that reduces false identifications through a combination of correlation, 
adduct and isotope clustering; while this approach has been shown to enhance annotation 
accuracy [224], additional laboratory analyses, such as ion dissociation and comparison to 




disentangle the impacts of matrix effects and dilution effects under the current study 
design.  
It is possible that the different sampling sites, i.e., blood draw from the forearm and suction 
blisters on the thigh, introduced variability in the composition of these fluids, although we 
do not expect this variability to be significant, given that plasma is part of systemic 
circulation. If the concentrations of metabolites at sampling sites are variable, the 
metabolite fold changes between suction blister ISF and plasma may have been affected. 
The method for suction blister generation required a 45-minute vacuum application at 
elevated temperatures; due to this procedure, host responses to blister generation, 
inflammatory reactions, and wound responses may be observed, resulting in artifacts in the 
suction blister ISF that would not be present in ISF from unperturbed skin. Thus, we cannot 
dismiss the possibility that some of our findings in suction blister ISF (e.g., metabolites 
elevated in suction blister ISF) might be influenced by the injury induced through the 
suction blister sampling method. In addition, different fluid collection protocols may 
introduce variability in the metabolites detected. To address this issue in part, future studies 
will explore the ISF and plasma metabolomes with varying sample dilutions and sampling 
strategies. Finally, the study had a small sample size, and we were unable to infer how sex, 
age, and other participant characteristics influenced our results. Nonetheless, the current 
study supports the use of ISF as a useful fluid for biomarker monitoring using HRM 





To our knowledge, this is the first study to compare the human suction blister ISF and 
plasma metabolomes with untargeted HRM profiling. We found that dermal ISF has a 
distinct metabolite composition that may provide value as a source of biomarkers for 
diagnostics and monitoring. Our findings suggest that suction blister ISF may be a unique 
source of several biomarkers, including several nucleotides, epidermally-derived 
metabolites, and dietary compounds. Additionally, many clinical biomarkers were well 
correlated between suction blister ISF and plasma, suggesting that ISF has the potential to 
serve as a surrogate source of biomarkers conventionally detected in plasma. Overall, 
metabolomic profiling performed in this study provides early evidence that ISF has the 
potential to serve as a substitute and/or complement to plasma-based biomarker detection 
in future clinical practice and research studies.  
 Methods 
5.5.1 Obtaining plasma and interstitial fluid samples 
The study was conducted using 10 healthy human volunteers and was approved by the 
Institutional Review Board (IRB) at the Georgia Institute of Technology. Written informed 
consent was obtained from all volunteers. Blood samples were taken from the forearm by 
venipuncture. Skin suction blister fluid was collected from suction blisters generated on 
the thigh by applying suction at 50 – 70 kPa below atmospheric pressure at a temperature 
of 40°C for ~45 min until blister formation was complete. See Appendix B for details. 




Suction blister ISF samples were diluted from 15 μL to 50 μL with water. 50 μL of biofluid 
(plasma or diluted suction blister ISF) was added to 100 μL of acetonitrile, vortexed and 
allowed to equilibrate. Proteins were precipitated by centrifuge. Aliquots were analyzed 
using reverse-phase C18 liquid chromatography (Ultimate 3000, Dionex, Sunnyvale, CA) 
and Fourier transform mass spectrometry (Q-Exactive, Thermo Scientific, Waltham, MA). 
Data was extracted using apLCMS[225] with modifications by xMSanalyzer [226]. See 
Appendix B for details. The metabolomics dataset is available upon request to the 
corresponding authors. 
5.5.3 Statistical analysis and metabolite feature identification  
Statistical analysis, network/pathway analysis, and metabolite set enrichment analysis were 
performed in RStudio v0.99.486[227] and MetaboAnalyst 3.0.[192] Metabolites were 
identified with analytical standards and accurate mass matching in KEGG[187] and 
HMDB[189] using custom dataset-wide and feature-specific deconvolution and 
identification algorithms. See Appendix B for details. 
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6 CHAPTER 6: DEVELOP A MICRONEEDLE SYSTEM TO SAMPLE 
INTERSTITIAL FLUID IN HUMAN PARTICIPANTS AND IDENTIFY 
BIOMARKERS IN THE INTERSTITIAL FLUID COMPARED TO BLOOD. 
 Introduction 
Identification and measurement of biomarkers have increasing importance in advancing 
research and detecting and treating diseases [228]. Biomarkers are molecules found in body 
fluids such as blood, urine, and saliva that provide information about physiological status 
Diagnosis and monitoring are central to effective healthcare; e.g. diabetes management by 
blood glucose testing, quick detection of infectious diseases like HIV and ability to 
characterize cancers by blood sampling. Blood monitoring is limited by need for expert 
training, difficulty of continuous monitoring, and pain and apprehension associated with 
blood draws [229]. Urine and saliva are more accessible but have limited biomarkers and 
variable concentrations [230].  
The most prevalent fluid in the body is interstitial fluid (ISF), constituting 75% of 
extracellular fluid and 15-25% of body weight. ISF surrounds cells and tissues, acting as a 
bridge between blood and cells [48]. It contains systemic biomarkers and can also be used 
for continuous monitoring. ISF contains local tissue biomarkers that can provide 
information about cellular and tissue physiology [51]. Previous studies have shown that 
ISF contains unique biomarkers not otherwise found in plasma [50].  
Currently, ISF is used clinically for continuous glucose monitoring [231] and in research 




microenvironment [233].  More widespread use of ISF is limited because ISF is hard to 
sample. In the skin, which is the most accessible organ of the body, ISF is mostly present 
in the lowermost skin layer of dermis, which is 70% ISF by volume [71]. Dermal ISF can 
be sampled by biopsy, but it is painful, requires medical expertise, can lead to scarring, and 
collects a mixture of extracellular ISF and intracellular material [234]. Alternatively, 
suction blisters, created by applying suction for an hour at elevated temperature, are filled 
with ISF. However, this procedure is cumbersome, feels uncomfortable, causes lasting skin 
damage, and provides fluid contaminated with injury markers not truly representative of 
ISF [73].  
Microdialysis and open-flow microperfusion require implantation of a semipermeable 
membrane or steel-mesh tubing into skin, often under local anesthesia, which causes tissue 
damage, requires many hours to perform and collected analytes are limited by the 
permeability of the membrane [80, 85]. Reverse iontophoresis uses electric current to draw 
ISF components towards skin surface, but is limited to collection of small molecules, may 
irritate skin and requires frequent calibration because of skin permeability variation [87]. 
Alternatively, biosensors placed inside the body provide in situ measurement in ISF, e.g. 
for continuous glucose monitoring [231]. However, this requires a dedicated, implanted 
sensor for a given biomarker and risks infection, biofouling, and discomfort of an 
indwelling device.  
An ideal system to sample ISF should reliably collect ≥1 µL of ISF (i.e., sufficient for 
many analytical assays; be minimally invasive to avoid artifacts due to tissue damage or 




believe these criteria can be met using microneedles (MN), which are micron-scale needles 
that press into skin, penetrate past the outer skin barriers, and access dermal ISF in a 
minimally invasive manner. MNs have been studied clinically for drug delivery 
applications, where they are well tolerated and easy to use, making them well-suited for 
routine use in research and medicine [103]. However, previous studies of MNs for ISF 
sampling have been limited by sub-microliter sampling volumes.  
In this study, we developed a MN-based method to sample microliter volumes of ISF from 
skin in a relatively simple and minimally invasive manner using relatively low-cost and 
commercially available equipment. We have assessed acceptability of this method by 
studying skin tolerability, pain and patients’ opinions. The utility of this method was 
studied by comparing our results against ISF collection from suction blisters and plasma 
collection by venipuncture. We also analyzed ISF collected using MNs for biomarkers of 
clinical interest and/or unique to dermal ISF, and compared pharmacokinetics of a model 
biomarker in ISF versus plasma. 
 Results 
6.2.1 Design of microneedle patch to sample interstitial fluid 
We designed an ISF collection method that uses MNs to create pathways for ISF flow from 
skin using vacuum as a convective driving force. Prior approaches have employed solid, 
swellable MNs, which are limited in ISF collection by MN volume [142], and hollow MNs 
collecting biomarkers by diffusion or convection of ISF through MNs by capillary action, 




driving force for ISF flow within MNs, but rely on slow diffusion of ISF through dermis 
to the dermis-MN interface.  
In our design, vacuum application initiates a convective driving force that moves ISF 
through dermis to the skin surface through MN-generated pathways. These micropores are 
created by pressing a patch containing an array of five MNs into skin and then removing it 
(Fig 1a). Vacuum is applied over micropores to transport ISF through dermis and 
micropores to the skin surface (Figure C. 1 in Supplementary Information, Appendix C).  
A challenge in method development was bleeding. Since skin is highly vascularized, 
vacuum application to skin punctured with MNs collected blood along with ISF. We 
therefore studied the effect of MN length, vacuum pressure, and timing of vacuum 
application in human participants. Reducing MN length from 650 to 250 µm reduced 
chances of blood contamination upon vacuum application (Figure C. 2 in Appendix C). We 
did not try shorter MN lengths due to concerns that they would not reliably insert into skin 
without a high-velocity applicator [162]. Delaying vacuum application for up to 10 min 
after MN application did not affect bleeding, but reducing vacuum pressure from -50 to -
17 kPa reduced bleeding (Figure C. 3 in Appendix C). Bleeding was eliminated by slowly 
increasing vacuum to -50 kPa over the course of ~3 min after puncture with 250 µm MNs. 
This method was used in all subsequent studies. 
This optimized method collected 2.3±2.6 µL clear ISF with no visual traces of blood within 




reduce variability of ISF collection, but the current method was capable of reliably 
collecting useful quantities of ISF for analysis.  
6.2.2 Collection of ISF from human participants 
We collected ISF from 21 human participants including 10 males and 11 females aged 





Table C. 1). The procedure involved covering skin with a transparent film skin dressing 
(Tegaderm) containing 1-cm diameter openings where MN treatment was performed 
(Figure 6.1). Insertion and removal of MNs was well tolerated with faint visual evidence 
of micropores in skin (Figure 6.1d). After administration of vacuum over the micropores 
for up to 20 min, skin appearance was largely unchanged (Figure 6.1c). Closer examination 
revealed droplets of ISF on the skin surface (Figure 6.1e). Collection and examination of 
ISF showed it was clear with a slight yellow tinge. One day later, there was generally no 
evidence of MN treatment, indicating swift recovery of skin (Figure 6.2f,g). Overall, ISF 
collection with MN treatment was a simple, minimally invasive, and relatively rapid 
method that was well tolerated by human participants.  
For comparison, epidermis and dermis were separated to form ISF-filled suction blisters 
by applying vacuum at 40°C for up to 1 h. Draining the blister with a needle and syringe 
collected suction blister fluid (SBF), which was similar in appearance to ISF collected by 
MN (Figure 6.1b) Consistent with literature [236], suction blister treatment caused local 
erythema and edema, which resolved within a few days, and in some cases induced 
prolonged skin pigmentation. Compared to MN treatment, suction blister treatment caused 
significantly more severe and longer-lived tissue trauma, was more cumbersome and time-




   
Figure 6.1: Representative images of microneedle (MN) device and interstitial fluid 
(ISF) collection by microneedle (MN) treatment compared to suction blister. (a) 
Stainless steel MN patch (right) shown next to a conventional lancet (left). Each of the 
five MNs (shown with arrow) is 250 µm in length, 200 µm in width at the base and 
tapering to 10 µm tip diameter. Inset shows a magnified view of a single MN. (b) 
Suction blisters formed after extended vacuum application on skin (-50 kPa to -70 
kPa at 40°C for up to 1 h) being drained with a needle and syringe to collect suction 
blister fluid (SBF). (c) Skin after MN application and vacuum administration (-50 
kPa at room temperature for 20 min) to draw out ISF. Three treatment sites are 
shown, surrounded by Tegaderm skin covering, before ISF was removed from skin 
surface. (d) Magnified view of skin immediately after MN application. Some spots 




generally not associated with bleeding. (e) Magnified view of skin immediately after 
MN treatment (i.e., including vacuum administration). Droplets of ISF can be seen on 
the skin surface above micropores. (f) Skin shown 24 h after MN treatment. (g) 
Magnified view of skin 24 h after MN treatment shows no redness or erythema. 
Images 2b-f are all from the same subject and are representative of the study 
population. 
 
Although MN treatment did not induce apparent adverse effects to skin, we carried out 
histopathological analysis of skin biopsies from MN-treated hairless rats to further assess 
safety. Visual observation of skin after MN treatment showed slight swelling and erythema 
that resolved within a few hours. Examination of histopathological tissue sections by a 
board-certified dermatopathologist revealed minor focal inflammation at 4 h after MN 
treatment (Figure 6.2b) that resolved within 24 h (Figure 6.2c).  
 
Figure 6.2: Representative images of H&E-stained sections of skin from the back of 
hairless rats in vivo before and after MN treatment. (a) Histology of skin section taken 
from the back before MN treatment. (b) Histology of skin site taken from a biopsy 4 
h after MN treatment. Black arrow shows a site of minor focal inflammation. (c) 
Histology of skin 24 h after MN treatment did not show signs of inflammation. 
 




We collected ISF from MN treatment, SBF from suction blisters and plasma from 
venipuncture from the cohort of 21 participants to compare biomarker compositions of 
the three fluids. High-quality data were available for 20 participants from high-resolution 
metabolomics using liquid chromatography-mass spectrometry (LC-MS) (demographics 




Table C. 2 in Appendix C). This analysis detected 10,338 features with hydrophilic 
interaction chromatography (HILIC), which better detects lipophilic compounds and 7,703 
features with reverse-phase C18 chromatography, which better detects polar compounds 
(Figure 6.3). Among features found in HILIC, 63% were common to all three body fluids; 
79% were common to plasma and ISF, suggesting that these metabolite measurements in 
ISF may be a surrogate for plasma; and 1% were unique to ISF, suggesting that these 
biomarkers can be uniquely assayed in ISF. Similar data were obtained from C18 
chromatography, except 14% of features were unique to ISF, indicating that polar 
metabolites are more likely to be specifically found in ISF compared to lipophilic 
metabolites.  
 
Figure 6.3: Venn diagram showing the overlap of features in ISF from MN treatment, 
suction blister fluid and plasma from venipuncture. Samples were analyzed using (a) 
hydrophilic interaction chromatography (HILIC) and (b) reverse-phase C18 liquid 
chromatography. After filtering, a total of 10,338 and 7,703 features were detected 




the feature was detected in that fluid in more than 10% of samples (≥ 3 of 20 samples). 
Figures not to scale. 
 
Comparing the 10,208 features found in ISF or SBF by HILIC, only 72% were common to 
both fluids, which demonstrates that ISF and SBF are not identical fluids, probably because 
of their different methods of sampling. To better interpret differences between ISF and 
SBF, a swab was wiped across intact skin and analyzed for biomarkers. Because ISF was 
collected from the skin surface, it may contain more epidermal and skin surface biomarkers 
than SBF. Consistent with this expectation, among 1,740 features detected in ISF and 
absent from SBF, 58% were found in the skin wipe. Among 1,102 features detected in SBF 
and absent from ISF, 65% were found in the skin wipe (Figure C. 4 in Appendix C). 
However, it should also be noted that 70% of features detected in skin swabs were also 
found in plasma (Figure C. 5 in Appendix C), indicating that biomarkers found on the skin 
surface are not necessarily contaminants. Indeed, prior studies have shown that dermal and 
systemic biomarkers can be collected from the skin surface [237]. Additional studies are 
needed to better understand differences between ISF and SBF, and the role of epidermal 
and skin surface biomarkers. Results from C18 chromatography were similar (Section C.3 
in Appendix C).  
We conducted a targeted evaluation of 90 medically-relevant biomarkers in ISF, SBF and 
plasma. Of these, 68 were detected in at least one fluid (Table C. 3 in Appendix C); Table 
3 shows a truncated list. Most biomarkers (65%) were found with high frequency (presence 




in ISF, which further emphasizes that ISF contains many of the same biomarkers as plasma. 
In contrast, 11% of biomarkers were commonly found in ISF but not in plasma, which 





Table 3: Prevalence of selected clinically relevant biomarkers in ISF, SBF and plasma 
in matched samples from 20 human participants.  
Biomarker Prevalence of biomarker†  
Plasma ISF SBF 
Clinical Markers 
   
Cholesterol 100% 80% 100% 
Cortisol§ 100% 30% 80% 
Creatinine 100% 100% 100% 
Homocysteine* 20% 55% 55% 
Urea 100% 100% 100% 
Glucose 100% 100% 100% 
Lactic acid* 75% 100% 100% 
Uric acid 100% 100% 100% 
Nucleotide-related Metabolism 
  
Hypoxanthine* 0% 80% 100% 
Xanthine* 25% 90% 100% 
Uridine 100% 100% 100% 
Vitamins and Cofactors 
  
Choline 100% 100% 100% 
Pantothenic acid (Vitamin B5) 50% 60% 95% 
Tetrahydrofolic acid* 40% 60% 30% 
Fatty Acid Metabolism 
  
Acetyl-carnitine§ 85% 40% 100% 




Table 3 continued    
Margaric acid* 60% 100% 25% 
Myristoleic acid 85% 100% 45% 
Palmitoleic acid 90% 100% 55% 
Stearic acid 75% 100% 15% 
Lipid Metabolism 
   
Sphingosine* 10% 100% 50% 
Leukotriene B4* 50% 100% 50% 
Respolvin E2 100% 100% 75% 
Sterol Metabolism 
   
Deoxycholic acid§ 100% 55% 100% 
Taurodeoxycholic acid§ 100% 50% 100% 
†Prevalence among 20 samples; §Biomarkers found with high frequency in plasma, but not 
in ISF; *Biomarkers found with high frequency in ISF, but not in plasma.  
 
To further study biomarkers in ISF with high frequency and generally absent in plasma, 
we used data-driven annotation approaches to identify 116 such biomarkers. Among 24 
clinically significant biomarkers, 15 were not frequently present (<50%) in SBF, possibly 
because they were more prevalent in epidermis or skin surface. Ten of these 15 









Table 4: Prevalence of clinically relevant biomarkers detected uniquely or 
predominately in ISF compared to plasma in matched samples from 20 human 
participants.  
Biomarker Medical significance† Prevalence of biomarker§   
Plasma ISF SBF 







micronutrient and drug, 
suppresses immune response, used 




Glycogen energy storage 10% 100
% 
60% 
Diethanolamine*  cosmetic formulations, carcinogen 5% 100
% 
60% 
Sphingosine* signaling molecule in skin 10% 100
% 
50% 





environmental pollutant used as 





Citicoline naturally occuring and also a 





















natural form of estrogen - plays a 







Table 4 continued    
Arginosuccinic 
acid 
biomarker for urea cycle disorder 0% 95% 25% 
Porphobilinogen biomarker for acute porphyrias, 
currently urine based detection 
10% 95% 20% 
N1,N12-
Diacetylspermine 
cancer biomarker 0% 95% 15% 
Triethanolamine* commonly used in skin care 
products 
0% 90% 0% 
Prostanoic acid basic building block of 
prostaglandins 




bile acid derivative - reduces liver 
fat and fibrosis 
0% 85% 0% 
Inosine cardiac disease biomarker 5% 80% 100% 
Hypoxanthine cardiac disease biomarker 0% 80% 100% 
Barbaloin product of aloe vera - anti-
inflammatory, cathartic 
properties 
0% 70% 10% 
AMPA neurological biomarker 10% 65% 90% 
Bromochloroaceti
c acid 
present in brominated disinfected 
water and may cause adverse 
reproductive outcomes 
5% 65% 10% 
20-COOH-
Leukotriene B4 
Involved in vasodilation 5% 55% 5% 
†See Figure C. 4 in Appendix C for references in support of medical significance; 











Table C. 5 in Appendix C). Of note are 2-arachidonoylglycerol, an endocannabinoid 
produced in the epidermis that is involved in inflammatory regulation [238], and 
corticosterone, which activates in the skin in response to inflammation and other stressors 
[239]. This indicates that SBF may contain artifacts that result from tissue trauma inherent 
to the suction blister sampling method.  
MN treatment was well tolerated. Participants reported that pain during MN treatment was 
not different from suction blister or venipuncture, while suction blister sampling was 
significantly more painful than venipuncture (Figure C. 6a). Ongoing pain after the 
procedure was reported by almost half of participants with suction blisters, but only by 5% 
after MN treatment (Figure C. 6b). Tenderness was reported by 90% of participants at 
suction blister sites, but only 24% after MN treatment.  Erythema was seen at 89% of 
suction blister sites, split between grade 1 and grade 2 in severity, whereas erythema at MN 
sites was less common (76%) and less severe (all grade 1). Localized swelling observed at 
40% of suction blister sites and 57% of MN sites was always contained within the 1-cm2 
sites of vacuum application. Overall, MN treatment was well tolerated and generally had 
fewer adverse effects compared to suction blisters. 
6.2.4 Monitoring systemic biomarker pharmacokinetics in ISF and plasma 
Our measurements so far compare the presence of biomarkers in different body fluids, but 
do not address dynamic relationships as biomarkers are transported between body 
compartments. We therefore studied pharmacokinetics of a model biomarker (caffeine) in 




expected to transport and equilibrate easily between blood and ISF [240], can be safely and 
easily administered to human participants, and its pharmacokinetics are well known [241]. 
ISF and blood were sampled by MN treatment and fingerstick, respectively, in 9 healthy 
adult subjects (Table C. 7 in Appendix C) who had abstained from caffeine consumption 
for 36 h. Baseline caffeine concentrations in ISF and plasma in all participants were below 
0.5 µg/mL, consistent with expected values >24 h after caffeine abstention [242]. After 
consuming Diet Coke containing 43 mg of caffeine, caffeine concentrations in ISF and 
plasma increased for ~2 h and then decayed until the end of the 8 h study (Figure 6.4a). 
There was a good correlation between caffeine in ISF and blood (r2=0.73, Figure 6.4b), 
with a mean ISF/blood ratio of 0.95±0.52. Caffeine pharmacokinetic parameters are not 
significantly different from each other (r>0.05, Figure 6.4c) and are consistent with 
literature values [243]. Three participants later drank caffeine-free Diet Coke, which 
resulted in caffeine concentrations in ISF and plasma below 0.25 µg/mL at all times (Figure 
6.4a).  
 
Figure 6.4: Concentration of caffeine in ISF and plasma in 9 human participants. (a) 




or caffeine-free Diet Coke. (b) Correlation between caffeine concentrations in ISF 
compared to plasma.(c) Pharmacokinetic parameters for caffeine concentrations in 
ISF and plasma. All data shown as mean (SD). See text for definition of symbols.  
 
Sensations reported by participants were similar for MN and fingerstick; participants 
reported very slight or slight pain and stinging (Figure C. 7 in Appendix C). MN treatment 
induced mild erythema localized at the treatment sites that disappeared within a few days 
(Figure C. 10a in Appendix C). No pain or swelling was reported. In contrast, fingerstick 
did not cause erythema but resulted in mild, transient tenderness (Figure C. 10b in 
Appendix C).  
 Discussion 
ISF is a novel body fluid of increasing interest as a source of biomarkers providing 
information about both dermal and systemic physiology as well as drug pharmacokinetics. 
ISF is also of interest for continuous monitoring of biomarkers because, unlike blood, it 
does not clot. However, progress in this field has been significantly limited by lack of 
simple, rapid, reliable and minimally invasive methods to sample ISF. Current methods 
include suction blisters [73], microdialysis [80, 244] and open flow microperfusion [85] 
which require expert training, take one or more hours to complete, cause skin injuries that 
require days to weeks to fully heal and often require local anesthesia due to their invasive 
nature.  
Previous studies have demonstrated use of MNs to sample ISF. However, hollow MNs 




insertion into skin [169, 172] have generally collected sub-microliter ISF volumes, which 
is less than required for most diagnostic tests [235]. Here, we developed an ISF collection 
method using MNs to create pathways for ISF transport and using vacuum to provide a 
driving force that draws ISF from skin. We believe this new method will be broadly useful 
to the scientific and possibly future clinical communities to collect useful quantities of ISF 
(i.e., ≥1 µL) using a minimally invasive method that is well-tolerated and relatively rapid 
and simple to do. Moreover, the method uses equipment that is commercially available at 
relatively low cost.  
In this study, we collected ISF, SBF and plasma from 20 human participants and found 
more than 10,000 features by LC-MS analysis, more than two-thirds of which were 
common to ISF and plasma. This indicates that ISF may be a surrogate for plasma in some 
cases. More features (14%) we detected unique to ISF using the C18 column compared to 
1% using HILIC. Potssibly skin contains more lipophilic molecules that are captured better 
by C18 compared to HILIC. Altogether, our data indicate that biomarkers in ISF derive 
mostly from plasma, but there are also biomarkers specific to skin, many of which probably 
result from metabolic processes in the tissue.  
Using a targeted approach to detect clinically valuable biomarkers, we found that most 
biomarkers detected in plasma were also in ISF, further supporting the idea that ISF may 
be a substitute for blood for diagnostic tests such as cholesterol, urea, creatinine, glucose, 
etc. Biomarkers found uniquely in skin include nucleosides associated with RNA like 




and neuroprotective agent for possible treatment of Parkinson’s disease and multiple 
sclerosis). We also found porphobilinogenis (currently used to detect porphyria in urine-
based tests) and arginosuccinic acid (biomarker for urea cycle disorders). Several 
dermatologically relevant biomarkers like sphingosine (structural component of skin with 
signaling functionality) and diethanolamine (carcinogen found in skin products) were also 
detected in ISF. Additionally, exogenous molecules probably from environmental 
exposures were found, like bromocholoroacetic acid (possible carcinogen associated with 
water purification), tributylin chloride (reproductive toxin found in paint), and barbaloin 





Table C. 4 for details).  
We also compared biomarkers in ISF and SBF. Although most features found these 
biofluids were common to both, 21% were found only in ISF and 10% were found only in 
SFB, probably due to differences in sampling methods. For example, 2-
arachidonoylglycerol and corticosterone (biomarkers associated with inflammation) were 






Table C. 5 for details). In contrast, Leukotrine B4 (biomarker for vasodilation) was found 
in ISF samples, possibly because MN application can cause mild erythema.  
The pharmacokinetics of caffeine (used as a safe model biomarker) in ISF closely matched 
plasma, probably because small, hydrophilic molecules like caffeine rapidly equilibrate 
between blood and ISF across capillary walls (e.g., like glucose does [245]). This indicates 
the possibility of using ISF to continuously monitor biomarkers currently monitored in 
plasma, such as glucose, lactate, and urea, without indwelling, subcutaneous probes.  
Device development required optimization to prevent ISF contamination with blood from 
broken capillaries. We noted that blood only appeared under vacuum, perhaps because 
MNs make very small incisions in capillaries that can self-seal, but vacuum forces them 
open. We found that using very short MNs (250 µm) and slowly ramping up vacuum after 
MN application could avoid bleeding and collect clean ISF samples.  
ISF collection using MNs was well tolerated, with mild, transient erythema and reports of 
brief, minor pain similar to fingerstick. We believe that most pain came from sharp edges 
on the MN array backing, as opposed to the MNs themselves; this problem can be fixed 
with minor design modification. In support of this assertion, prior studies using much larger 
arrays of longer MNs have been reported painless [103, 246].  
Limitations of this study include need for further validation of findings in larger 
populations, since this study included data from only 21 human participants; careful 




on LC-MS data only; analysis of ISF for a broader range of compounds, such as proteins; 
further determination of the significance of biomarkers found in ISF and their relevance to 
human physiology; and device improvements that minimize pain, as discussed 
immediately above.  
 Conclusions 
Progress in studying ISF as a source of biomarkers for tissue physiology, dermatological 
drug pharmacology, novel diagnostic assays and other applications has been limited by 
lack of simple, minimally invasive methods to collect ISF. In this study, we developed a 
method to sample ISF from skin using a MN-based device that is well-tolerated, relatively 
rapid and simple to perform, and provides microliter quantities of ISF in a minimally 
invasive manner using relatively low-cost, commercially available equipment. ISF 
sampled from human participants and analyzed for metabolites by LC-MS was found to 
have most molecular features in common with plasma and/or SBF, but several of features 
were unique to ISF, including biomarkers of medical significance. The pharmacokinetics 
of a model compound, caffeine, in ISF closely matched plasma. These findings suggest 
that ISF can be a source of valuable biomarkers as a non-clotting alternative to blood and 
a source of biomarkers unique to ISF for dermal and systemic physiology. Sampling ISF 
from skin using a MN patch has the potential for widespread use in research for new 
biomarker discovery and drug development, as well as for possible future translation in the 
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 Materials and methods 
6.6.1 Microneedle patch fabrication and sterilization:  
MN patches were designed in Solidworks 2016 software (Solidworks, Waltham, MA) and 
fabricated from grade 316 stainless steel as five-needle planar arrays (Tech-Etch, 
Plymouth, MA) by photo etching. MN length varied from 250 µm to 650 µm, with a cross-
sectional area of 200 µm by 25 µm at the base and a sharp tapered tip of 10 µm diameter. 
MN patches were disinfected by washing with sterile 70% isopropyl alcohol (VWR, 
Radnor, PA) in a class II BSL hood (Thermo Fisher Scientific, Waltham, MA), packaged 
into self-sealing sterilization pouches (Crosstex International, Englewood, CO) and 
sterilized using an ethylene oxide sterilization cycle (AN74i Anprolene Gas Sterilizer, 
Andersen Products, Haw River, NC) that was validated using a product immersion method 
(WuXi AppTec, Marietta, GA).  
6.6.2 ISF sampling using microneedle patches 
ISF sampling through skin using MN patches was a two-step process: MN patch 
application to create micropores in the skin followed by application of vacuum to draw out 




6.6.2.1 Microneedle patch application 
 The site of MN patch application on the participant’s forearm was disinfected using an 
alcohol swab (BD Alcohol Swab, BD, Franklin Lakes, NJ), and an area of ~50 mm2 was 
marked with a pen. The investigator inserted a patch comprising a five-MN planar array at 
the site and then removed it immediately. This process was rapidly repeated 20 times per 
site to create an array of 100 micropores at each site. Future studies could use a single patch 
comprising, for example, 100 MNs inserted simultaneously.  
6.6.2.2 Vacuum application 
Vacuum was applied using a Negative Pressure Cutaneous Suction System (NP-2, 
Electronic Divestities, Ridge Road, Finksburg, MD). The vacuum chamber was aligned 
with skin sites that received MN treatment. Each chamber had a bottom plate with up to 
five 8 mm diameter orifices through which vacuum contacted the skin. Vacuum as low as 
-50 kPa (gauge) was applied for up to 20 min. In the optimized protocol, vacuum was 
slowly ramped down to -50 kPa over the course of ~3 min. After stopping the vacuum and 
removing the orifice plate, clear fluid on the skin surface was collected using sterile 
medical gauze (Ultrapure non-woven sponges, CrossTex International, Lawrenceville, 
GA) and stored in a low protein-binding tube (Eppendorf North America, Westbury, NY) 
prior to placing in a -80°C freezer. 




Two optimization studies were performed on a cohort of 3 male and 2 female human 
participants with ages of 28±4 years. All procedures were approved by the Georgia Tech 
Institutional Review Board (IRB) and written consent was obtained from all subjects before 
the study. 
In the first study, patches containing MNs of 250 µm, 450 µm or 650 µm length were 
applied to skin as described above to create 100 micropores at each skin site. Vacuum was 
then applied at -17 kPa, -34 kPa or -50 kPa (gauge). The skin was observed for up to 5 min 
to determine if bleeding occurred.  
In the second study, patches containing MNs of 250 µm length were applied to the skin to 
create 100 micropores at each skin site. Then, (i) vacuum of -17 kPa (gauge) was applied 
immediately after MN patch treatment or (ii) vacuum of -50 kPa (gauge) was applied 0, 5 
or 10 min after MN patch treatment or (iii) vacuum was slowly ramped down from 0 to -
50 kPa (gauge) over the course of ~3 min after MN patch treatment. If bleeding occurred, 
vacuum was stopped at 15 s and any fluid on skin surface was collected. In the absence of 
bleeding, fluid was collected after 20 min of vacuum application. 
6.6.4 Blood collection by venipunture 
Venipuncture samples were taken from the forearm, collected into K3 EDTA tubes (BD 
Vacutainer Blood Collection Tube) and spun down at 1,400 rcf for 15 min (Eppendorf 
centrifuge 5702 RH, Eppendorf AG, Hamburg, Germany) to separate the plasma, which 
was collected in Protein lo-bind tubes (Eppendorf Lo-bind). Capillary blood samples were 




GA) and collected into heparin mini collection tubes (MiniCollect Lithium Heparin with 
Gel Separator, Gernier Bio One North America, Monroe, NC). The tubes were spun down 
at 1,400 rcf  for 15 min (Eppendorf centrifuge 5702 RH) to separate the plasma, which was 
collected in Protein lo-bind tubes. All plasma samples were stored at -80°C until analysis. 
6.6.5 Suction blister fluid collection from suction blisters 
SBF was collected by the method developed by Kiistala [73]. Suction blisters were created 
on the thigh of each participant as a site easily accessible when wearing shorts and one that 
can be discretely covered for cosmetic reasons until suction blisters have fully healed. The 
skin site was first thoroughly disinfected with an alcohol swab. Suction was then applied 
using a Negative Pressure Cutaneous Suction System [247, 248]. Sterile orifice plates with 
3 holes (8 mm diameter each) along with the suction cup were firmly attached to the skin 
using straps. Suction at -50 to -70 kPa (gauge) was applied at 40C for ~45 min until blister 
formation was complete. Fluid from intact and hemoglobin-free blisters was collected 
using a Micro-Fine syringe (BD Biosciences, San Jose, CA) and stored in Protein lo-bind 
Eppendorf tubes at -80C.  
6.6.6 Skin surface swab 
Sterile medical gauze wetted with sterile USP-grade water was rubbed against the skin for 
30 s and stored in Protein lo-bind Eppendorf tubes at -80C.  




Six hairless rats (6 months old, female, Charles River Laboratories, Wilmington, MA) each 
received three treatments. MN patch plus vacuum, MN patch only, and vacuum only. For 
MN patch application, a patch comprising five 250 µm-long MNs was applied repeatedly 
on the back to create an array of 100 micropores as described above. For vacuum 
application, vacuum was applied at -50 kPa (gauge) for 10 min. At 4 or 24 h post-treatment, 
animals were euthanized by carbon dioxide gas asphyxiation and the treated skin was 
collected using an 6-mm biopsy punch along with untreated skin controls. After fixation in 
formalin, skin was prepared for histopathological analysis by sectioning and staining with 
hematoxylin and eosin followed by microscopic examination by a board-certified 





6.6.8 Pain and skin tolerability measurements 
6.6.8.1 Pain 
To assess pain, participants were asked if a procedures was painful. If yes, they were asked 
to rate the pain on a Visual Analog Scale of 1 (no pain) to 10 (worst possible pain). 
6.6.8.2 Skin tolerability 
Skin tolerability was measured using a quantitative skin scoring scale adapted for MN 
patches using established guidelines for clinical studies [104] (see Table C. 6 in Appendix 
C). Each skin site was scored for pain, tenderness, erythema (size and intensity) and 
swelling on a grading scale of 0 to 4. Pain and tenderness were scored based on the 
participant's response, whereas erythema and swelling were measured by the investigator. 
Participants were asked if they felt pain at the skin site at various times after skin treatment 
(e.g., MN patch administration) was complete. This pain was assessed separately from the 
pain associated with MN patch application, which is addressed immediately above. 
Tenderness was defined as any pain felt at the skin site when the investigator gently 
touched it. Erythema size was measured using a ruler scale and intensity was measured by 
visual observation of the skin site. Swelling was measured by the investigator by gently 
moving her thumb over the skin site to identify any raised surfaces on the skin. The 
investigator recorded a numerical score for each of these tests and photographically imaged 





6.6.8.3 Sensory perceptions 
Participants were asked if they felt the following sensory perceptions during skin treatment 
(e.g., MN patch administration): pain, burning, stinging, tingling, itching, warmth and 
tightness. If the participant replied yes to any of the above sensations, the participant was 
further asked to rate those sensations as very slight, slight, moderate, strong or very strong, 
and was also asked if those sensations felt comfortable.  
6.6.9 Analytical techniques 
6.6.9.1 Determination of blood volume 
Collected blood volume was measured by determining hemoglobin content in blood 
samples using a Triton / NaOH-based method (Hemoglobin Assay Kit, Sigma-Aldrich, St. 
Louis, MO). Hemoglobin content in a blood sample was normalized against hemoglobin 
content in the capillary blood of the same participant to obtain the amount of blood in each 
sample. 
6.6.9.2 Determination of ISF volume 
Collected ISF volume was measured by determining sodium ion concentration in the 
collected fluid. Sodium ion concentration was determined using a sodium ion sensitive 
electrode (perfectION comb NA, Mettler Toledo Inc., Columbus, OH). The sodium ion 
content measured in the samples was normalized against a standard sodium ion 




expectation that sodium ion concentration is constant in the body fluids of heathy 
participants [89].  
6.6.9.3 High-resolution metabolomics 
Body fluids (ISF, SBF and plasma) were profiled using untargeted high-resolution 
metabolomics (HRM) with dual column/polarity liquid chromatography. Body fluid 
samples were diluted from 10 μL to 50 μL with distilled water, and 50 μL of diluted biofluid 
was added to 100 μL of acetonitrile and 2.5 μL of a mixture of 14 stable isotope standards. 
Samples were vortexed and allowed to equilibrate before proteins were precipitated by 
centrifuge. Samples were analyzed using hydrophilic interaction chromatography (HILIC; 
XBridge BEH Amide XP, 2.1 mm x 50 mm x 2.5 μm particle size, Waters, Milford, MA) 
in positive electrospray ionization mode, which better captured polar and semi-polar 
metabolites, and using reverse-phase C18 liquid chromatography (stainless steel column, 
2.1 mm x 50 mm x 3 μm particle size, Higgins, Mountain View, CA) in negative-ion mode, 
which better captured fatty acids and other nonpolar metabolites. The dual chromatography 
setup interfaced to a high-resolution Fourier transform mass spectrometer (Q-Exactive HF, 
Thermo Scientific, Waltham, MA).  
For each mode, analyses were performed with three technical replicates with an injection 
volume of 10 μL and mass-to-charge ratio (m/z) scan range of 85 to 1275. Body fluid types 
were analyzed in separate batches, with samples randomized within each fluid and distilled 
water blanks and pooled reference plasma (Q-Standard) samples analyzed prior to and 




extraction was performed using apLCMS[250] and xMSanalyzer[251] as m/z features, with 
an m/z feature defined by m/z, retention time, and ion abundance. Triplicates were averaged 
prior to data analysis. A feature was defined as “present” in a sample if the ion intensity in 
the sample was greater than two times the mean ion intensity of that feature in the water 
blank samples.  Data were filtered to remove features that were not present in ≥50% of 
samples in at least one body fluid. 
6.6.9.4 Metabolite identification:  
Clinically-relevant biomarkers were identified by comparing m/z features to base peaks 
generated from an in-house library of authentic reference standards run under similar assay 
conditions[249]. Features were matched to metabolites in the library with a threshold of 10 
ppm. Metabolites unique to ISF were identified with a custom dataset-wide deconvolution 
algorithm and Kyoto Encyclopedia of Genes and Genomes (KEGG)[187] database 
matching (± 10 ppm). High-confidence matches (metabolites with two or more correlated 
adducts and/or isotopes with similar retention times) were curated to remove unlikely peak 
groupings and/or biologically-implausible compounds. The presence of a metabolite was 
evaluated by examining the presence of the base peak in the feature grouping.   
6.6.9.5 Determination of caffeine concentration 
The amount of caffeine in the collected ISF and plasma was measured using ELISA 





6.6.9.6 Calculation of pharmacokinetic parameters 
Cmax was the highest caffeine concentration measured in ISF/plasma from each participant. 
tmax was the time at which Cmax was measured. Area under the curve, AUC(0-8h), was 
calculated using the linear trapezoidal rule. To estimate half-life, t1/2, an elimination rate 
constant (ke) was obtained as the slope of the elimination curve on a semilog plot, and then 
t1/2  was calculated as t1/2 = ln(2)/ ke. To estimate clearance (CL), the apparent volume of 
distribution (VD) was multiplied by ke. VD was calculated as D/C0 where D is the dose of 
caffeine (43 mg) and C0 is the intercept of the elimination curve on the y axis. 
6.6.10 Statistics 
All statistical analysis was conducted using Graphpad Prism 7 Software (GraphPad 
Software, La Jolla, CA). Statistical differences were analyzed using Student’s t-test. P-





7 CHAPTER 7: DISCUSSION 
Measurement of biomarkers in body fluids is a valuable tool used to accurately diagnose 
and subsequently monitor diseases. Biomarker detection has enabled revolutionary 
technologies such as early disease diagnosis, continuous monitoring for disease 
management, and novel drug development. Biomarkers are detected in body fluids such as 
blood, urine, saliva, sweat, and tears. In addition to these body fluids, ISF is of great interest 
as a source of valuable biomarkers for diagnostic applications. Recent developments such 
as the need for regular or continuous monitoring of analytes, a need to understand 
metabolic processes in-depth for drug development, and the need to be able to sample 
biomarkers non-invasively has opened the potential for ISF as a body-fluid of interest.  
A major limitation of clinically used techniques to sample ISF is the invasiveness of 
techniques such as sensor implantation, biopsy, microdialysis, or open-flow 
microperfusion. Other techniques such as reverse iontophoresis are limited by the inability 
to sample large molecules, and suction blisters cause discomfort and skin pigmentation that 
can take weeks to heal. MNs have shown promise as a technology to sample ISF through 
skin in a non-invasive manner. Previous studies to sample ISF using MNs have been 
limited by the small sample volumes of ISF which are not sufficient for multiple analyte 
measurement. This study developed a MN-based device that samples multiple microliters 
of ISF within a clinically relevant time frame of 20 min and translated this technology to 




The first aim of this study was to build a broad understanding of transport of ISF through 
skin to enable an optimized MN design. In this aim, we evaluated different mechanisms to 
sample ISF from skin using different MN-based devices. Using this knowledge, we 
developed a MN-based system that could sample multiple microliters of ISF from human 
skin within 20 min.  
MNs give access to the dermal ISF but cannot collect or pool the ISF on the skin surface 
on their own. There is a need for a driving force that drives ISF through the MNs or 
micropores onto the skin surface. This driving force can come from a concentration 
gradient, applied pressure gradient or osmotic pressure gradient. To generate these driving 
forces, various MN systems were designed.  
Hydrogel MNs provided a ISF concentration gradient to drive ISF flow into the MNs. 
Hollow and porous MNs provided capillary forces to absorb the fluid and in turn provided 
a concentration gradient for ISF in the dermis. Osmotic MNs relied on a solution of higher 
osmotic strength than the ISF to provide a pressure gradient to drive ISF towards the 
micropore. Finally, MN systems that generated a pressure gradient in the dermis were 
designed to drive convective flow in the dermis – either by direct pressure application or 
application of vacuum to the skin surface. It was observed that the flow rate increased by 
orders of magnitude in the following order: hydrogel MNs<porous/hollow MNs<osmotic 
MNs<pressure-driven MNs.  
To further understand the transport phenomenon in skin, we modelled the flow of ISF in 




sampling of ISF by MNs – transport of ISF through the dermis to the MN surface, 
partitioning of ISF across the dermis-MN interface into the MNs, transport of ISF through 
the MN/micropore on the skin surface. Determination of the rate limiting step is key to 
developing a system that maximizes ISF flow rate.  
It was observed that for a slow swelling hydrogel like polyvinyl alcohol, ISF transport in 
the hydrogel matrix was rate limiting. As the hydrogel system becomes fast swelling, the 
diffusivity of ISF in the hydrogel is higher than diffusivity in the skin and transport through 
skin becomes rate limiting. After this any improvement in the swelling of the hydrogel 
would make only incremental improvement in the ISF flow rate as the rate liming step 
shifted from the hydrogel to the dermis.  
In case of hollow MNs or porous MNs, ISF at the surface was instantaneously absorbed. 
This maximized the concentration gradient in the dermis. Thus the rate limiting step is flow 
of ISF through the dermis. It is possible to increase the flow rate of ISF incrementally by 
increasing the surface area of the MN, which also has an upper bound because of the 
relatively small size of MNs and a limit on the number of MNs contained within a patch.  
A micropore filled with an osmotic solution that has higher osmotic strength than 
surrounding ISF generates a pressure gradient that drives ISF towards the micropore. 
However, since the osmolyte itself is a small water soluble molecule, it diffuses into the 
dermis. Thus the osmotic pressure gradient decreases with time. A higher molecular weight 




prevents the back flow of osmolyte into the dermis might help to maintain the pressure 
gradient for longer times and thus increase the flow rate of ISF.  
Finally exerting a convective force on the dermis to force ISF towards the micropores 
generates a steady pressure gradient that does not diminish with time. Hence, pressure 
driven convection gives the highest ISF sampling rates. The flow of ISF is limited by the 
flow conductivity of ISF in skin. Vacuum application can generate a maximum pressure 
gradient of 1 atm and there is no theoretical upper bound to the maximum positive pressure 
that can be applied to skin. However, skin tolerance to pressure for the time duration of 
pressure application may put a upper bound on this value. Overall, theoretical modelling 
of ISF in skin suggested that flow within the dermis was rate limiting, and to maximize ISF 
flow rate would require a high pressure gradient through the dermis. 
Based on these observations, a vacuum based system was chosen as the optimum system 
to draw ISF through skin. MN insertion and immediate removal from skin created 
micropores over which vacuum application resulted in ISF flow to the surface. It was 
observed that the skin which contained the micropores needed to be either curved and 
placed over a firm support or stretched out in order to draw ISF to the surface. This is 
presumably because under the absence of tension, the micropores collapsed and closed the 
pathway for the ISF to flow towards the skin surface. Presence of any covering on the 
micropores during vacuum application, such as a gauze pad, hindered the flow of ISF 
towards the skin surface because of lowered pressure drop and surface tension drop. As the 




highest ISF flow was obtained when the micropores had no covering during vacuum 
application.  
This system was tested on human participants to sample ISF, and multiple microliters of 
ISF were extracted from skin of human volunteers. It was seen that concentrations of 
glucose and total protein in ISF and companion plasma samples correlated and were similar 
in both fluids. Thus commonly measured analytes can be detected in ISF and ISF can be 
used as an alternative to blood for monitoring these biomarkers. 
In addition to development of a MN patch to sample the ISF, it was important to evaluate 
the composition of ISF and establish ISF as a body fluid of clinical value. Previous studies 
have studied the proteomics of ISF and compared it to plasma. However, the small 
molecule composition of ISF has not been significantly studied before. Therefore, a 
metabolomic analysis was carried out on suction blister ISF obtained from 10 healthy adult 
participants and compared with plasma samples obtained from those participants. Analysis 
by mass spectrometry revealed that a total of 7044 m/z features were present in in all 
samples of which 79% were common between ISF and plasma, 15% were unique to suction 
blister ISF and 6% were unique to plasma. In general, plasma had a higher proportion of 
hydrophobic molecules and ISF had a greater percentage of hydrophilic molecules. Most 
endogenous metabolites were found in both fluids.  
The metabolites in ISF included common clinical biomarkers such as glucose, cholesterol, 
creatinine, and urea.  Also present were metabolites associated with amino acid 




compounds such as pesticides, phytochemicals and dietary compounds. This shows that 
ISF is a source of endogenous as well as exogenous metabolites and has great potential as 
a source of valuable biomarkers. Several clinically relevant molecules were identified to 
be unique or elevated in ISF compared to plasma. These compounds fell into several groups 
– phospholipids, purines, spermidines, methionine related compounds, and dietary derived 
compounds. This indicates the potential to use ISF to measure clinically relevant 
biomarkers in ISF that are are not easily detected in plasma. Dermatologically relevant 
molecules such as urocaninc acid were found uniquely in ISF which indicates the potential 
of dermal ISF in drug development and drug monitoring of dermatological drugs.  
Similarly, we found that several biomarkers were correlated between ISF and plasma. 
Notably these include several amino acids, nucleic acids, and neurotransmitter related 
metabolites. Pathways associated with protein biosynthesis, betaine metabolism, 
methionine metabolism, and glycine, serine, and threonine metabolism were 
overrepresented among correlated metabolites. This indicates that several biomarkers that 
are currently monitored in blood can also be detected in ISF reliably. Overall, this study 
established metabolomics as a useful technique to study the composition and evaluate the 
value of ISF as a source of biomarkers. The understanding of similarities and differences 
between ISF and plasma can further enable the research and use of ISF for diagnostic 
applications. 
Having developed a method ex-vivo to sample ISF using MNs and having established to 
potential of ISF as a valuable diagnostic fluid, we next adapted the MN system to reliably 




invasive, be able to sample 1-10 µl within 20 min and the sampled ISF should match the 
composition of ISF in unperturbed skin. First, we optimized the system of MN application 
and vacuum application to reliably sample a clean ISF sample from skin within 20 min. 
Human skin is highly vascularized and MN application to create micropores damages 
blood vessels. Upon vacuum application, the blood from the damaged vessels effuses out 
leading to contamination of the ISF with blood. Lowering the MN length from 750 µm to 
250 µm reduced the amount of bleeding but did not stop it completely. Lowering the 
maximum vacuum applied further reduced the amount of blood but also proportionately 
reduced the amount of ISF that could be collected. Finally, slowly ramping up the vacuum 
to the maximum value instead of a spontaneous vacuum application was seen to eliminate 
any contamination with blood, giving a clean ISF sample.  
Using this, ISF was sampled from a cohort of 21 participants using up to 50 kPa vacuum 
for 20 min. Along with ISF, companion plasma samples from venipuncture as well as 
suction blister ISF from suction blisters were also obtained. Of all the features detected, 
around 2/3rd were common between MN ISF and plasma. This indicates that MN ISF can 
be used as a surrogate for plasma in some scenarios. Targeted analysis of 90 established 
biomarkers determined that 76 were found in at least one body fluid. Of these, 57 were 
found in more than 50% of all ISF and plasma samples. 7 metabolites were less common 
in plasma compared to ISF. These include tryptophan, sphingosine, leukotriene, 
hypoxanthine, xanthine, pantothenic acid (Vitamin B5), and tertahydrofolic acid. This 
indicates that ISF may be better than plasma to monitor certain biomarkers as they are more 




cartinine, cortisol, methyl-histidine were found more commonly in plasma compared to 
ISF, indicating that ISF may not be suitable to monitor certain biomarkers.  
We also found certain metabolites that were uniquely found in ISF. These include 
micronutrients such as gamma-tocopherol, citicholine, acetyl-glucosamine; several 
important endogenous metabolites such as glycogen, nebularine, angiotensin, estradiol 
cypionate; and other exogenous biomarkers such as barbaloin, diethanolamine, tributyltin 
chloride. A few of these biomarkers are not found in suction blister ISF suggesting that this 
method samples fluid from the skin surface that are not accessed by suction blister ISF. 
Thus this method of collecting ISF has the potential to access and monitor unique 
biomarkers, increasing the diagnostic value of this fluid.  
In addition to detecting the presence and absence of certain biomarkers, we also studied 
the dynamic changes in biomarker concentration in ISF as compared to plasma from 
fingersticks. Caffeine was chosen as a model biomarker which was ingested orally by 9 
participants at time zero. The levels of caffeine in ISF and plasma were monitored over a 
period of 8 h. The concentration of caffeine in ISF followed the concentration in plasma 
very closely with a steady rise in concentration for the first 2 h, followed by a steady decay 
for the next 6 h and no evidence of any lag time (when sampling every 30 min). Measured 
pharmacokinetic parameters such as Cmax, tmax, AUC0-8h, t1/2 and clearance were similar in 
ISF and plasma. Thus, ISF using MNs can capture dynamic variations in biomarkers that 




To assess the pain, skin tolerability and acceptability of the MN treatment we evaluated 
the pain experienced by the participants, studied skin tolerability up to 5 days after MN 
treatment and asked for participant feedback on the sensations experienced during MN 
treatment. The pain experienced from MN treatment was not statistically different to the 
pain experienced with suction blisters, venipuncture or fingerstick. In contrast, the pain 
experienced with suction blisters was significantly higher than the pain with venipuncture. 
The pain associated with MN treatment could mostly be attributed to MN application rather 
than vacuum application. This pain could be reduced by better design of the MN patch 
backing.  
MN treatment was in general well-accepted by the skin. Mild erythema was observed at 
the site of MN treatment that generally resolved within 4 days. The erythema was contained 
within the area of MN treatment. No pain and minimal tenderness were felt at the site 3 
days after MN treatment by some participants. Any swelling resolved within 24 h. In 
contrast, pain at site of fingerstick was felt by some participants up to 24 h after treatment 
and tenderness was felt up to 5 days after treatment. Suction blisters generated higher 
intensity erythema in higher percentage of participants. The pain and tenderness at the skin 
site after the procedure was also seen in higher percentage of participants.  
When asked, the sensations experienced during MN application, participants reported pain 
and stinging as the dominant sensations. A similar response was seen for fingersticks. In 
general participants said that they were comfortable with all the sensations experienced 
with MN applications for 47% of the time as opposed to 53% with fingersticks. Overall 




fingerstick and venipuncture with respect to pain and other sensations. MNs are well 
tolerated compared to suction blisters because of milder erythema, pain, tenderness and 
also the absence of any pigmentation/dark spots a few days after MN treatment. Given the 
acceptability of these methods, it is expected that a MN based method would also be well-
accepted clinically for diagnostic applications.  
In sum, we have developed a reliable method to sample ISF through skin based on a 
thorough experimental and theoretical evaluation of ISF transport in skin and of different 
MN designs. Using pressure driven convection as a result of vacuum application, we 
successfully sampled microliter volumes of ISF from skin of human participants. We 
established ISF as a body fluid of interest and a source of valuable biomarkers by 
evaluating its composition using metabolomics. Using the MN system, we further explored 
ISF composition from MNs and showed that the system could be used reliably for novel 
biomarker detection. We also established the acceptability and skin tolerability of MN 
treatment. We believe this technology can become a platform for greater exploration of 





8 CHAPTER 8: FUTURE WORK 
 Miniaturization and adaptation of microneedle system for clinical use 
The current system design is effective to reliably sample ISF through skin. However, it is 
not practical or adaptable for clinical use in the current form. Future work needs to be done 
to engineer the system to become simpler. 
8.1.1 MN patch design 
The current MN design requires manual insertion to create micropores. The MN patch 
needs to be designed such that the needles insert to the desired depth with one single push 
using a thumb or an applicator. The shape of the backing and the geometry of the MNs can 
be optimized such that the MNs insert painlessly and create sufficiently large micropores 
for ISF transport. Ideally this would involve a 2-D MN array that has ~100 MNs in a square 
centimeter area and can create 100 micropores with one insertion instead of repeated MN 
insertions required in this study. 
8.1.2 Wearable vacuum chamber 
The system for vacuum application is bulky and not directly adaptable for clinical 
applications. Design of a smaller suction cup that ramps up the vacuum over a set time 
period would be ideal in a clinical setting. Current devices such as handheld vacuum pumps 
used for cupping therapy, or vacutainer blood collection tubes can be adapted to modify 
the current setup. This could greatly accelerate the clinical acceptability of this MN system 




8.1.3 One step process 
The current MN treatment includes MN application and vacuum application – which is a 
two- step process.  To adapt the system for clinical use, a simpler portable system and a 
one-step process will be beneficial. This could be done by designing a spring loaded 
application system that is integrated into the suction cup, and that inserts and removes MNs 
creating micropores. Otherwise, MNs can be integrated on the suction cup such that 
vacuum is generated by the action of pressing MNs on the skin. Converting the current 
system to a simpler one-step system could greatly aid in increasing the practicability and 
adaptability of this system to clinical applications. 
 Expanding the scope of microneedle patches to point-of-care diagnostic systems 
A major portion of this work has been to develop a method to sample ISF from skin of 
human participants and show a first demonstration of the utility of the MNs and ISF 
towards clinical applications. A major advantage of MN based devices is their ease of use, 
cost-effectiveness, and portability which makes it ideal for point-of-care applications. 
Thus, the next step for MN development is to develop a point-of-care system with MNs 
that is able to diagnose disease. 
The first step is to assess ISF for diagnosis of a disease. This would require testing of the 
system in two populations – a diseased population vs. a healthy population. A detailed 
understanding of the relation between concentration of relevant biomarkers in ISF vs 
plasma needs to be established. Other important factors to consider are the variations in 




of false positives or negatives.  The current system relies on Na+ measurement to calibrate 
the volume of ISF sampled. The variability with this method needs to be studied and a 
robust method for internal calibration needs to be developed to improve the accuracy of 
the process.  
The next step would be to integrate MN patch and ISF detection in a point-of-care system. 
Recent techniques such as lab-on-a-chip microprocessors, paper microfluidics, Raman 
spectroscopy can enable point of care testing. Combining these technologies with ISF 
sampling using a MN patch can truly enable point-of-care diagnosis with MNs. 
These advances would establish the use of MN systems and ISF for diagnostic purposes 
and could accelerate the development of this technology for clinical applications.  
 Evaluation of factors affecting interstitial fluid flow after microneedle 
treatment in humans 
8.3.1 Age and ethnicity 
Applications of MN-based diagnostic device could be for a wide population range – these 
include people of different ages, ethnicities and hence different skin types. It is important 
to evaluate the efficacy of ISF sampling on these different skin types. It is important that 
the optimized MN device design should have equal efficacy for people of all ages and 
ethnicities. 




Hydration levels of an individual may affect the water content in the dermis and hence the 
volume of ISF available for sampling. There is a need to establish correlations between 
hydration and ISF sampled by modifying the water intake of individuals or artificially 
hydrating the skin prior to MN treatment.  
A thorough evaluation of the various factors affecting ISF flow in humans and 
identification of the important parameters will enable the development of a robust MN 
system that can function well in all populations even under extreme conditions. 
 Evaluation of prolonged wear of microneedles on skin tolerability 
Use of MNs for monitoring applications may need prolonged wear of the device – 
especially in cases of continuous monitoring. It is important to consider the pain, safety, 
acceptability, and tolerability of the MN system for prolonged wear. In the current study, 
MNs were quickly inserted and removed, and vacuum was kept in place for a maximum of 
20 min.  
Although pain experienced with vacuum application is shown to be minimal, prolonged 
application of vacuum may increase the pain and discomfort associated with the procedure.  
Also, prolonged vacuum application even at lower levels may lead to skin tissue damage. 
It is important to assess in-vivo the changes in skin physiology that occur as a result of 
prolonged wear. Different populations such as the children or the elderly may have 
different skin maturity and may react differently to MN treatment. Thus studying the 





Similarly, micropores that remain open for longer periods of time are more susceptible to 
infection. To evaluate the possibility of infection with micropore creation, challenge 
studies need to be carried out. It may be necessary to integrate anti-microbial agents into 
the system to minimize infection risk during prolonged wear.  
This study would allow for a thorough assessment of the safety of MN patches and help 





9 CHAPTER 9: CONCLUSIONS 
Diagnosis and monitoring of disease is often done by measuring biomarkers found in 
blood, urine, saliva and other bodily fluids. Another rich source of biomarkers is the ISF 
that surrounds cells and tissues in the body, but difficulty in accessing this fluid has limited 
its use in research and medicine. In this study, we conducted experimental studies coupled 
with theoretical modeling to design a MN patch that penetrates into superficial layers of 
skin and thereby enables withdrawal of ISF through micropores in a simple, minimally-
invasive manner. We have shown that this MN based system can sample multiple 
microliters of ISF within 20 min.  
By exploring the metabolomic profile of ISF, we have shown that ISF can be used as a 
surrogate for blood in some cases or also to detect valuable biomarkers that are unique or 
elevated in ISF compared to blood. The MN patch can be used to detect these unique 
biomarkers in ISF and also to detect dynamics of biomarker variations as is currently done 
using plasma. This patch can help researchers access ISF to advance discovery of novel 










SUPPORTING INFORMATION FOR CHAPTER 4 
A.1.1. ISF content in skin 
  
Figure A. 1: Estimation of ISF content in skin: Total ISF content reported in 
literature (solid line, 70 wt% (1)), total ISF content was determined by lyophilizing 
skin (dashed line, 61 ± 10 wt%). Mobile ISF loss (data points) is plotted over time, 
reaching a value of 20 wt% after 20 min. Mobile ISF loss is the amount of ISF that 
could be removed from the dermis and was not otherwise bound or encapsulated. To 
estimate this, pig skin ex vivo measuring 4 cm2 was placed under 8.9 kg weight, and 

































A.1.2. Effect of osmotic driving force on ISF collection over time 
 
Figure A. 2: ISF volume sampled from pig skin ex vivo over time by osmosis. An array 
of 10 uncoated, metal MNs was used to create micropores in skin. A 400 mg/mL 
solution of maltose was then placed on the skin surface to provide an osmotic driving 
force. Data show mean ± SD (n=4). 
 
A.1.3. Effect of number of MNs on ISF volume collected by osmosis 
 
Figure A. 3: ISF volume sampled from pig skin ex-vivo by osmosis. An array of 10 or 
50 coated, metal MNs was used to create micropores in the skin. A 400 mg/mL 




force. The volume of ISF sampled increases with increasing number of MNs. Data 
show mean±SD (n=4). *** p-value<0.001 
 
A.1.4. Effect of number of MNs on ISF sample volume 
  
Figure A. 4: ISF sample volume collected from pig skin ex vivo using suction (-85 kPa) 
after puncture with different numbers of metal MNs measuring 750 µm in length. 
Data show mean ± SD (n≥3). 
 
A.1.5. Effect of MN length on ISF sample volume  
 
Figure A. 5: ISF sample volume collected from pig skin ex vivo using suction for three 




A.1.6. Effect of MN geometry on ISF sample volume 
  
Figure A. 6: ISF sample volume collected from pig skin ex vivo using -85 kPa suction 
for MNs with different geometries. The planar metal MNs constitute a 2 x 5 array of 
MNs measuring 750 µm in length and 200 µm by 25 µm in cross section at the base. 
The conical polymer MNs constitute a 10 x 10 array of MNs measuring 600 µm in 
length and 300 µm in diameter at the base. The pyramidal polymer MNs constitute a 
10 x 10 array of MNs measuring 500 µm in length and 250 µm by 250 µm in cross 
section at the base. Data show mean ± SD (n≥3). 
 





Figure A. 7: ISF sample volume collected from pig skin ex vivo using -85 kPa suction 
for different pig skin configurations using MNs with different geometries. The MNs 
were the same as described in Figure A. 6. Curved skin had a radius of curvature of 
5 mm. Stretched skin had a strain of ~100%. Data show mean ± SD (n≥3). 
 
A.1.8. Schematic of positive pressure application for ISF sample collection 
 
Figure A. 8: A schematic showing how positive pressure was applied to pig skin ex 
vivo to sample ISF to simulate pinching the skin. After application of MNs, the skin 
was folded with the micropores at the apex of curvature, and a weight was rested on 
the upper skin surface while the lower skin surface was placed on a rigid surface. 
Force applied to skin was detected via a sensor placed between the skin layers.  ISF 
eluted from skin was collected using a paper strip on the skin surface. 
 






Figure A. 9: Microneedle design and apparatus for vacuum application to skin of 
human participants. (a) MN patch configuration used for insertion into skin to create 
micropores. (b) Suction apparatus used to create vacuum on the skin site (red arrow 
indicates the suction cup, black arrow indicates the vacuum pump and regulator). (c) 
Top view of skin sites through the suction cup as vacuum is being applied to skin (each 
of the five regions of exposed skin have a diameter of ~1 cm).  
 
A.1.10. Correlations between concentrations of glucose and total protein in ISF and 
plasma of human participants 
 
Figure A. 10: Concentration of analytes in ISF vs. plasma of 11 healthy human 
participants. (a) Concentration of glucose in ISF vs. plasma. Dotted line indicates best 






A.2. Theoretical model to predict ISF collection rates  
A.2.1. ISF collection by diffusion into hydrogel microneedles  
In this section we model two different hydrogel systems: physically crosslinked PVA 
hydrogel MNs developed in this study and chemically crosslinked rapidly swelling, 
methacrylated hyaluronic acid (MeHA) hydrogel MNs recently published by Chang et al. 
[169]. 
ISF collection using hydrogel MNs involves ISF first diffusing through dermis and then, 
upon partitioning into the hydrogel, diffusing through the hydrogel matrix. Diffusive 







with the following boundary conditions: C(x, 0) = C0, C(0, t) = Cderm
inter , C(∞, t) = C0, 
where C is ISF concentration in dermis, Dderm is ISF diffusivity in dermis (8.72 x 10-10 m2/s, 
see Eq. 2), Cderm
inter  is ISF concentration in dermis at the MN interface, C0 is ISF 
concentration in unperturbed dermis (0.7 g/mL) [71], t is time and x is position. 
Diffusivity of ISF in dermis was estimated using values for permeability of water through 








where 𝜑 is the solute partition coefficient (ratio of concentration of solute in porous 
medium to free solution in the dermis, 0.7 (1)), Dderm is diffusivity of ISF, L is thickness of 
the barrier (thickness of dermis = 1.7 mm) and K is water permeability in dermis (6.11 x 
10-7 m/s, [254]). Substituting the values into Eq. 2 gives Dderm = 8.72 x 10-10 m2/s. 
Integrating Eq. 1 and applying the boundary conditions, we get ISF flow rate at the dermis-









 (C0 − Cderm
inter )A (3) 
where A is MN surface area, which is 5.12 x 10-8 m2 for the PVA MN, based on inserted 
MN dimensions of 100 µm x 100 µm at the base with 250 µm height and a pyramidal 
shape, and is 7.6 x 10-8 m2 for the MeHA MN, based on inserted MN dimensions of 125 
µm x 125 µm at the base with 300 µm height and a pyramidal shape.  







with the following boundary conditions: C(x, 0) = 0, C(0, t) = CMN
inter, C(∞, t) = 0, 
where C is ISF concentration in MN, CMN
inter is ISF concentration in the MN at the dermis 
interface and DMN is ISF diffusivity in MN. DMN for PVA hydrogels is 1.8 x 10-11 m2/s (4) 
and DMN for rapidly swelling MeHA hydrogels can be approximated as equal to self-




Integrating Eq. 4 and applying the boundary conditions, we get ISF flow rate at the dermis-











Since ISF flow leaving the dermis equals ISF entering the MNs, Eqs. 3 and 5 are equal. 
CMN
inter and Cderm
inter  are related to each other by the partition coefficient, which is the ratio of 
equilibrium concentration of ISF in the MN (0.67 g/mL, obtained experimentally by 
measuring weight before and after equilibrium swelling of PVA hydrogel) and the dermis 




inter = k = 0.96        (6) 
Flow into the MNs was calculated over regular time intervals of 1 min. The predicted ISF 
concentration profiles and collection rate for PVA MNs are shown in Figure A. 11a,b. This 
analysis predicts a sample volume collected by a 100-MN PVA patch over 12 h to be 0.029 
µL. The experimental value is 0.003±0.001 µL. The predicted value is ~10 fold larger than 
the predicted value, but is in reasonable agreement, given the simplified theoretical analysis 
with no fitted parameters. Because the diffusivity of ISF in the hydrogel is smaller than in 
the dermis, this results in the rate-limiting step for uptake being the diffusion of ISF within 
the hydrogel (Figure A. 11a).    
For rapidly swelling MeHA hydrogel MNs, the analysis predicts a sample volume collected 




determined by Chang et al. [169] is ~2.5 µL over 20 min, which is in good agreement with 
the predicted value. In this case, the diffusivity in the dermis is smaller than in the hydrogel, 
and hence flow through the dermis is the rate-limiting step. 
 
  
Figure A. 11: Model predictions of ISF collection by diffusion into hydrogel 
microneedles. (a) Concentration profile of ISF in the dermis and PVA MN at time 0 
min (black line) and 12 h (dotted line). (b) ISF volume collected from skin into PVA 
MNs over time (c) Concentration profile of ISF in the dermis and MeHA MN at time 
0 min (black line) and 20 min (dotted line). (d) ISF volume collected from skin into 





A.2.2. ISF collection by diffusion into micropores  
ISF collection by diffusion into micropores is modelled in the same way as ISF collection 
by diffusion into hydrogel MNs, except the ISF diffusivity in the micropore is taken to be 
that of water self-diffusivity, ~2.3 x 10-9 m2/s [256] and the micropore geometry differs 
from that of the hydrogel MN, such that the micropore-dermis interfacial area, A is 5 x 10-
8 m2 (based on 500 µm MN insertion depth, MN pore cross sectional dimensions of 50 µm 
x 10 µm and assuming the MN pore retracts ~4 fold after removing the MN with original 
cross-sectional area of 200 µm x 25 µm [123]).  
The predicted ISF concentration profiles and collection rate for micropores are shown in 
Figure A. 12. This analysis predicts a sample volume collected by 10 micropores over 20 
min to be 0.15 µL. The experimental value is 0.039±0.035 µL, which is ~4-fold lower than 
the predicted value, but is in reasonable agreement, given the simplified theoretical analysis 





Figure A. 12: Model predictions of ISF collection by diffusion into micropores. (a) 
Concentration profile of ISF in the dermis and micropore at time 0 min (black line) 
and 20 min (dotted line). (b) ISF volume collected from skin into micropores 
 
A.2.3. ISF collection by capillary flow into porous microneedles and hollow microneedles 
Collection of ISF by capillary action involves two steps: (i) flow through dermis towards 
the MN or micropore and (ii) uptake and flow in the MN or micropore.  








where Q is flow rate of ISF, ∆P is pressure difference across the capillary, L is length of 
capillary (500 µm), and µ is viscosity of ISF (assumed to be similar to plasma viscosity, 
0.0012 Pa.s [257]). 





where 𝛾 is surface tension of ISF (assumed to be similar to water 0.072 N/m at 370C) and 




Estimated flow after 20 min through a capillary with radius ~ 5 µm (corresponding to a 
single pore in filter paper, which is contains many porous pathways) or 130 µm 
(corresponding to a 25G needle) is 14 µl or 250 ml, respectively..  
Since the experimental ISF collection values are much lower than flow rates through the 
bore of a hollow needle or that expected through a large network of capillaries in a porous 
paper MN, uptake of ISF by porous filter paper or a hollow MN can be considered 
instantaneous. As confirmation of this expectation, when 20 µl of water was pipetted onto 
the porous paper MNs, the water was absorbed into the paper within seconds. Therefore, 
we assumed that ISF coming to the dermis-MN interface is absorbed instantaneously and 
the concentration of ISF at the interface is 0.  







                                                                                               (9) 
with the following boundary conditions: C(x, 0) = C0 , C(0, t) = 0, C(∞, t) = C0 where C 
is concentration of ISF in dermis, 𝐷𝑑𝑒𝑟𝑚 is ISF diffusivity in dermis (8.72 x 10
-10 m2/s, see 
above) and C0 is ISF concentration in unperturbed dermis (0.7 g/mL). 













The exposed outer surface area of a porous paper MN sandwiched between two metal MNs 
is 2.7 x 10-8 m2 (based on MN dimensions of 50 µm x 200 µm cross-sectional area and 400 
µm insertion depth and void fraction of 68%) and area of the open tip of a hollow 25G MN 
is 5.3 x 10-8 m2 (based on an inner diameter of 260 µm) (see Fig 2). Substituting these 
values in the flux equations, the predicted ISF concentration profiles and collection rate are 
obtained and shown in Figure A. 13.  
 
The predicted ISF volume collected by each MN over 20 min follows. For a porous paper 
MN it is 0.021 µL and for a hollow 25G MN is 0.041 µL.  The experimentally observed 
flow rates for porous paper MN is 0.0033±0.0031 µL and for a hollow 25G MN is 
0.025±0.019 µL. The predicted values are 6.4 and 1.6 times larger than the experimental 
values, which represents reasonable agreement given the simplifying assumptions of this 
analysis with no fitted parameters. Since the rate of transport through MN capillaries is 
much faster than through dermis, the rate of ISF uptake is limited by the diffusion of ISF 





Figure A. 13: Model predictions of ISF collection by capillary flow into porous and 
hollow microneedles (MNs). (a) Concentration profile of ISF in the dermis and MN 
at time 0 min (grey line) and 12h (dashed line). (b) ISF volume entering MNs over 




A.2.4. ISF collection by osmotically driven flow through micropores 
Flow of ISF from the dermis towards a micropore filled with an osmolyte is mediated by 
an osmotic pressure gradient. This pressure gradient is proportional to the concentration 
gradient of the osmolyte on both sides of the micropore-dermis interface. In our MN 
system, there is no semipermeable membrane separating the osmolyte from the dermis. 
Hence, the osmolyte diffuses out of the micropore. We modeled this system by 




osmotically driven convection into the micropore. We assume that within the micropore, 
mixing is instantaneous and concentration of maltose is uniform. 







        (11) 
with the following boundary conditions: CMal(x, 0) = 0, CMal(0, t) =
CMal derm
inter , CMal(∞, t) = 0  where CM is concentration of maltose in dermis, CMal derm
inter  is 
concentration of maltose in the dermis at the micropore interface, Dmal is diffusivity of 
maltose in dermis (2.6 x 10-10 m2/s [258]). 







inter A       (12) 
where QMal
Diff is the rate of maltose diffusing out of the micropore, t is time and A is surface 
area of the micropore (1.3 x 10-7 m2, based on micropore dimensions of 100 µm base width 
and 600 µm length). CMal derm
inter  is related to concentration of maltose in the micropore by a 
partition coefficient k=0.7 (10). The initial concentration of maltose in the micropore is 
400 mg/mL (1.17 M). Osmotic pressure of 1.17 M maltose solution is 2.6 MPa [259]). 
Diffusion of maltose out of the micropore and into the dermis creates a concentration 




gradient decreases over time as the maltose continues to diffuse deeper into the dermis 
(Figure A. 14). This pressure gradient is responsible for osmotic flow of ISF into the 
micropore. The rate of ISF coming into the micropore by osmosis can be calculated by 
combining Darcy’s Law for flow of ISF in a porous medium (i.e., dermis) [260] with Van’t 
















where Q̇ISF is flow rate of ISF into the micropore, κ is flow conductivity of ISF in dermis, 






 [45, 262]), PMal
Osmotic is osmotic pressure of maltose, L 
is the characteristic length (here the length of dermis required to drop maltose concentration 
to 1% of wall concentration, 1.82√4Dmalt, as determined by analytical solution for 
concentration obtained from Ficks second law and fixing the ratio of 𝐶 CMal derm
inter⁄  at 0.01), 
CMal derm
inter  is the concentration of maltose at the micropore-dermis interface. 
The CMal derm
inter  and Q̇ISF were computed over time iterations of 1s. The predicted ISF 
concentration profiles and collection rate are shown in Figure A. 14. The predicted amount 
of ISF absorbed by each micropore over 20 min is 0.036 µL. The experimental flow rate is 
0.021±0.020 µL/ µpore, which is in good agreement. Predicted ISF flow rate decreases 
over time as more maltose diffuses out of the micropore. The decrease of osmotic pressure 
over time as the osmolyte diffuses into the dermis limits the pressure gradient and 





Figure A. 14: Model predictions of ISF collection by osmotically driven flow through 
micropores. (a) Concentration profile of ISF (black lines) and maltose (gray lines) in 
the dermis and micropore at time 0 min (solid lines) and 20 min (dashed lines). (b) 
ISF volume entering a micropore over time.  
 
A.2.5. ISF collection by pressure-driven convection via micropores  
Flow under pressure through the dermis can be modelled as flow through a porous medium 






A         (14) 
where 𝑄𝐼𝑆𝐹 is the flow rate of ISF through dermis, 𝜅 is the flow conductivity of dermis 






) [262], L is the characteristic 
length (here thickness of dermis,  L=0.0017 m), ΔP is the applied pressure difference (85 




10-7 m2, based on micropore dimensions of 200 µm x 100 µm cross-sectional area and 650 
µm length). Flow rate of ISF through the micropore can be estimated by the Hagen-
Poiseulle equation and is found to be much greater than the flow rate through dermis 
(calculation not shown). Thus, the rate of ISF collection is limited by the applied pressure 
drop and the flow conductivity of dermis. 
The predicted ISF concentration profiles and collection rates are shown in Figure A. 15. 
For application of suction, the predicted flow rate for a 10-MN array over 20 min is 0.2 
µL, as compared to the experimental value of 0.84±0.60 µL. F or positive pressure 
application, the predicted flow rate is 0.12 µL, as compared to the experimental flow rate 
of 0.29±0.20 µL. These predictions are in reasonable agreement with experiments, given 
the simplified theoretical analysis with no fitted parameters  
  
 
Figure A. 15: Model predictions of ISF collection by pressure-driven convection via 
micropores.  (a) Concentration profile of ISF in the dermis and micropore at time 0 
min (solid black  line) and 12 h (dashed black line). (b) ISF volume entering 




A.2.6. Correlation between experimental values 
The predicted values match the experimentally observed values for volume of ISF collected 
over 20 min reasonably well, especially given the simplified theoretical analysis with no 
fitted parameters, and are often within the error bars of the data. The volume of ISF is 
largest for pressure-driven convection, followed by osmosis, use of capillary flow in 
hollow or porous MNs and diffusion into hydrogel MNs or micropores. 
 
  
Figure A. 16: Predicted (grey dots) and experimental (black bars) values for ISF 
volume collected from skin over 20 min for each of the mechanisms discussed. (ISF 





A.3. Materials and methods 
A.3.1 Microneedle fabrication 
Hydrogel microneedles: Hydrogel MNs were prepared by dissolving PVA (31-50 kDa, 
99% hydrolyzed, Sigma Aldrich, St. Louis, MO) in water at 95°C to make a 15% (w/v) 
solution. The solution was cast onto silicone (Sylgard 184, Dow Corning, Midland, MI) 
molds containing a 10 x 10 array of cavities in the inverse shape of MNs, and vacuum was 
applied for 30 min to allow the solution to enter the mold cavities, as described previously 
[263]. The filled molds were kept at 80°C for 3 – 4 h to crosslink the PVA. The molds were 
then dried overnight at room temperature (20 – 25°C) and humidity (20 – 50 % rh), after 
which the dried MN arrays were peeled from the molds (Fig. 1a,b). The resulting MNs 
were 520 µm tall and 220 µm by 220 µm at the base, tapering to a sharp tip. The MNs were 
arranged in a 10 x 10 array in an area of 0.50 cm2.  
Solid metal microneedles: Stainless steel microneedles were fabricated as five-needle 
planar arrays (Tech-Etch, Plymouth, MA). Each microneedle was 750 µm tall, with a cross-
sectional area of 200 µm by 25 µm (Fig 1d).  
Porous microneedles: To make porous MNs, a sheet of filter paper (Whatman #1 
chromatography paper, GE Healthcare, Chicago, IL) was adhered to an array of solid metal 
MNs using double-sided adhesive tape (Hi-Tack Medical Transfer Adhesive 1, 504XL, 4.0 
mil, 62# Liner, 3M, St. Paul, MN). With the metal side up, the stainless steel acted as a 
protective mask during etching with a raster laser beam (Versa Laser VLS 3.50, Universal 




resulting metal-paper MN array was attached to another metal MN array with adhesive 
tape, effectively sandwiching the paper between two metal MN arrays. The metal MNs 
provided mechanical strength, while the filter paper provided the porous medium for 
collection of ISF (Fig. 2a).  
Hollow metal microneedles: To make hollow MNs, hypodermic needles (25, 30 and 33 
gauge, Becton Dickinson, Franklin Lakes, NJ) were shortened to ~1.5 mm in length from 
the luer-lock hub by cutting the needle using a cordless rotary tool (Dremel 800, Robert 
Bosch Tool Corporation, Mount Prospect, IL), as described previously [264]. The needle 
was further shortened to ~750 µm in length and the bevel was produced by grinding the 
shortened needle at a 60° angle against the sanding band attachment of the rotary tool. A 
constant stream of water was flowed through the needle bore to prevent heat buildup and 
the metal from melting (Fig 2c).  
10-MN arrays: To make solid MNs in 10-MN arrays, two planar arrays of solid metal MNs 
were aligned with a sheet of filter paper adhered using double-sided tape between their 
base plates but not between the MNs themselves (Fig. 1d).  
Coated metal microneedles: Coated MNs were made by dipping solid metal MNs five 
times into an aqueous solution of 40% (w/v) maltose (Sigma Aldrich, St. Louis, MO) (Fig 





A.3.2. Measurement of ISF content in skin 
Pig ear skin was obtain freshly excised from feeder pigs (generously provided by Hollifield 
Farms, Conyers, GA) and then frozen at –80°C until use. To measure ISF content in the 
skin, pieces of skin were pre-weighed (0.10-0.15 g per piece) and lypophilized (Freezone 
6 liter freeze dryer, Labconco, Kansas City, MO), as described previously [265]. The 
weight loss after lyophilization was taken to equal the ISF content in the skin, assuming 
complete water removal by lyophilization. Use of pig skin in this study was exempt from 
review by the Georgia Tech Institutional Animal Care and Use Committee.  
To measure the amount of ISF that could be removed from the skin under pressure, pre-
weighed pieces of pig skin (2.0-2.5 g per piece) were placed on a benchtop over tissue 
paper (Kim-wipes, Kimberly-Clark, Neenah, WI). A load of 9.1 kg was placed on the skin, 
which applied a pressure of ~220 kPa over the ~4 cm2 of skin surface area. The weight loss 
of the skin was measured periodically for 20 min.  
A.3.3. Measurement of ISF collection from skin during microneedle-based protocols 
Skin preparation: Pig ear skin was sandwiched in a Franz diffusion cell between the donor 
and receiver chambers using a clamp (PermeGear, Hellertown, PA). The system was sealed 
using Parafilm (Bemis Company, Neenah, WI). The receiver chamber was filled with a 1 
mg/mL solution of sodium fluorescein (Sigma-Aldrich) in phosphate-buffered saline. The 
setup was kept overnight at 37°C to equilibrate the skin with the fluorescein solution. The 
skin was then used for testing of ISF collection during MN-based protocols. To verify that 




equilibration was taken by removing the epidermis and micropipetting out ISF from the 
dermis. Fluorescein concentration in this ISF was 1.1 ± 0.4 mg/mL.  
ISF collection using hydrogel microneedles: Hydrogel MN arrays were inserted into 
porcine skin on a benchtop by pressing the MNs into the skin using the back of the thumb. 
The MN arrays were secured to the skin using adhesive tape (3M, St. Paul, MN). The skin 
with the MN patch was again sandwiched in Franz cells as described above, and left in 
place for 12 h at 370C to allow the MNs to extract ISF.  
ISF collection using capillary action: Three methods were used. 1) The porous MN arrays 
were inserted into pig skin on a benchtop, and left in skin for 20 min to allow MNs to 
absorb surrounding ISF. The MNs were then removed and the two stainless steel layers 
were separated to expose the paper. 2) To make micropores in skin, a 10-MN patch was 
inserted into pig skin and removed immediately to create an 2x5 array of 10 micropores. 
The skin was left for 20 min to allow the micropores to absorb surrounding ISF. Fluid on 
the skin was wiped off using a tissue-paper wipe (Kim-wipe, Kimberly Clark, Neenah, 
WI). 3) The hollow MNs were attached to a 3mL syringe and inserted into pig skin. The 
MNs were left in place for 20 min, after which the MNs were removed and ISF inside the 
hollow MNs was collected for further analysis. 
ISF collection enhanced by osmosis: Two methods were used. 1) The coated MN patch 
was inserted into pig skin and left in skin for 5 min to allow the maltose to dissolve off the 
MNs in the skin. The patch was removed to create 10 micropores in the skin filled with 




with a tissue-paper wipe. 2) To fill micropores with osmolyte solution, the plain/coated 
stainless steel MNs were inserted into skin to create micropores. 10 µL of maltose solution 
was pipetted on the skin site. The system was left for 20 min to allow the micropores to 
take up ISF. Fluid on the skin surface was collected with tissue-paper wipes.  
ISF collection by pressure-driven convection through micropores: For suction, a 10-MN 
array was inserted into skin and removed immediately to create micropores. The 
micropores were covered with paper: tissue-paper wipes (Kim-wipes), gauze pads 
(Johnson and Johnson, New Brunswick, NJ) or plasma treated gauze pads (Plasma Cleaner 
PDC-32G, Harrick Plasma, Ithaca, NY). A suction cup attached to a vacuum pump 
(Laboport Series N840.1.2FTP Pump, KNF Neuberger, Trenton, NJ) was placed over the 
micropores, and suction was applied for the desired amount of time. After stopping the 
vacuum pump, the MN pore covering was removed and soaked in 1 mL of DI water for 24 
h to elute out the ISF contents. To make a curvature on the skin surface, a curved disc 
(Skittles, Wrigley Company, Chicago, IL) was placed beneath the skin and the skin was 
secured to a wooden board under mild tension. To stretch out the skin, the ends of the skin 
piece were stretched out by hand and secured to a wooden board.  
For MNs utilizing pressure, a 10-MN patch was inserted into pig skin and removed 
immediately to make micropores. The skin piece was folded in half with the pores at the 
apex, and placed horizontally on the benchtop (Figure A. 8b in Appendix A). The 
micropores were covered with a tissue-paper wipe to absorb the ISF that eluted out. 
Pressure was applied using different cast-iron weights (Body Solid, Forest Park, IL) to 




10N, Tekscan, South Boston, MA). The load was kept for the desired amount of time. After 
the load was taken off, the ISF absorbed by the issue-paper wipe was collected. 
Quantification of ISF volume extracted ex vivo: To elute out all the ISF components 
absorbed using MN patches, the MNs or the tissue paper or gauze used to collect the ISF 
was soaked in DI water for 24 h. The concentration of fluorescein in the samples was 
measured against a standard calibration curve of fluorescein on a standard 96 well plate 
(Costar Black Polypropylene, Corning, Corning, NY). The plates were analyzed in a plate 
reader (Synergy MX, BioTek Instruments, Winooski, VT) at an emission wavelength of 
525 nm and absorption wavelength of 590 nm. The amount of ISF absorbed was calculated 
based on the detected concentration in the unknown samples and the known fluorescein 
concentration in skin at 1mg/mL.  
Collection of ISF from skin of human volunteers: ISF was collected from selected skin sites 
of 6 human volunteers. The cohort consisted of 5 males aged 24 ± 2 years and 3 females 
aged 26 ± 1 years. Before MN application, the site was disinfected using an antiseptic 
solution (Hibiclens Antiseptic Skin Cleanser, Mölnlycke Health Care US, Norcross 
Georgia) and alcohol swabs (Becton Dickinson), and then marked using a pen and 
template. Solid metal MNs were terminally sterilized using ethylene oxide treatment and 
inserted into the skin at the marked sites and then removed within 30 s. To avoid possible 
contamination of ISF with blood, capillaries damaged by MNs were allowed to repair for 
≤ 20 min after MN insertion. Suction was applied at –34-68 kPa to the skin site (NP-2, 
NPCSS, Electronic Diversities, Finksburg, MD) for 20 min to withdraw ISF from the skin 




sterile gauze pads (Johnson and Johnson), which were then soaked in 0.5 mL DI water to 
elute out the contents absorbed by the gauze. All human volunteers provided informed 
consent. This study was approved by the Georgia Tech Institutional Review Board.  
Determination of ISF volume and biomarkers collected from skin in vivo: The ISF volume 
collected was measured by determining the sodium ion concentration in the collected fluid. 
Sodium ion concentration was determined using a sodium ion sensitive electrode 
(perfectION comb NA, Mettler Toledo, Columbus, OH). The sodium ion content in the 
samples was normalized against a standard sodium ion concentration in ISF of 135 mmol/L 
[48]. This technique has been used in the past to calibrate analyte levels for an individual 
when variable volumes of body fluid are sampled [89]. The amount of glucose in the 
sample was measured using a glucose assay (Amplex® Red Glucose Assay Kit, Thermo 
Fisher Scientific, Waltham, MA) and divided by the volume of ISF collected to obtain 
concentration. The total protein content was detected using a micro BCA assay (Micro 
BCA Protein Assay Kit, Thermo Fisher Scientific) and divided by the volume of ISF 
collected to obtain concentration. 
A.3.4 Statistics 
Statistical analysis was performed using Graphpad Prism 7 software (Graphpad Software, 
La Jolla, CA). Statistical significance was assessed using t-tests. P-value<0.05 was taken 






SUPPORTING INFORMATION FOR CHAPTER 5. 
 
B.1. Supplementary methods 
B.1.1. Obtaining plasma and ISF samples 
The study was conducted using 10 healthy human volunteers and was approved by the 
Institutional Review Board (IRB) at the Georgia Institute of Technology. Written informed 
consent was obtained from all volunteers. The cohort consisted of 7 males aged 24 ± 6 
years and 3 females aged 27 ± 7 years. Blood samples were taken from the forearm by 
venipuncture. The blood samples were collected into K3 EDTA tubes (Vacutainer Blood 
Collection Tube, Becton Dickinson, Franklin Lakes, NJ) and spun down at 9,000 rpf for 
15 min (5702 RH centrifuge, Eppendorf, Hamburg, Germany) to separate the plasma. 
Plasma was collected in LoBind Protein tubes (Eppendorf) and stored at -80°C.  
Skin suction blister fluid was collected from suction blisters generated on the thigh by the 
method developed by Kiistala.[73] The skin was first disinfected with alcohol wipes and 
then suction was applied using  a NP-2 Negative Pressure Cutaneous Suction System 
(Electronic Divestities, Ridge Road, Finksburg, MD). The sterile orifice plates with 5 
circular holes (8 mm diameter each) along with the suction cup was firmly attached to the 
skin using straps. Suction at 50 – 70 kPa below atmospheric pressure was applied at a 




and hemoglobin-free blisters was collected using a Micro-Fine syringe (Becton 
Dickinson). The fluid was stored in LoBind Proetin tubes (Eppendorf) at -80C.  
B 1.2. High-resolution metabolomics 
Plasma and ISF samples were prepared for HRM analysis using established methods.[185, 
266, 267] Because only 15 μL of ISF was available for HRM, all ISF samples were diluted 
to 50 μL using LC-MS grade water prior to sample preparation. Stored aliquots were first 
thawed on ice, and then 50 μL of biofluid (plasma or diluted ISF) was added to 100 μL of 
acetonitrile containing a mixture of stable isotopic standards, vortexed and allowed to 
equilibrate for 30 min. Proteins were precipitated by centrifuge (16.1 × g at 4°C for 10 
min), and extracts were stored in a refrigerated autosampler until analysis (<24 h). 
Triplicate 10 μL aliquots were analyzed using reverse-phase C18 liquid chromatography 
(Ultimate 3000, Dionex, Sunnyvale, CA) and Fourier transform mass spectrometry (Q 
Exactive, Thermo Scientific, Waltham, MA) operated in positive electrospray ionization 
mode, resolution (FWHM) of 70,000 and mass-to-charge (m/z) range of 85-1,250[268, 
269]. All samples were analyzed in one batch, with a pooled plasma quality control 
reference sample included at the beginning and end of the run. Raw data files were 
extracted and processed (e.g., peak picking and retention time alignment) using 
apLCMS[225] with modifications by xMSanalyzer,[226] with each unique mass-to-charge 
(m/z) feature defined by m/z, retention time and ion abundance.  




Statistical analyses were conducted using the metabolite “feature table,” a spreadsheet 
produced after data extraction and alignment. The feature table contains information on 
all m/z features, with the first and second columns containing feature m/z values and 
retention times, respectively, and subsequent columns containing the metabolite 
intensities in the study samples. The “presence” or “absence” of a metabolite feature in 
a sample was defined by its “missingness” in the feature table (i.e., value of 0), which 
reflects whether the feature was detected or not detected, respectively. 
Metabolite features that were elevated in ISF compared to plasma were identified using 
a paired fold change analysis. This was assessed on the raw dataset by first replacing 
missing values with one-half the minimum value for each feature, then calculating the 
log2-fold changes (ISF/plasma) within each pair for each feature; here, features with log2-
paired fold changes > 1.0 (equivalent to raw fold changes > 2.0) in at least 8 of 10 sample 
pairs were considered significant and selected for further characterization. 
Correlations of m/z feature intensities between plasma and ISF samples were assessed 
on the raw dataset using Spearman rank-order correlation coefficients. The m/z features 
that were strongly correlated between plasma and ISF (Spearman rho > 0.7, p < 0.10) 
and were present in at least 4 out of 10 sample pairs were selected for further 
characterization by manual annotation. 
B1.4. Metabolite feature identification 




Initial annotation of metabolites present in ISF and plasma (Tables S1 and S2) was 
completed using a data-driven approach that combined Kyoto Encyclopedia of Genes and 
Genomes (KEGG)[187]
 
database matching (± 5 ppm) with a custom dataset-wide 
deconvolution and identification algorithm; metabolites with two or more associated 
adducts/isotopes (adduct groups) were selected for further characterization. Matches were 
curated to remove unlikely peak groupings and/or biologically-implausible compounds so 
that each adduct group was matched uniquely to a single chemical compound. Metabolites 
were also identified by comparing features to an in-house library of metabolites from 
authentic reference standards run under identical assay conditions;[249] study features 
were matched to reference standard metabolites using an accurate mass threshold of 5 
ppm and retention time threshold of 30 s. 
B1.4.2. Manual annotation 
We used a manual annotation scheme to annotate features from the fold change and 
correlation analyses. To accurately identify features elevated in a biofluid, we used a 
custom grouping algorithm to attempt to assign features to adduct groups by parent 
monoisotopic mass, and we removed all features that were not the most intense peaks 
(i.e., ‘base peaks’) within their adduct groups. For strongly-correlated features identified 
in the correlation analysis, we also used the grouping algorithm to assign these features 
to adduct groups. If multiple features from the same metabolite were found among the list 
of strongly-correlated features, the feature with the strongest correlation was retained for 
further characterization. Manual compound matching was then conducted in the Human 
Metabolomics Database (HMDB)[270]
 











(if the feature was not assigned to an adduct group). 
Final curated annotation tables reflect metabolite features with a unique database match, 
or when multiple matches were found, the most biologically-likely match. Putative 
annotations were assigned confidence scores (1-4, where 4 is highest): an annotation with 
a score of 4 reflects that the metabolite feature was successfully assigned to a metabolite 
cluster and the monoisotopic mass had a unique compound match in HMDB; score of 3, 
the feature was assigned to a metabolite cluster, but the annotation was selected as the 
most biologically- plausible match from 2 possible compounds; score of 2, the feature 







; and score of 1, the feature was not assigned to a cluster and the 







. Compounds were assigned to categories based on biological knowledge of 
metabolite structures and/or functions. 
B1.5. Network and pathway analysis 
Biological functions of metabolites correlated between plasma and ISF were 
characterized by Mummichog,[271]
 
which unifies network and pathway analysis to 
predict metabolite identities and functional metabolic changes in untargeted 
metabolomic datasets. Briefly, the Spearman correlation results were entered into 
Mummichog, with the requirement that the [M+H]
+ 
ion was present for a predicted 




represents the high-confidence metabolites identified from a combined network module 
analysis and pathway analysis; subnetworks in the activity network with ≤ 3 nodes were 
omitted from the figure. All metabolic pathways significant at an adjusted p < 0.01 were 
included in Figure B. 1. To assess the biological roles of the metabolites identified in 
the network modules, all KEGG IDs from significant modules were searched in the 
KEGG BRITE database[187]
 
to find common biological functions. 
B1.6. Metabolite set enrichment analysis 
Metabolite set enrichment analysis (MSEA) was conducted in MetaboAnalyst 3.0.[272]
 
Briefly, MSEA works by comparing a list of compounds from a study against a collection 
of defined metabolite sets (i.e., covering metabolic pathways, disease states), and 
“overrepresented” metabolite sets within the study metabolite list are identified.[273]
 
In 
the current study, lists of curated, putatively-identified compounds (by HMDB ID) were 
used for MSEA; overrepresented pathways were assessed using the pathway-associated 
metabolite set library (88 metabolite sets); metabolite sets consisting of < 3 metabolites 






Table B. 1: Metabolites detected in ISF. 






Cholesterol RS 10 10 
 Creatinine DD/RS 10 10 
 Glucose DD/RS 10 10 
 Urea DD 10 10 
Amino acid 
metabolism 
Alanine DD/RS 10 10 
 
Arginine DD/RS 10 10  
Asparagine DD/RS 10 10  
Aspartate DD 7 9  
Aspartate 4-semialdehyde DD 10 10 
 Betaine DD 10 10 
 Cucurbitine DD 10 10  
Citrulline DD/RS 10 10  
Glutamate DD/RS 10 10  
Glutamine DD/RS 10 10  
Histidine DD/RS 10 10  
Kynurenine RS 10 9 
 (Iso)leucine DD/RS 10 10 
                                                 






Table B.1 continued     
Lysine DD/RS 10 10  
Methionine DD/RS 10 10  
Ornithine DD 10 10  
Oxoproline RS 10 10  
Phenylalanine DD/RS 10 10 
 Pipecolate DD 9 10  
Proline DD/RS 10 10  
Serine DD/RS 10 10  
Threonine RS 10 10  
Tryptophan DD/RS 10 10  
Tyrosine DD/RS 10 10  
Valine DD 10 10 
Lipids 2-
Aminoethylphosphocholate 
DD 10 10 
 3-Dehydroteasterone DD 10 10 
 3-Oxododecanoic acid DD 10 10 
 Dodecanamide DD 10 9 
 Glycodeoxycholate DD 10 4 
 Lauric acid RS 3 7 
 Linolenic acid RS 4 1  
LysoPC(16:1) RS 10 10  
LysoPC(18:0) RS 7 10  




Table B.1 continued     
PC(34:2) RS 10 10  
PC(36:2) RS 10 10  
PC(36:3) RS 10 10  
PC(36:4) RS 10 10  
PC(38:4) RS 10 10 
 Prostaglandin G2 DD 8 3  
sn-glycero-3-
Phosphocholine 
RS 10 10 
Arginine/proline 
metabolism 
4-Aminobutanoate DD 10 10 
 5-Amino-2-oxopentanoic 
acid 
DD 10 10 
 Creatine DD/RS 9 10 
Carnitine 
metabolism 
Acetylcarnitine RS 10 10 
 Crotonobetaine DD 10 10 
 Octanoylcarnitine DD 10 7 
 O-Decanoyl-L-carnitine DD 10 7 
 Palmitoylcarnitine DD/RS 10 2 
Histidine 
metabolism 
Histamine DD 10 10 
 Methylhistamine DD 10 10 
 N-Acetylhistamine DD 10 10 




Table B.1 continued    
Linoleic acid 
metabolism 
13(S)-HPODE DD 10 7 
 9(10)-EpOME DD 10 10 
 Linoleic acid DD 10 9 
Pyrimidine 
metabolism 
5,6-Dihydrothymine DD 10 10 
 
5,6-Dihydrouracil DD 10 10 
 5-Methylcytosine DD 10 10 
 Thymine DD 10 10 
Purine 
metabolism 
Deoxyadenosine DD 5 9 
 
Hypoxanthine DD/RS 10 10  
Uric acid DD/RS 10 10 
 Xanthine RS 10 3 
Sphingosine 
metabolism 
Ethanolamine phosphate DD 1 8 
 





DD 10 10 
 Butanoylphosphate DD 10 9 
 Calcium L-aspartate DD 10 1 
 Formyl phosphate DD 9 4 
 Fructose DD 10 7 




 Harmalol DD 10 9 
 Hydantoin DD 10 10 
 Lenticin DD 9 7 
 N1,N12-Diacetylspermine DD 10 6 
 Taurine DD 10 10 
 Tetrahydropteridine DD 10 10 
 Toxopyrimidine DD 10 10 
 Trimethylamine N-oxide DD 10 10 
 Tryptophol DD 9 7 
Pesticides 2-Hydroxybiphenyl DD 10 3 
 alpha-Naphthylthiourea DD 10 7 
 Athidathion DD 10 10 
 Bis(4-
chlorophenyl)methane 
DD 9 7 
 Carbendazim DD/RS 6 7 
 Chlorthiophos DD 10 10 
 Demeton-S-methyl DD 10 2 
 Diisopropyl phosphate DD 10 10 
 Fenuron-TCA DD 10 10 
 Fosamine DD 8 10 
 Metaldehyde DD 10 7 
 Methamidophos DD/RS 10 3 
 Prohydrojasmon DD 10 10 






1-Methylnaphthalene DD 10 7 
 Benzoic acid RS 10 1 
 4-Fluorocyclohexadiene-
cis,cis-1,2-diol 
DD 10 7 
Carcinogens 2-Naphthylamine DD 10 10 





DD 10 10 
Phytochemicals Lophophorine DD 10 9 
 Otonecine DD 10 10 
 Piperidine DD 10 10 
 Piperine DD 10 4 







DD 6 1 
 2,5,6-Tribromo-1-
methylgramine 




DD 10 8 
 Botrydial DD 10 4 
 Dibromobisphenol A DD 10 8 




 N-Cyclohexylformamide DD 1 10 
 N-Ethylammelide DD 10 9 
 Octachlorostyrene DD 10 9 
 Rhododendrin DD 10 8 
 Triethanolamine DD 0 10 
 Tritriacontane DD 0 9 
 
Table B. 2: Metabolites not detected in ISF. 









DD 10 0 
 Aflatrem DD 9 0 
 Ammelide DD 10 0 
 Bisphenol A 
bis(chloroformate) 
DD 10 0 
 Malathion DD/RS 10 0 
 Nabam DD 9 0 
 Triadimefon DD/RS 10 0 
 Trp-P-1 DD 10 0 
 Tuliposide B DD 10 0 
                                                 






Table B.2 continued    
Lipids alpha-D-Galactosyl-
diphosphoundecaprenol 
DD 9 0 
 3-Oxooctanoyl-CoA DD 8 0 
Porphyrin 
metabolism 
5-Aminolevulinate DD 10 0 




EDTA DD 10 0 
 Iodine DD 10 0 
 Iodoform DD 10 0 
Other 
endogenous 
4,8-Dihydroxyquinoline DD 10 0 
 alpha-Ketoglutaramate DD 9 0 
 Inosine 5-diphosphate DD 9 0 
 





Activity network displays biologically-connected metabolites matched to significant 
features with high confidence, with the strength of correlation between ISF and plasma for 
each metabolite denoted by the color scale. For clarity, only subnetworks with ≥ 4 






SUPPORTING INFORMATION FOR CHAPTER 6 
 
C.1. Microneedle insertion and vacuum application to skin 
 
Figure C. 1: Schematic of microneedle (MN) insertion and vacuum application to 
skin: (a) Stainless steel MN patch ready for insertion into skin comprising SC-stratum 
corneum, VE-viable epidermis, DR-dermis. (b) MN patch inserted into skin across 
epidermis and into superficial dermis. (c) Micropores created in skin after MN 
removal. (d) Vacuum applied over the micropores draws ISF to the skin surface 
(dashed blue arrows). 
 
C.2. Optimization of ISF sampling method 
ISF sampling method was optimized to enable reliable collection of ISF that minimized 
contamination with blood, the objective was to develop a method that reliably and 
reproducibly samples 1-10 µL of pure ISF from skin within 20 min. To achieve this 
outcome, key design parameters such as MN length, vacuum pressure, and timing of 





Blood vessels may break due to contact with MNs and/or applied vacuum, which can lead 
to blood contaminating the ISF. Since blood vessels are present to a greater extent deeper 
in dermis [71], more shallow depth of MN insertion and weaker vacuum should reduce 
bleeding. We found that insertion of MN of three different lengths (250 µm, 450 µm and 
650 µm) followed immediately by application of vacuum at -34 kPa or -50 kPa (gauge) 
resulted in bleeding onto the skin surface (Fig. S.2). Vacuum at -17 kPa (gauge) also led to 
bleeding when preceded by treatment with 650 µm long MNs, but the chances of bleeding 
decreased at shorter MN lengths, although 40% of participants still bleed when using 250 
µm MNs (Fig S.2.) We did not reduce MN length below 250 µm because insertion of 
shorter MNs into skin is unreliable because of skin elasticity during insertion [274]. 
 
Figure C. 2: Effect of microneedle (MN) length and vacuum pressure on bleeding 





We found that ISF collection varied dramatically among individual micropores in an array 
that all received the same MN and vacuum treatment. In general, the large majority of 
micropores remained dry. For example, after treatment with 250 µm-long MN and -17 kPa 
(gauge) vacuum, typically 5-10 micropores produced small droplets of blood and 5-20 
micropores produced clear ISF among the 100 micropores in the array (data not shown). 
This resulted in 3.7±3.4 µL of blood and 1.5±2.7 µL of ISF being collected (Fig S.2). The 
heterogeneity of micropores with blood is probably due to the small odds of a given MN 
hitting a capillary to cause highly localized bleeding at the site of the micropore. The cause 
of heterogeneity of micropores producing ISF is less clear.  
As a further attempt to eliminate bleeding, we delayed the onset of vacuum application in 
order to let broken capillaries reseal through the process of blood coagulation that starts 
within a few seconds [275]. Delaying application of vacuum at -50 kPa (gauge) for up to 
10 min had no effect on bleeding; 7-8 µL of blood came out with little or no ISF (Fig S.3a). 
We finally tried to slowly increase the vacuum from 0 kPa to -50 kPa (gauge) over the 
course of ~3 min. This reduced the amount of bleeding to almost zero and allowed us to 
collect 2.3±2.6 µL of ISF based on experiments repeated three times on every participant 






Figure C. 3: Effect of timing of vacuum application on bleeding and ISF sampling 
from the skin of 5 human participants. (a) Volume of blood collected from skin within 
15 s and (b) volume of ISF collected after vacuum application at -17 or -50 kPa (gauge) 
either 0, 5 or 10 min after MN patch treatment. # indicates blood was collected over 
20 min (not just 15 s). MN patches comprised 250 µm long MNs that were used to 
generate 100 micropores. Box plots show 5th, 25th, 50th, 75th and 95th percentiles (n = 
5 replicates) 
 
C.3. Detection of biomarkers in interstitial fluid, suction blister fluid and plasma 
Analysis of ISF from MN treatment, SBF from suction blisters and plasma from 
venipuncture from a cohort of 20 participants using high-resolution metabolomics using 
liquid chromatography-mass spectrometry (LC-MS) detected 10,338 features with 
hydrophilic interaction chromatography (HILIC), which better detects lipophilic 
compounds and 7,703 features with reverse-phase C18 chromatography, which better 
detects polar compounds. Among features found in HILIC and C18, 63% and 50% were 
respectively common to all three body fluids; 79% and 60% were respectively common to 
plasma and ISF, suggesting that these metabolite measurements in ISF may be a surrogate 




biomarkers can be uniquely assayed in ISF (Fig. 3). Comparing the 10,208 and 7,255 
features found respectively in ISF or SBF, only 72% and 64% were respectively common 
to both fluids, which demonstrates that ISF and SBF are not identical fluids, probably 
because of their different methods of sampling.  
To better interpret differences between ISF and SBF, a swab was wiped across intact skin 
and analyzed for biomarkers. Because ISF was collected from the skin surface, it may 
contain more epidermal and skin surface biomarkers than SBF. Consistent with this 
expectation, among 1,740 and 1,880 features detected in ISF and absent from SBF by 
HILIC and C18, respectively, 58% and 79% were respectively found in the skin wipe. 
Among 1,102 and 732 features detected in SBF and absent from ISF, respectively, 65% 
and 36% were respectively found in the skin wipe (Fig S.4). However, it should also be 
noted that 70% and 46% of features detected in skin swabs were respectively also found in 







Table C. 1: Demographics of 21 participants in ISF, SBF, and plasma metabolomics study 
 
Age (years) 
Mean (SD) 28.4 (7.1) 
Median (IQR) 26 (24-31) 
Sex 
Male (%) 10 (48%) 
Female (%) 11 (52%) 
Ethnic origin† 
White (%) 9.5 (45%) 
Black (%) 4.5 (21%) 
Asian (%) 7 (33%) 
BMI (kg/m2)§ 
Mean (SD) 23.1 (3.4) 
Median (IQR) 22.4 (20.4-25.6) 
 
†Ethnic origin was self-reported, participants were allowed to select multiple options (for 
subjects that chose multiple ethnicities, the calculated fraction was assigned to each 
ethnicity); §Height and weight were self-reported; SD = standard deviation; IQR = 





Table C. 2: Demographics of 20 participants in ISF, SBF, and plasma metabolomics study 
 
Age (years) 
Mean (SD) 28.4 (7.3) 
Median (IQR) 26 (23-31) 
Sex 
Male (%) 10 (50%) 
Female (%) 10 (50%) 
Ethnic origin† 
White (%) 9.5 (47.5%) 
Black (%) 3.5 (17.5%) 
Asian (%) 7 (35%) 
BMI (kg/m2)§ 
Mean (SD) 23.1 (3.5) 
Median (IQR) 22.3 (20.2-25.6) 
 
†Ethnic origin was self-reported, participants were allowed to select multiple options; 





Figure C. 4: Venn diagram showing overlap of features in ISF from MN treatment, 
suction blister fluid and surface swab. Samples were analyzed using (a) hydrophilic 
interaction chromatography (HILIC) and (b) reverse-phase C18 liquid 
chromatography. Features (i.e., ion peaks) were first screened for detection in ≥ 10 of 
20 subjects in at least one sample type. After filtering, a total of 10,316 features were 
detected. After filtering, a feature was considered “present” in a fluid if the feature 
was detected in that fluid in greater than 10% of samples (≥ 3 of 20 samples). Figure 
not to scale. 
 
Figure C. 5: Venn diagram showing overlap of features in plasma and surface swab. 
Samples were analyzed using (a) hydrophilic interaction chromatography (HILIC) 




considered “present” in a fluid if the feature was detected in that fluid in greater than 
10% of samples (≥ 3 of 20 samples). Figure not to scale. 
 
Table C. 3: Prevalence of selected clinically relevant biomarkers in ISF, SBF and plasma 
in matched samples from 20 human participants.  
 
Biomarker Prevalence of biomarker†  
Plasma ISF SBF 
Amino Acid Metabolites 
   
5-Hydroxy-l-trytophan 45% 60% 15% 
Hippurate 85% 85% 90% 
Kynurenine 90% 80% 95% 
Methionine sulfoxide 100% 100% 100% 
Methyl-histidine 80% 25% 55% 
Oxoproline 100% 100% 100% 
Amino Acids 
   
Alanine 100% 100% 100% 
Arginine 100% 100% 100% 
Aspartic acid 100% 100% 100% 
Citrulline 100% 100% 100% 
Cystine 100% 100% 100% 
Glutamic acid 100% 100% 100% 
Glutamine 100% 100% 100% 
Histidine 100% 100% 100% 




Table C.3 continued    
Methionine 100% 100% 100% 
Ornithine 100% 100% 100% 
Phenylalanine 100% 100% 100% 
Proline 100% 100% 100% 
Serine 100% 100% 100% 
Sum Leucine, Isoleucine 100% 100% 100% 
Taurine 100% 100% 100% 
Threonine 100% 100% 100% 
Tryptophan 100% 100% 100% 
Tyrosine 85% 100% 100% 
Valine 100% 100% 100% 
Clinical Markers 
   
Cholesterol 100% 80% 100% 
Cortisol 100% 30% 80% 
Creatinine 100% 100% 100% 
Homocysteine 20% 55% 55% 
Urea 100% 100% 100% 
Glucose 100% 100% 100% 
Lactic acid 75% 100% 100% 
Uric acid 100% 100% 100% 
Fatty Acid Metabolism 
   




Table C.3 continued    
Carnitine 100% 100% 100% 
11,14-Eicosadienoic acid 100% 100% 100% 
Adrenic acid 100% 100% 100% 
alpha-Linolenic acid 100% 95% 95% 
Arachidonic acid 100% 90% 100% 
Docosahexaenoic acid 100% 95% 100% 
Docosapentaenoic acid 100% 95% 100% 
Eicosapentanoic acid 100% 100% 100% 
gamma-Linolenic acid 100% 95% 95% 
Gondoic acid 100% 100% 100% 
homo-gamma-Linolenic acid 100% 100% 100% 
Linoleic acid 100% 95% 100% 
Margaric acid 60% 100% 25% 
Myristic acid 90% 100% 75% 
Myristoleic acid 85% 100% 45% 
Oleic acid 100% 100% 100% 
Palmitic acid 95% 100% 75% 
Palmitoleic acid 90% 100% 55% 
Stearic acid 75% 100% 15% 
Lipid Metabolism 
   
sn-glycero-3-Phosphocholine 100% 100% 100% 




Table C.3 continued    
Leukotriene B4 50% 100% 50% 
Resolvin E2 100% 100% 75% 
Nucleotide-related Metabolism 
  
Hypoxanthine 0% 80% 100% 
Xanthine 25% 90% 100% 
Uridine 100% 100% 100% 
Sterol Metabolism 
   
Deoxycholic acid 100% 55% 100% 
Taurodeoxycholic acid 100% 50% 100% 
TCA Cycle 
   
Citric acid 100% 100% 100% 
Malic acid 100% 100% 100% 
Pyruvic acid 100% 100% 100% 
Vitamins and Cofactors 
   
Choline 100% 100% 100% 
Pantothenic acid 50% 60% 95% 
Tetrahydrofolic acid 40% 60% 30% 






Table C. 4: Prevalence of clinically relevant biomarkers detected uniquely or 
predominately in ISF compared to plasma in matched samples from 20 human participants.  
Biomarker Medical significance Prevalence of biomarker§   
Plasma ISF SBF 
Urocanic acid* photocarcinogenesis, UV 
chromophore [196] 
0% 100% 100% 
N-Acetyl-D-
glucosamine 
micronutrient and drug, 
suppresses immune response, 
used to treat autoimmune 
diseases [276] 
10% 100% 90% 
Glycogen energy storage [277] 10% 100% 60% 
Diethanolamine* cosmetic formulations, 
carcinogen [278] 
5% 100% 60% 
Sphingosine* signaling molecule in skin [279] 10% 100% 50% 
Nebularine nucleoside 0% 100% 20% 
Tributyltin chloride environmental pollutant used as 
antifouling agent, now largely 
banned [280, 281] 
10% 100% 10% 
Citicoline naturally occuring and also a 
nutrient supplement [282, 283] 
10% 100% 5% 
Angiotensin (5-8) angiotensin cascade modulates 
vasoconstriction 
5% 100% 5% 
Pentadecanoic acid marker for intake of milk fat 
[284] 
10% 100% 0% 
Gamma Tocopherol form of vitamin E, micronutrient 
[285] 
5% 100% 0% 
Estradiol cypionate natural form of estrogen - plays a 
role in reproduction, lactation 
[286] 
0% 100% 0% 
Arginosuccinic acid biomarker for urea cycle disorder 
[287] 




Table C.4 continued    
Porphobilinogen biomarker for acute porphyrias, 
currently urine based detection 
[288] 
10% 95% 20% 
N1,N12-
Diacetylspermine 
cancer biomarker [289] 0% 95% 15% 
Triethanolamine* commonly used in skin care 
products [290] 
0% 90% 0% 
Prostanoic acid basic building block of 
prostaglandins [291] 




bile acid derivative - reduces liver 
fat and fibrosis [292] 
0% 85% 0% 
Inosine cardiac disease biomarker [293, 
294] 
5% 80% 100% 
Hypoxanthine cardiac disease biomarker [293] 0% 80% 100% 
Barbaloin product of aloe vera - anti-
inflammatory, cathartic properties 
[295] 
0% 70% 10% 
AMPA neurological biomarker [296] 10% 65% 90% 
Bromochloroacetic 
acid 
present in brominated disinfected 
water and may cause adverse 
reproductive outcomes [297] 
5% 65% 10% 
20-COOH-
Leukotriene B4 
Involved in vasodilation [298] 5% 55% 5% 
 
 






Table C. 5: Metabolites identified unique to suction blister fluid (SBF) compared to 
microneedle (MN) patch derived ISF. 
 
Biomarker Prevalence of biomarker†  
Plasma ISF SBF 
1-Methylpyrrolinium 0% 0% 95% 
Coniine 5% 10% 95% 
N-Methyl-L-histidine 0% 5% 100% 
Octamethyltrisiloxane 10% 5% 75% 
sn-Glycero-3-
phosphoethanolamine 
5% 5% 100% 
Guanosine 10% 10% 100% 
Corticosterone [299] 0% 0% 100% 
2-Arachidonoylglycerol [238] 0% 5% 95% 
Riboflavin 0% 0% 95% 
Hyperforin 0% 0% 95% 
2,3,6-Trichlorohydroquinone 70% 0% 55% 
Dichlorprop 0% 0% 80% 
Chlorethoxyfos 0% 0% 95% 






Figure C. 6: Tolerability of biofluid sampling methods in 21 human participants. (a) 
Pain associated with venipuncture, suction blister and MN treatment reported using 
a Visual Analog Scale (0 – 10) by 21 human participants. (b) Skin tolerability was 
assessed immediately after sampling by MN treatment or suction blister. All 
parameters rated on a scale of 0 to 4 (see Table S.5 in Appendix C).  
 
C.4. Skin tolerability measurements 
Table C. 6: Grading scale for skin tolerability measurements. 
 
* Used only with erythema (size) and induration/swelling.  




C.5. Pharmacokinetics of caffeine in interstitial fluid and plasma 
Table C. 7: Demographics of 9 participants in caffeine pharmacokinetics study 
Age (years) 
Mean (SD) 28 (4) 
Median (IQR) 26 (24-31) 
Sex 
Male (%) 6 (67%) 
Female (%) 3 (33%) 
Ethnic origin† 
White (%) 3 (33%) 
Black (%) 2 (22%) 
Asian (%) 4 (44%) 
BMI (kg/m2) § 
Mean (SD) 22.7 (2.2) 
Median (IQR) 22.4 (21.0-23.8) 
 
†Ethnic origin was self-reported, participants were allowed to select multiple options; 





C.6. Acceptability and tolerability of ISF connection by MN patch and plasma 
collection by fingerstick.  
 
Figure C. 7: Sensory perceptions reported by 9 human participants during MN 
treatment and fingerstick blood collection. Sensory perception of pain, stinging, 
burning, tingling, itching, warmth and tightness were reported by participants at five 
levels: very slight, slight, moderate, strong, and very strong. The pie chart displays 
the percent of treatments that participants reported that all sensations associated 
with the treatment were comfortable (white) or at least one was reported as not 






Figure C. 8: Pain of microneedle (MN) patch application, vacuum (following MN 
patch application) and fingerstick as reported by 5 participants on a scale of 0 (no 
pain) to 10 (worst possible pain). **** p<0.0001.  
 
 
Figure C. 9: Skin tolerability measurements made after microneedle (MN) patch 
treatment and fingerstick in 9 human participants. Skin tolerability parameters – 
erythema size, erythema intensity, swelling, pain and tenderness – were measured on 





Figure C. 10: Skin tolerability over 5 days after microneedle (MN) treatment and 
fingerstick in 9 human participants. Skin was assessed for erythema size, erythema 
intensity, swelling and tenderness and pain. (a)  Skin tolerability after MN treatment. 
No participants reported on-going pain. (b) Skin tolerability after fingerstick. No 
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